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Abstract  
 
Obesity is now a global epidemic, which represents a significant health problem. Obesity is defined 
as an excessive accumulation of adipose tissue mass, thus understanding adipose biology has 
become imperative to uncovering novel drug targets in the fight against obesity. Purinergic 
signalling has been implicated in a wide variety of physiological functions, however very little is 
currently known about the role of purinergic signalling in human adipocytes and their progenitor 
cells. This project aimed to characterise the P2 receptor profiles in both primary human adipose-
derived mesenchymal stromal cells (AD-MSCs) and in vitro differentiated adipocytes and then 
determine the functional roles of these receptors in each cell type.  
AD-MSCs and in vitro differentiated adipocytes express almost all of the known subtypes of P2 
receptors and transient elevations of intracellular calcium levels are observed in both cell types in 
response to exogenous application of ATP, ADP and UTP. However subtype-selective antagonism 
revealed that only P2Y2 and P2Y6 receptors are functionally active in AD-MSCs, and P2Y1, P2Y2 and 
P2Y12 receptors mediate nucleotide-evoked calcium responses in adipocytes. It is unclear what 
physiological functions P2Y2 and P2Y6 receptors mediate in AD-MSCs, but in adipocytes, P2Y2 
receptors appear to regulate basal lipolysis. Selective antagonism and shRNA-mediated knockdown 
of P2Y2 receptors resulted in an increase in basal glycerol release. In this study, it was determined 
that continuous P2Y2 activation suppresses basal lipolysis by maintaining calcium tone within 
adipocytes to tonicly inhibit calcium-sensitive isoforms of adenylate cyclase. This prevents the 
cytoplasmic accumulation of cAMP, thus inhibiting the activation of protein kinase A-mediated 
stimulated lipolytic pathways. These findings imply that P2Y2 receptors may be a novel and 
interesting drug target for modulating adipose tissue expansion. Further research is required to 
fully investigate the physiological roles of all of the P2 receptor subtypes expressed in these cells.      
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PPARγ Peroxisome proliferator-activated receptor gamma 
PTx Pertussis toxin 
MESC Mesenchymal stem cells 
MOI Multiplicity of infection 
MSC Mesenchymal stromal cells 
qRT-PCR Quantitative real time polymerase chain reaction 
RANTES Regulated on activation, normal T cell expressed and secreted 
RBP4 Retinol binding protein 4 
RPLP0 Ribosomal Protein Lateral Stalk Subunit P0 
RT-PCR Reverse transcription polymerase chain reaction 
SAA Serum amyloid A 
SAT Subcutaneous adipose tissue 
SBS Salt buffered solution 
SERCA Smooth endoplasmic reticular Ca2+ ATPase 
shRNA Short hairpin ribonucleic acid 
SOCE Store-operated calcium entry 
STIM1 Stromal interaction molecule 1 
T2DM Type 2 diabetes mellitus 
TNFα Tumour necrosis factor alpha 
TG Triglyceride 
UCP-1 Uncoupling protein 1 
UDP Uridine diphosphate 
WAT White adipose tissue  
WHO World Health Organisation 
UTP Uridine triphosphate  
VAT Visceral adipose tissue 
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Chapter 1: Introduction  
1.1 Obesity 
Obesity is a pathological condition characterised by the abnormal or excessive accumulation of 
body fat capable of effecting an individual’s health and wellbeing (WHO, 2018). Obesity is currently 
a worldwide epidemic with global estimates indicating that more than 1.9 billion adults are 
classified as overweight, of which 650 million are obese (WHO, 2016). The global prevalence of 
obesity has been steadily increasing over the past four decades (Afshin et al., 2017). Many 
countries, including the United Kingdom, now have a greater than 60% prevalence of overweight 
and obese adults (WHO, 2016) (Figure 1.1A), which is accompanied by a distressing increase in 
childhood obesity. Most countries that exhibit an abundance of overweight adults have a greater 
than 30% prevalence of overweight children and adolescents (WHO, 2016) (Figure 1.1B). It is 
estimated that 41 million children under the age of 5 and 340 million children aged between 5 and 
19 worldwide are classified as overweight or obese (WHO, 2016). Although, as a proportion there 
are less overweight children than adults, the rate of increase in childhood obesity exceeds that of 
adults in many countries (Afshin et al., 2017). The substantial rise in global obesity is likely to be 
fuelled by environmental factors, such as the surge in the availability, affordability and accessibility 
of high calorie foods and a decrease in physical activity due to urbanisation (Swinburn et al., 2011).  
Body mass index (BMI) values are the most widely used classification system to identify overweight 
and obese adults (Table 1.1). BMI values are determined by dividing an individual’s weight in 
kilograms by their height in meters squared (BMI = weight (kg)/height (m)2). The BMI thresholds 
shown in Table 1.1 only apply to adults. For children and adolescents (five to 19 years old) the 
thresholds are adjusted according to age, with BMI values of greater than one or two standard 
deviations above the WHO Growth Reference median being defined as overweight or obese 
respectively. For children aged between two and five, weight-for-height values of greater than two 
and three standard deviations above WHO Child Growth Standards median are considered 
overweight and obese respectively (WHO, 2018). Although widely adopted, the BMI system is 
criticised for its inability to accurately measure total fat mass and fat distribution (Nuttall, 2015), 
which are both key indicators of metabolic risk (Kissebah et al., 1982, 1989; Fox et al., 2009). Waist 
measurements are able to overcome some of these criticisms, as waist circumference and waist-
to-hip ratios measure abdominal obesity, which is associated with an increased risk for developing 
metabolic syndrome (Després and Lemieux, 2006). Waist circumferences of greater than 102 cm 
and 88 cm for men and women respectively indicate elevated risk (Lean et al., 1995). However, 
these thresholds cannot be universally applied, as studies indicates that ethnicity can also impact 
on cardiovascular risk, thus lower cut-offs are required for individuals of Asian descent (Misra et al., 
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2005). Despite the  criticisms of the BMI classification system, it is still the most extensively used 
system and BMI is a strong predictor of overall mortality in individuals that fall above and below 
the healthy range (Whitlock et al., 2009).  
 
Table 1.1 International classification of human body weight using body mass index (BMI) values. 
BMI values are calculated by dividing an individual’s weight in kilograms by the square of their 
height in meters. These values apply to both sexes and all ages, excluding children under the age of 
19.     
Body mass index (kg/m2) Classification 
< 18.5 Underweight 
18.5 - 24.9 Healthy weight 
25.0 - 29.9 Overweight 
> 30.0 Obese 
 
20 
 
 
Figure 1.1 Map depicting the prevalence of overweight and obese adults and children per country. 
(A) Proportion of adults (aged 18 or over) with BMI values of above 25 kg/m2 in each country. (B) 
Proportion of children and adolescents (aged 5 to 19 years old) with BMI values of greater than one 
standard deviation above the WHO Growth Reference median per country. Colour coding refers to 
different percentages for each map as indicated by the respective keys in each panel. Data shown 
is from 2016 and was adapted from the World Health Organisation’s website. Source: 
http://www.who.int/gho/ncd/risk_factors/overweight/en/ Last accessed 6.8.18.
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1.2 Wider impacts of obesity 
The global rise in the incidence of obesity represents a major health and economic issue. It’s 
estimated that a larger overweight population in the United Kingdom costs the National Health 
Service £3.2 billion (Allender and Rayner, 2007). More importantly, obesity poses a significant 
health problem, with 7.1% of deaths worldwide attributed to being overweight or obese (Afshin et 
al., 2017). There is an almost log-linear increase in the risk of death as BMI increases over 25 kg/m2 
(Di Angelantonio et al., 2016), where each 5 kg/m2 increase in BMI above the healthy range is 
associated with a 41% increase in risk of vascular mortality and 210% elevated probability of 
diabetic mortality, as well as a 29% higher risk of overall mortality (Whitlock et al., 2009). Vascular 
diseases, such as cardiovascular disease (CVD), accounts for almost 70% of all of the deaths 
associated with being overweight (Afshin et al., 2017). BMI values of between 30 and 35 kg/m2 are 
predicted to result in a two to four year reduction in median lifespan, whereas BMI values of 40 to 
45 kg/m2 may reduce median life expectancy by a staggering eight to ten years (Whitlock et al., 
2009). Between 1990 and 2015, the total number of deaths associated with being overweight or 
obese increased by 28.3% (Afshin et al., 2017).  
Although the excessive expansion of adipose tissue observed in obesity is an independent risk factor 
for mortality, obesity is also strongly associated with the development of other metabolic diseases, 
such as type 2 diabetes mellitus (T2DM) and CVD. This occurs, because adipose tissue plays a 
prominent role in energy metabolism, and dysfunction of adipose tissue disrupts the carefully 
balanced homeostatic systems in place to maintain healthy metabolism. Metabolic syndrome is 
characterised by the concurrent presence of multiple interrelated risk factors for T2DM and CVD. 
Symptoms include hypertension, hypertriglyceridemia, elevated plasma free fatty acids (FFA), 
hyperglycaemia and obesity (particularly abdominal obesity). Many obese individuals display liver 
steatosis, which is known to contribute to insulin resistance and may lead to the development of 
non-alcoholic fatty liver disease (Bjørndal et al., 2011).  
There are numerous factors that are capable of affecting an individual’s personal risk for developing 
obesity and its related comorbities. These include socioeconomic status, counterindications from 
pharmaceutical treatments, epigenetics, the gut microbiome and endocrine disruptors (McAllister 
et al., 2009). However regardless of the underlying cause of obesity, obesity and related metabolic 
disorders are at least in part due to adipose tissue dysfunction caused by overwhelming the body’s 
capacity to safely store excess calories within adipocytes (Zhao, 2013). Thus, a fundamental 
understanding of adipose tissue functioning is necessary to fully comprehend the molecular 
mechanisms involved in the pathogenesis of obesity. Currently the best interventions for combating 
obesity are maintaining a healthy diet and exercising and/or bariatric surgery. Only limited success 
has been attained with pharmacological inventions (Apovian, 2016). The global increase in the 
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incidence of obesity and related comorbidities means that new and effective strategies for tackling 
the problem of obesity are urgently required. Identification of novel mechanisms and drug targets 
could save or at least improve the quality of life of countless people across the globe, as well as 
significantly reducing the financial burden of obesity. 
  
1.3 Types of adipose tissue and adipocytes  
There are three distinct types of adipocytes: white, brown and beige adipocytes. These adipocytes 
are contained within two different types of adipose tissue, white and brown adipose tissue (WAT 
and BAT respectively). As their names suggest, WAT predominantly contains white adipocytes, 
whereas the primary cell type in BAT is brown adipocytes. Beige adipocytes are found sporadically 
within WAT depots (Kiefer, 2017).  
Although neonates have a relative abundance of BAT, the amount of BAT reduces with age and the 
vast majority of adipose tissue in adult humans is WAT (Lecoultre and Ravussin, 2011). However, 
small depots of BAT are present in adults as well (Cypess et al., 2009; van Marken Lichtenbelt et al., 
2009; Virtanen et al., 2009). BAT is easily distinguishable by its highly distinctive morphology. Brown 
adipocytes are multilocular and contain an abundance of mitochondria (Figure 1.2), which contain 
cytochrome enzymes with iron as a cofactor. The coloured cytochromes and the highly vascular 
nature of BAT gives rise to the dark red or ‘brown’ appearance of BAT (Lee et al., 2013). The primary 
functions of BAT, or brown adipocytes, is to generate heat via non-shivering thermogenesis and to 
decrease metabolic efficiency by accelerating the rate of food combustion (Cannon and 
Nedergaard, 2004). Brown adipocytes achieve these functions via uncoupling protein 1 (UCP-1), 
which is expressed almost exclusively in the inner mitochondrial membrane of brown adipocytes. 
When humans are exposed to cold temperatures or there is an excess of energy, sympathetic 
nervous stimulation of BAT leads to activation of β3-adrenergic receptors expressed on the surface 
of brown adipocytes, which triggers the breakdown of triglycerides to release FFAs. The FFAs are 
then transported into the mitochondria and bind to and activate UCP-1. The FFAs also undergo β-
oxidation and consequently fuel the electron transport chain to generate a proton gradient 
between the inner and outer mitochondrial membranes. The protons travel back through the inner 
membrane via UCP-1, thus rapidly dissipating the gradient to generate heat instead of ATP. After 
lipolysis is terminated, residual FFA are oxidised and UCP-1 reverts back to its basal inhibited state 
(Cannon et al., 2004; Nicholls and Rial, 2016). There is an inverse relationship between the 
abundance of BAT and weight (Cypess et al. 2009; van Marken Lichtenbelt et al. 2009) and in recent 
years there has been much interest in trying to manipulate BAT to enhance energy expenditure to 
combat obesity, although this will not be discussed further as this project focuses predominantly 
on white adipocytes and their progenitor cells.  
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WAT is the biological caloric reservoir of the body. In times of nutrient excess, adipose tissue is able 
to expand by storing excess nutrients as triglycerides in specialised lipid droplets within adipocytes 
(Ahmadian et al., 2010). Like BAT, WAT also has highly distinctive morphology. White adipocytes, 
the primary cell type in WAT, are very large unilocular cells that contain large lipid droplets that 
take up more than 90% of the interior of the cells (Sheldon, 2011). The lipid droplets displace all 
the other organelles, including the nucleus, to the periphery of the cell (Figure 1.2). 
WAT also contains beige adipocytes (also known as brite adipocytes), which are dynamic cells that 
can transition from white (energy storage) to brown (energy expenditure) phenotypes when 
exposed to certain stimuli, via a phenomenon termed adaptive thermogenesis or ‘browning’ 
(Rutkowski et al., 2015; Roh et al., 2018). There are thought to be specific pools of beige adipocytes 
precursors within WAT, which are induced to differentiate in response to adrenergic, thermogenic 
or hormonal stimuli (Kajimura et al., 2015). Unlike white adipocytes, which do not express UCP-1, 
beige adipocytes are capable of upregulating their expression of UCP-1 and adopting a more 
classical brown adipocyte phenotype (Kalinovich et al., 2017; Roh et al., 2018). Beige adipocytes are 
morphologically distinct from white adipocytes as they are multilocular and contain more 
mitochondria (Figure 1.2).  
 
24 
 
 
Figure 1.2 Schematic diagrams of the different types of adipocytes, including the major morphological features and functions of each cell type. 
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1.4 White adipose tissue 
WAT consists of tightly packed white adipocytes surrounded by nerves and blood vessels (Figure 
1.3). The tissue also contains immune cells, beige adipocytes and adipocyte precursor cells that all 
contribute to maintaining healthy WAT (Cristancho and Lazar, 2011; Kiefer, 2017). WAT is 
subdivided into subcutaneous and visceral adipose tissue (SAT and VAT respectively). Although the 
distribution of SAT and VAT varies from person-to-person and is dependent on a variety of factors 
including age, sex, ethnicity and diet (Wajchenberg, 2000), on average SAT accounts for 80-90% of 
total body fat, whereas VAT accounts for 5-20% of total body fat (Karastergiou et al., 2012). SAT is 
located directly below the skin, with specific depots in the abdominal, subscapular, gluteal and 
femoral regions (Karastergiou et al., 2012), whereas VAT is located around the vital organs in the 
mesentery, omentum, pericardium and mediastinum (Kwok et al., 2016). SAT is the primary site of 
long-term nutrient storage, but it also serves as a barrier against dermal infections, protects against 
external mechanical stress by cushioning organs and acts as a thermal insulating layer to limit heat 
loss via the skin (Kwok et al., 2016). Abdominal SAT is anatomically divided by the Scarpa's fascia 
into two layers: deep SAT (DSAT) and superficial SAT (SSAT) (Kelley et al., 2000; Walker et al., 2007). 
DSAT and SSAT are metabolically distinct. Expansion of SSAT appears to confer beneficial 
cardiometabolic effects in diabetic patients (Golan et al., 2012), whereas DSAT enlargement 
correlates with the development of insulin resistance (Kelley et al., 2000; Smith et al., 2001; 
Marinou et al., 2014). Like DSAT, increased VAT mass directly correlates with the development of 
insulin resistance, and VAT expansion is also a risk factor for CVD and T2DM (Wajchenberg, 2000; 
Ibrahim, 2010). The difference between SSAT and DSAT/VAT may be due to variation in the 
metabolic activity of white adipocytes in these depots. White adipocytes in both VAT and DSAT are 
known to more efficiently hydrolyse triglycerides than their SSAT counterparts (Hoffstedt et al., 
1997; Karastergiou et al., 2012), which means that DSAT and VAT release more free fatty acids (FFA) 
and elevate plasma FFA levels which promotes the development of insulin resistance (Björntorp, 
1990; Monzon et al., 2002). By contrast, SSAT displays lower lipolytic activity and higher insulin 
sensitivity, which suggests that white adipocytes in SSAT have a greater capacity to act as a 
physiological buffering system to store excess FFA in the form of triglycerides and consequently 
protect other tissues from lipotoxic effects (Frayn, 2002).  
There are also regional differences between the properties of white adipocytes within SAT. White 
adipocytes in abdominal SAT are more sensitive to stimulation of lipolysis than adipocytes in the 
gluteal regions (Wahrenberg et al., 1989). This is due to a predominance of anti-lipolytic signalling 
pathways in lower body adipose tissue depots versus their upper body counterparts (Manolopoulos 
et al., 2012). In addition, femoral SAT depots are prone to expand via hyperplasia, whereas 
abdominal SAT preferentially expands via hypertrophy (Tchoukalova et al., 2010). Hypertrophy is 
associated with an increased metabolic risk (Weyer et al., 2000). These depot differences underlie 
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the assertion that upper body obesity, but not lower body obesity, is associated with metabolic 
dysfunction (White and Tchoukalova, 2014). 
 
27 
 
 
 
Figure 1.3 Images of primary human subcutaneous abdominal white adipose tissue. (A) Brightfield 
image of a 6 μm section of human adipose tissue stained with haematoxylin and eosin taken at 
100X magnification. (B) Image of human adipose tissue autofluorescence taken using a multiphoton 
microscope (200X magnification) showing a large blood vessel intersecting through the adipocytes. 
In both images only the plasma membranes of the adipocytes are visible.  
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1.5 Mesenchymal stromal cells 
Adipocytes, like chondrocytes, osteoblasts and myocytes, are derived from mesenchymal stem cells 
(MESCs). In adult humans, approximately 10% of mature adipocytes are renewed annually via 
adipogenesis (Spalding et al., 2008). Adipogenesis, as well as hypertrophy for mature adipocytes, 
enables the expansion of adipose tissue mass in response to a surplus of energy. Adipogenesis is a 
very complex process, which begins when MESCs undergo the process of commitment to create 
preadipocytes, which are morphologically indistinguishable from their progenitors (Cristancho et 
al., 2011). Wnt signalling, bone morphogenetic proteins and the confluency of the cells are key 
drivers of commitment. Preadipocytes are then either maintained as progenitor cells by inhibiting 
further progression of adipogenesis or they are induced to terminally differentiate (Cristancho et 
al., 2011). Differentiation of preadipocytes commences with the activation of a transcriptional 
cascade to produce several adipocyte specific proteins, including leptin, adiponectin and fatty acid 
binding protein 4. There are a huge variety of transcription factors that play a role in adipogenesis, 
including a pivotal role for peroxisome proliferator-activated receptor γ (PPARγ), as well as 
CCAAT/enhancer-binding protein-α (C/EBPα), C/EBPβ and C/EBPδ. C/EBPβ and C/EBPδ drive 
expression of PPARγ during the early stages of differentiation and then C/EBPα maintains 
expression later in the process (Rosen and Spiegelman, 2006). Lower rates of adipogenesis are 
associated with increased incidence of visceral obesity, adipocyte hypertrophy and higher fasting 
blood glucose levels (Lessard et al., 2014). This suggests that efforts to improve the adipogenic 
potential of progenitor cells may oppose this metabolically unhealthy phenotype. 
 
WAT represents the most abundant and easily accessible source of mesenchymal stromal cells 
(MSCs) in adult humans. The term MSC refers to the multipotent plastic-adherent cells that can be 
isolated from bone marrow and other tissues, including adipose tissue (Dominici et al., 2006). As 
MESCs are morphologically indistinguishable from preadipocytes and dedifferentiated mature cells, 
it is likely that multipotent cells extracted from adipose tissue (MSCs) are a heterogenous 
population of cells (Baer and Geiger, 2012). A lack of specific markers for these different cell types 
means that the multipotent cells extracted from adipose tissue cannot be accurately referred to as 
MESCs or preadipocytes and must instead be referred to as MSCs. In addition to differentiating to 
adipocytes, MSCs are also capable of differentiating in vitro to osteoblasts, chondrocytes, myocytes 
and neurons (Ning et al., 2006; Uccelli et al., 2008; Karantalis and Hare, 2015). This has led to several 
clinical trials to determine whether MSCs can be used therapeutically to regenerate damaged tissue 
(Thesleff et al., 2011; Houtgraaf et al., 2012; Jo et al., 2014). The initial results are promising and 
propose that MSCs exert their beneficial effects by migrating to the site of injury and utilising their 
regenerative capacity, as well as having an immunomodulatory effect at the injury site (Cho et al., 
2009; Feisst et al., 2015). However, the process of MSC senescence severely diminishes the 
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potential benefits of this treatment. Senescence adversely affects migration and proliferation of 
MSCs, as well as impairing their capacity to differentiate (Turinetto et al., 2016; Kim and Park, 2017). 
In addition, senescent MSCs secrete pro-inflammatory factors, rather than anti-inflammatory 
cytokines, thus potentially exacerbating the original injury (Turinetto et al., 2016). A greater 
understanding of the molecular mechanisms that underline normal MSC functioning is needed to 
be able to overcome these issues.  
 
1.6 White adipocytes 
Unlike other cell types, white adipocytes have specifically developed to accumulate triglycerides 
without experiencing lipotoxicity (Konige et al., 2014). Their ability to store neutral lipids underlies 
their distinctive morphology, which consists of greater than 90% of the interior of the cell being 
occupied by one large lipid droplet which displaces all the other organelles, including the nucleus, 
to the cell periphery (Figure 1.2 and 1.3). White adipocytes are highly dynamic cells that facilitate 
both storage and release of nutrients, via lipogenesis and lipolysis respectively, in response to an 
individual’s energy stasis. They are also capable of synthesising and releasing a wide variety of 
adipokines, which regulate systemic metabolism (Halberg et al., 2008).  
White adipocytes can dynamically change their size depending on their lipid content. Hyperplasia 
of adipocytes occurs when there is a surplus of energy, such as after a meal, and there is a 
predominance of lipogenesis over lipolysis (Bódis and Roden, 2018). The term lipogenesis 
encompasses both fatty acid and triglyceride synthesis (Kersten, 2001). Although endogenous de 
novo lipogenesis (DNL) can occur in adipose tissue, in the postprandial state DNL primarily occurs 
in the liver and then the triglycerides are transported to adipose tissue to be safely stored within 
adipocytes (Postic and Girard, 2008). However, fatty acids are also acquired directly via dietary 
intake of fats and indirectly via increased carbohydrate consumption leading to activation of fatty 
acid synthase (FAS) in adipose tissue, which facilitates conversion of glucose to fatty acids 
(Hillgartner et al., 1995). It is thought that DNL in adipose tissue promotes a more metabolically 
healthy phenotype than DNL in the liver, because DNL in WAT generates metabolites, such as FA 
esters of hydroxy FA, which enable crosstalk between WAT and other organs involved in insulin 
sensitivity and energy metabolism (Yilmaz et al., 2016), whereas liver DNL is linked to liver 
hepatosteatosis (Cao et al., 2008). Obesity is associated with a down-regulation of lipogenic genes 
in WAT and an upregulation of lipogenic genes in the liver, thus promoting metabolic dysfunction 
(Ranganathan et al., 2006; Eissing et al., 2013; Bódis et al., 2018).  
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1.7 Lipolysis  
In addition to storing energy when there is an excess of nutrients (fed state) via lipogenesis, white 
adipocytes are also able to release energy via lipolysis when there is an energy deficit (fasting state) 
(Kersten, 2001; Nielsen et al., 2014). Lipolysis encompasses the sequential hydrolysis of 
triglycerides (TG) to their component parts of free fatty acids (FFAs) and glycerol. This process is 
mediated by three lipases: Adipose triglyceride lipase (ATGL), hormone-sensitive lipase (HSL) and 
monoglyceride lipase (MGL). ATGL catalyses the initial rate-determining hydrolysis of TG to 
diglycerides (DG) (Zimmermann et al., 2004), then DGs are hydrolysed to monoglycerides (MG) by 
HSL (Haemmerle et al., 2002) and finally MG is broken down to glycerol by MGL (Fredrikson et al., 
1986). Each step yields one FFA molecule, therefore each TG molecule ultimately yields three FFAs. 
Adipocytes are the only cell type in the body that are capable of secreting FFAs into the 
bloodstream. These FFAs can subsequently travel to distant peripheral tissues and act as a substrate 
for β-oxidation to generate ATP to fuel cellular processes (Kolditz and Langin, 2010). Loss of lipid 
from adipocytes causes a reduction in adipocyte size, which may ultimately lead to weight loss.  
In addition to acting as an energy source, it has been determined that many of the products of 
lipolysis, such as DG, MG and FFAs, are involved in intracellular and systemic signalling mechanisms 
(Zechner et al., 2012). However augmented concentrations of these intermediate products of 
lipolysis have been linked to the development of insulin resistance in peripheral tissues (Boura-
Halfon and Zick, 2009; Copps and White, 2012). Excessively elevated levels of FFA in the plasma is 
widely thought to be involved in the development of insulin resistance and T2DM, thus indicating 
that dysregulation of lipolysis in obese individuals is likely to have adverse effects on insulin 
sensitivity (Nielsen et al., 2014).  
There are two forms of lipolysis: basal and stimulated lipolysis. Basal lipolysis is the omnipresent 
low levels of triglyceride hydrolysis that occurs spontaneously in the absence of external stimuli, 
whereas stimulated lipolysis facilitates a more substantial release of FFAs and glycerol in response 
to external stimuli.  
1.7.1 Stimulated lipolysis 
There are a variety of substances that are able to initiate stimulated lipolytic pathways in white 
adipocytes, including hormones, cytokines and nervous stimulation. Fasting initiates sympathetic 
nervous stimulation of WAT via catecholamine-mediated activation of β-adrenoreceptors on the 
surface of white adipocytes (Fain, 1973) (Figure 1.4). Similarly, activation of other Gs-coupled 
receptors, such as thyroid stimulating hormone (TSH) receptors (Endo and Kobayashi, 2012) and 
melanocortin receptors (Cho et al., 2005; Rodrigues et al., 2013), also stimulate lipolysis. Activation 
of Gs-coupled receptors stimulates adenylate cyclase (AC) to generate cyclic AMP (cAMP). 
Cytoplasmic accumulation of cAMP activates protein kinase A (PKA) (Langin, 2006), which in turn 
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phosphorylates HSL and perilipins on the surface of the lipid droplet to allow translocation of HSL 
from the cytoplasm to the lipid droplet (Miyoshi et al., 2006). Phosphorylation of perilipins also 
promotes the release of comparative gene identification-58 (CGI-58) (Sahu-Osen et al., 2015), 
which is a potent co-activator of ATGL that increases the activity of ATGL by up to 20-fold (Schweiger 
et al., 2006; Miyoshi et al., 2008). At the surface of the lipid droplet, ATGL begins hydrolyzing TGs 
and to produce DGs, which act as a substrate for HSL. Then MGL catalyses the breakdown of MG to 
FFA and glycerol (Figure 1.4). The FFA are recycled or released into the bloodstream where they are 
able to travel to distant organs to be utilised as a cellular energy source (Ahmadian et al., 2010). 
ATGL and HSL are the main drivers of TG hydrolysis. Studies indicate that knocking out ATGL or HSL 
expression in mice leads to an approximately 70% reduction in β-adrenergic stimulated lipolysis. 
Furthermore, selective inhibition of HSL in ATGL knockout mice results in a 95% reduction in TG 
hydrolase activity versus wildtype mice (Schweiger et al., 2006).  
Cardiac hormones, such as atrial natriuretic peptides (ANP) and B-type natriuretic peptides (BNP), 
can also stimulate lipolysis (Sengenès et al., 2003). Cardiac hormones are released from the heart 
in response to myotubal distension and travel via the bloodstream to WAT where they bind to 
guanylyl cyclase (GC)-linked type-A natriuretic peptide receptors expressed on the surface of white 
adipocytes. This stimulate the conversion of GTP to cyclic GMP, which in turn activates protein 
kinase G (PKG), which acts in the same manner as PKA to stimulate lipolysis (Sengenès et al., 2000) 
(Figure 1.4). In addition, other hormones such as growth hormone (GH) also stimulate lipolysis 
(Hansen et al., 2002). Although the exact mechanism is not well understood, it is hypothesized that 
GH renders adipocytes more responsive to β-adrenergic stimulation (Doris et al., 1994; Yang et al., 
2004) and less responsive to the anti-lipolytic effects of insulin (Johansen et al., 2003).  
Furthermore, cytokines are also capable of stimulating lipolysis in adipocytes. Tumour necrosis 
factor α (TNFα) significantly decreases the expression of phosphodiesterase (PDE) 3B (H. H. Zhang 
et al., 2002), thus reducing the breakdown of cAMP to allow cAMP accumulation and consequent 
activation of PKA-mediated lipolysis. TNFα also increases ATGL activity by initiating remodeling of 
core components of the lipolytic machinery (Nielsen et al., 2014).  
1.7.2 Anti-lipolytic pathways 
Although catecholamines stimulate lipolysis via β-adrenergic receptors, they can also inhibit 
lipolysis via activation of α2-adrenergic receptors. α2-adrenergic receptors are Gi-coupled, thus 
activation of these receptors inhibits AC to prevent the elevation of cytoplasmic cAMP levels and 
subsequent initiation of lipolysis (Nielsen et al., 2014) (Figure 1.4). Similarly activation of other Gi-
coupled receptors, such as adenosine A1 receptors (Fredholm and Sollevi, 1977; Ohisalo, 1981; 
Johansson et al., 2008) and neuropeptide Y-Y1 receptors (Serradeil-Le Gal et al., 2000), also has an 
inhibitory effect on lipolysis. 
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However, the main anti-lipolytic pathway is mediated by insulin. There is a post-prandial elevation 
of plasma insulin levels, which is capable of inhibiting lipolysis (Jensen, 1995), while also promoting 
lipogenesis (Czech et al., 2013). The anti-lipolytic effects of insulin are achieved by activating 
phosphodiesterases 3B, which leads to degradation of cAMP and subsequent deactivation of PKA-
mediated lipolysis. Insulin binding to insulin receptors expressed on the surface of adipocytes 
induces autophosphorylation of the receptors and subsequent phosphorylation of insulin receptor 
substrate (IRS) proteins (White, 1998). IRS proteins then activate phosphatidylinositol 3-kinase 
(PI3K), which generates phosphatidylinositol-3,4,5- triphosphate (PIP3), which in turn activates 
phosphoinositide-dependent kinase and this activates protein kinase B (PKB)-mediated activation 
of PDE3B (Alessi et al., 1997; Stokoe et al., 1997; Nielsen et al., 2014) (Figure 1.4).  
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Figure 1.4 Schematic diagram of the molecular mechanisms governing stimulated lipolytic 
pathways, including some inhibitory pathways. Lipolysis can be stimulated by activation of Gs-
coupled receptors, such as β-adrenoreceptors (βAR) and thyroid stimulating hormone receptors 
(TSH-R). Upon agonist binding, Gαs (Gs) proteins stimulate adenylate cyclase (AC) to produce cyclic 
AMP (cAMP). The accumulation of cAMP activates protein kinase A (PKA), which then 
phosphorylates hormone sensitive lipase (HSL) and perilipins (blue rectangle) on the surface of the 
lipid droplet. This allows HSL to translocate to the lipid droplet and it also causes comparative gene 
identification-58 (CGI-58) (black circle containing a white C) to dissociate from perilipins and bind 
to adipose triglyceride lipase (ATGL). ATGL then catalyses the hydrolysis of triglycerides (TG) to 
diglycerides (DG). DG are then further hydrolysed by HSL to monoglycerides (MG) and finally MGs 
are broken down to glycerol by monoglyceride lipase (MGL). Each step also yields one fatty acid 
(FA). Activation of guanylyl cyclase (GC)-linked type-A natriuretic peptide receptors (NPR) also 
stimulates lipolysis by stimulating accumulation of cyclic GMP (cGMP), which in turn activates 
protein kinase G (PKG), which acts in the same manner as PKA to stimulate lipolysis. There are also 
pathways that inhibit stimulated lipolysis, such as via α2-adrenoceptor (αAR) or adenosine A1 
receptor (A1) activation. Both of these receptors are Gi-protein (Gi) coupled receptors, thus their 
activation leads to an inhibition of AC. In addition, insulin also inhibits lipolysis by binding to insulin 
receptors (IR) and causing autophosphorylation of IRs, which then phosphorylates insulin receptor 
substrate (IRS) proteins. IRS proteins then activate phosphatidylinositol 3-kinase (PI3K), which 
eventually activates protein kinase B (PKB)-mediated activation of phosphodiesterase (PDE), which 
breaks down cAMP to prevent cAMP accumulation and subsequent induction of stimulated 
lipolysis. 
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1.7.3 Basal lipolysis  
In comparison to stimulated lipolysis, little is currently known regarding the underlying mechanisms 
governing basal lipolysis, though it has been suggested that perilipins and ATGL play a prominent 
role (Miyoshi et al., 2008). Under basal conditions, perilipins expressed on the surface of lipid 
droplets act as a barrier between the triglycerides within the lipid droplet and the lipases (ATGL and 
HSL) in the cytoplasm (Miyoshi et al., 2008) (Figure 1.5). Perilipins play an important role in limiting 
the extent of basal lipolysis. This is evidenced by the fact that perilipin knockout mice have smaller 
adipocytes and higher rates of basal lipolysis than their wildtype counterparts (Martinez-Botas et 
al., 2000; Tansey et al., 2001). In addition, CGI-58 reversibly interacts with perilipin A on the surface 
of the lipid droplet (Figure 1.5), thus preventing CGI-58 from interacting with ATGL and indirectly 
reducing ATGL activity (Granneman et al., 2007).  
In the basal state, ATGL localizes to both the cytoplasm and lipid droplet (Zimmermann et al., 2004; 
Granneman et al., 2007), whereas HSL predominantly resides in the cytoplasm (Granneman et al., 
2007) (Figure 1.5). ATGL Knockout mice display reduced FFA release under basal and stimulated 
conditions, which suggests that ATGL is likely to play a role in both basal and stimulated lipolysis 
(Schweiger et al., 2006). In addition, overexpression of ATGL is associated with an approximately 
two-fold increase in basal glycerol and FFA release (Kershaw et al., 2006), while ATGL silencing 
substantially decreased basal lipolysis (Bezaire et al., 2009). Interestingly, HSL-null mice display 
similar rates of basal lipolysis to their wildtype counterparts (Wang et al., 2001; Haemmerle et al., 
2002), and  HSL overexpression and silencing has no effect on the rate of basal lipolysis in human 
adipocytes (Bezaire et al., 2009). This suggests HSL has a limited role in basal lipolysis. Much more 
research is required to fully comprehend the complex molecular mechanisms involved in regulating 
basal lipolysis.   
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Figure 1.5 Schematic diagram of the molecular mechanisms governing basal lipolytic pathways. 
Under basal conditions, hormone sensitive lipase (HSL) localizes to the cytoplasm, whereas adipose 
triglyceride lipase (ATGL) localizes to both the lipid droplet and the cytoplasm and monoglyceride 
lipase (MGL) localizes to the lipid droplet. In addition, comparative gene identification-58 (CGI-58) 
(black circle containing a white C) is associated with perilipins (blue rectangle) on the surface of the 
lipid droplet, which indirectly limits ATGL capacity to hydrolyse triglycerides (TG) stored within lipid 
droplets. 
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1.8 Adipokine secretion  
In addition to being the primary site of long-term nutrient storage in the body, WAT also has a 
significant role as an endocrine organ. Adipose tissue is capable of secreting a wide repertoire of 
substances that are collectively termed adipokines. In recent years, hundreds of adipokines have 
been identified, some of which act in an autocrine or paracrine fashion within adipose tissue, 
whereas other adipokines are able to travel to distant sites to influence the metabolic activity of 
the other organs (Kim & Moustaid-moussa 2000). For example, when lipolysis is initiated, 
adipocytes release anti-lipotoxic adipokines, such as leptin, adiponectin and fibroblast growth 
factor 21, to protect peripheral tissues from the lipotoxic effects of lipid accumulation (Unger et al., 
2013). Leptin was the first adipokine to be identified (Zhang et al., 1994). It is secreted by 
adipocytes, but acts at specific leptin receptors within the hypothalamus to signal satiety and 
prompt an increase in energy expenditure to maintain an optimal adipose tissue volume (Klok et 
al., 2007). Fasting and catecholamines decrease leptin production, whereas overfeeding, insulin 
and glucocorticoids all increase levels of circulating leptin (Kim & Moustaid-moussa 2000). In 
comparison to leptin, adiponectin is produced in relatively large quantities (μg/ml adiponectin 
versus ng/ml leptin in the plasma) and is able to effect many different tissues, with the liver and 
skeletal muscle being two major target organs (Wang and Scherer, 2016). Adiponectin inhibits 
apoptosis, suppresses inflammation, inhibits lipolysis and promotes insulin sensitivity to improve 
systemic metabolism (Wedellová et al., 2011; Wang et al., 2016). Another example of an adipokine 
that decreases lipid uptake is angiopoietin-like 4 (ANGPTL4). ANGPTL4 is released in response to 
fasting and is known to inhibit lipoprotein lipase activity and decrease lipid uptake in rodent 
adipocytes (Köster et al., 2005; Lafferty et al., 2013). 
 
Adipocytes also secrete a wide variety of inflammatory cytokines and chemokines, such as tumour 
necrosis factor α (TNFα), interleukin (IL) 6 (Ronti et al., 2006) and RANTES (regulated upon 
activation normal T cell expressed and secreted) (Skurk et al., 2009). However, adipocytes can also 
secrete anti-inflammatory factors too, such as IL-1 receptor antagonist and IL-10 (Lago et al. 2007). 
The adipokine secretion profile alters according to the metabolic and redox state of white 
adipocytes (Cao, 2014). Although under normal conditions, this feature enables adipocytes to 
influence systemic metabolism to maintain energy homeostasis, in obese individuals, white 
adipocyte dysfunction leads to an increase in release of proinflammatory cytokines as well as a 
decrease in anti-inflammatory adipokines, such as adiponectin (Slawik and Vidal-Puig, 2007; 
Ibrahim, 2010). This in turn promotes low grade inflammation of adipose tissue, which participates 
in the development of cardiovascular complications and autoimmune conditions in obese 
individuals (Lago et al., 2007; Bódis et al., 2018).  
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1.9 Intracellular signalling mechanisms 
Activation of cell surface receptors initiates intracellular signalling cascades, which enables the 
transmission of extracellular signals from the cell surface to a multitude of intracellular targets in a 
process known as signal transduction (Cooper, 2000). Signals are transmitted via three different 
categories of cell surface receptors: ligand-gated ion channels, enzyme-linked receptors and G-
protein coupled receptors (GPCRs). Successful ligand binding to ligand-gated ion channels produces 
a conformational change in the receptor, which results in the receptor switching from its closed 
state to its open state, thus enabling passage of ions and other molecules through the plasma 
membrane. Enzyme-linked receptors are often protein kinases, such as tyrosine kinases, thus 
activation of these receptors leads to downstream phosphorylation of intracellular target proteins. 
Finally, GPCRs represent the largest family of membrane proteins. All receptors in this family share 
a common seven transmembrane domain structure and activation of these receptors regulates 
intracellular function indirectly via GTP-binding protein (G-protein) intermediate molecules or β-
arrestin (Purves et al., 2001).  
1.9.1 G-protein coupled receptors 
GPCRs regulate a diverse range of intracellular signalling cascades triggered by numerous stimuli, 
including hormones, neurotransmitters, lipids, nucleotides, ions, photons and odorants (Hilger et 
al., 2018). There are 826 different GPCRs in the human body and they are responsible for the 
majority of cellular signalling events (Wu et al., 2017). GPCRs are highly attractive therapeutic 
targets and currently approximately 30% all marketed drugs target GPCRs (Shonberg et al., 2015). 
GPCRs are subdivided according to their sequence homology into four major categories: rhodopsin-
like (class A), secretin-like (class B), metabotropic glutamate/pheromone (class C) and frizzled (class 
F) (Shonberg et al., 2015). The intracellular responses initiated by GPCR activation are broadly 
mediated via two different pathways: G-protein mediated and G-protein-coupled receptor kinase 
(GRK)-mediated phosphorylation and arrestin coupling (Hilger et al., 2018). Determination of the 
crystal structure of both active and inactive GPCRs has substantially increased our understanding 
of the conformational changes that occur in response to ligand binding (Shonberg et al., 2015; 
Zhang, Zhao, et al., 2015; Wu et al., 2017). Most commonly, GPCR activation leads to a major 
reorganisation and rearrangement of the transmembrane helices to expose an intracellular pocket 
that can effectively engage the relevant effector proteins (Hilger et al., 2018).  
Classical signal transduction via GPCRs is mediated via heterotrimeric G proteins. G proteins are 
composed of three subunits: Gα, Gβ and Gγ. Based on sequence homology of the α subunit, there 
are four major categories of G-proteins: Gs, Gi/o, Gq/11 and G12/13 (Table 1.2). Each class of G-protein 
activates different effectors and consequently mediates different signalling pathways. In the 
inactive state, GDP is bound to Gα and Gα associates with the Gβγ dimer to form a heterotrimer. 
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Upon receptor activation, GDP dissociates from Gα and is rapidly replaced by GTP, which initiates 
a conformational change in the receptor and the subsequent dissociation of Gα and Gβγ subunits. 
The Gα subunit is then able to mediate downstream signalling cascades by targeting effectors, 
which include adenylate cyclases and phospholipase C (Cooper, 2000; Hilger et al., 2018). The 
liberated Gβγ subunit can also recruit GRKs to the plasma membrane and regulate many 
downstream effectors too (Hilger et al., 2018). The intrinsic GTPase activity of Gα enables the 
hydrolysis of GTP to GDP, thus allowing the reassociation of the Gα and Gβγ subunits and 
terminating signalling.  
 
Table 1.2 Main effectors and actions of G-proteins within each of the four major classes of G-
proteins.  
G-protein 
class 
G-protein 
subunits 
Main effector Action Reference 
Gs Gαs Golf Adenylate cylases Stimulation; ↑ 
cAMP 
(Jones and Reed, 
1989; Yang et al., 
1997) 
Gi/o Gαtr, Gαtc, Gαg 
 
Gαi1-3 
Gαo 
Phosphodiesterases 
 
Adenylate cyclases 
c-Src 
Stimulation; ↓ 
cAMP 
Inhibition; ↓ cAMP 
Stimulation 
(Pierce et al., 2002) 
(Kristiansen, 2004) 
(Zorina et al., 2010) 
Gq/11 Gαq, 11, 14, 15/16 Phospholipase C Stimulation; ↑ Ca2+ (Mizuno and Itoh, 
2009) 
G12/13 Gα12 
Gα13 
Rho GTPase 
nucleotide 
exchange factors 
Stimulation (Siehler, 2009) 
 
 
1.9.2 Calcium signalling 
Calcium ions (Ca2+) are involved in almost all aspects of cellular functioning. Ca2+ acts as a highly 
versatile and ubiquitous second messenger that plays a vital role in numerous cellular processes 
(Berridge et al., 2000; Clapham, 2007). For example, calcium plays a central role in mesenchymal 
stem cell migration and adipogenesis (Shi et al., 2000; Pchelintseva and Djamgoz, 2018). 
Furthermore in white adipocytes, Ca2+ has been shown to be involved in lipolysis, secretion of 
adipokines and glucose uptake (Xue et al., 2001; Cammisotto and Bukowiecki, 2004; El Hachmane 
et al., 2018). Cells exert tight regulatory control to maintain a low intracellular concentration of Ca2+ 
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of approximately 100 nM under resting conditions, as calcium overload leads to apoptosis and 
necrosis (Berridge et al., 2000, 2003; Clapham, 2007). This represents an approximately 20,000-fold 
gradient between the intracellular and extracellular environment which contains mM 
concentrations of Ca2+. However, in response to various stimuli, intracellular Ca2+ levels can be 
transiently elevated up to approximately 1 μM to initiate various signalling pathways (Berridge et 
al., 2000). Ca2+ can enter the cell via voltage-gated Ca2+ channels and other ionotropic receptors, or 
activation of receptor tyrosine kinases and Gq-coupled receptors increases intracellular Ca2+ via 
release from intracellular stores. Initial increases in Ca2+ via entry from the extracellular space 
triggers additional release from the endoplasmic reticulum (ER) via Ca2+-sensitive ryanodine 
receptor (RyR) expressed on the surface of the ER (Clapham, 2007). Receptor tyrosine kinases or 
GPCRs can activate phospholipase C (PLC), which cleaves phosphatidylinositol 4, 5 bisphosphate 
(PIP2) into inositol (1,4,5) triphosphate (IP3) and diacylglycerol (DAG). IP3 binds to IP3 receptors 
expressed on the ER and triggers a conformational change that allows Ca2+ to flow out of the ER and 
into the cytoplasm, thus elevating intracellular calcium. The resulting emptying of the intracellular 
stores initiates translocation of stromal interaction molecule 1 (STIM1) in the ER to enable 
interaction between STIM1 and calcium release-activated calcium channel protein 1 (ORAI1) on the 
plasma membrane, which subsequently results in the opening of the ORAI1 channels to allow Ca2+ 
influx to replenish the intracellular stores (Smyth et al., 2010). ORAI1 channels remain open until 
the intracellular Ca2+ stores have been refilled. These store-operated calcium entry (SOCE) 
mechanisms have been demonstrated in both preadipocytes and mature adipocytes (Hu et al., 
2009; El Hachmane et al., 2018).  
 
Due to the potentially cytotoxic effects of elevated cytoplasmic Ca2+ levels, stimulus-induced 
augmented calcium levels are rapidly lowered by extrusion of Ca2+ out of the cell via plasma 
membrane Ca2+ ATPases (PMCA) transporters or into the endoplasmic reticulum cellular Ca2+ stores 
via smooth endoplasmic reticular Ca2+ ATPase (SERCA) transporters. In addition, sodium/calcium 
exchangers and Ca2+-activated potassium (or chloride) channels can also help to decrease 
intracellular calcium concentrations (Clapham, 2007). Decreasing intracellular calcium levels back 
to baseline levels terminates Ca2+-mediated signalling pathways.  
 
1.9.3 Cyclic AMP signalling 
Like calcium, cAMP is a ubiquitously expressed secondary messenger molecule that plays a pivotal 
role in a variety of cellular functions, including an essential role in lipolysis in white adipocytes 
(Section 1.7.1 and 1.7.2). Intracellular cAMP levels are regulated by the balance between the 
activity of adenylate cyclases (AC) and phosphodiesterases (PDE). There are ten isoforms of ACs. 
Nine are membrane-bound and regulated by G-proteins (AC1-9) (Sadana and Dessauer, 2009) and 
the tenth isoform (AC10) is a soluble AC that has unique enzymatic properties and does not respond 
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to G-proteins (Satrawaha et al., 2011). Activation of ACs leads to an accumulation of cAMP and 
consequent activation of various effectors, of which protein kinase A (PKA) is the most well 
characterised (Pierce et al., 2002). In contrast, both inhibition of ACs or activation of PDEs manifests 
in a reduction of intracellular cAMP and subsequent deactivation of downstream effectors 
(Sassone-Corsi, 2012). There is also some co-operation between cAMP and Ca2+-mediated signalling 
pathways, as both ACs and PDEs can be positively or negatively regulated by calcium signalling 
(Sadana et al., 2009).  
 
1.10 Purinergic signalling  
The concept of nucleotides acting as non-adrenergic, non-cholinergic neurotranmitters was first 
proposed by Professor Geoffrey Burnstock in 1970 (Burnstock et al., 1970). Shortly thereafter this 
phenomenon was termed ‘purinergic signalling’ (Burnstock, 1972). Despite previous evidence in 
support of the concept (Drury and Szent-Györgyi, 1929; Buchthal and Folkow, 1948; Emmelin and 
Feldberg, 1948; Holton, 1959), initially there was much resistance to the idea and it took a further 
20 years before purinergic signalling was truly accepted by the wider scientific community 
(Burnstock, 2014). Now, it is known that autocrine/paracrine signalling via extracellular nucleosides 
and nucleotides is one of the most common cell signalling mechanisms and purinergic signalling is 
implicated in a wide range of physiological processes including smooth muscle contraction, immune 
responses, embryonic development and maintaining homeostasis (Yegutkin 2014). These signalling 
pathways are regulated by specific purinergic receptors of which there are two broad categories, 
P1 and P2 receptors (Spedding & Weetman 1976; Burnstock 1978). P1 receptors are GPCRs 
activated by the nucleoside adenosine, whereas P2 receptors are activated by nucleotides and they 
are subdivided into two distinct subclasses known as P2X and P2Y receptors respectively (Burnstock 
& Kennedy 1985). 
 
1.11 Sources of extracellular nucleosides and nucleotides 
There are several different sources of extracellular nucleotides, including release from apoptotic or 
necrotic cells, secretion in response to various mechanical or chemical stimuli, exocytosis alone or 
in combination with other neurotransmitters and via ion-channels and transporters. Exocytosis is 
thought to be the method by which ATP is released by nerves, endocrine cells and platelets 
(Yegutkin 2014). Cells can also release ATP to mediate autocrine regulation of cellular activity, with 
some cells demonstrating constitutive release of ATP (Corriden and Insel, 2010; Sivaramakrishnan 
et al., 2012; Campwala and Fountain, 2013). Data from murine 3T3-L1 adipocytes and adipocytes 
isolated from pannexin 1 knockout mice suggests that ATP can be released via activated pannexin 
1 channels (Adamson et al., 2015). However, Adamson et al (2015) also showed that there are basal 
concentrations of ATP (<500 nM) released by adipocytes, which are not altered in pannexin 1 
41 
 
knockout mice and are unaffected by pharmacological activation and inhibition of pannexin 1, 
which suggests that additional ATP release mechanisms are also present in murine adipocytes. 
Irrespective of the source of ATP, when endogenous nucleotides are in the extracellular space they 
are able to directly interact with P2X and P2Y receptors expressed at the cell surface to initiate 
purinergic signalling cascades. The extracellular nucleotides can also be (or are subsequently) 
metabolised by cell surface ectonucleotidases, such as nucleoside triphosphate 
diphosphohydrolase-1 (CD39) and ecto-5’-nucleotidase (CD73), which produces metabolites that 
are able to interact with P1 and P2Y receptors. Finally, nucleosides are metabolised further and/or 
reabsorbed into the cell (Yegutkin 2008).  
 
Rodent white adipocytes maintained in vitro secrete small amounts of ATP (<500 nM) into the 
supernatant under basal conditions (Schödel et al., 2004; Adamson et al., 2015), which raises the 
possibility of white adipocytes regulating their own purinergic responses in an autocrine manner. 
As cells are very closely packed within WAT, ATP released from white adipocytes is likely to have 
paracrine effects on neighbouring cells, potentially including progenitor cells located throughout 
WAT. In a suspension of white adipocytes harvested from rats, 5 μM ATP had a half-life of 16 
minutes, which represents a 500-fold increase in half-life when compared to the metabolism of ATP 
in the bloodstream (Schödel et al., 2004). This indicates that white adipocytes may employ 
mechanisms to extend nucleotide viability, thus potentially prolonging activity of purinergic 
signalling pathways. In addition, adipose tissue is highly innervated, so co-release of ATP and 
noradrenaline from sympathetic nerves is likely to be another source of ATP in WAT (Fishman and 
Dark, 1987; Bartness and Bamshad, 1998; Bartness and Song, 2007).  
 
1.12 P1 receptors  
P1 receptors are GPCRs that are activated by adenosine. There four subtypes of P1 receptors: A1, 
A2A, A2B and A3. Adenosine has the highest affinity for A1 and A2A, which have opposing actions. 
Both A1 and A3 are Gαi-coupled receptors, whereas A2A and A2B are Gαs-coupled receptors. Thus, 
activation of A1 or A3 leads to a reduction in adenylate cyclase activity and a decrease in the 
concentration of intracellular cAMP, whereas A2A or A2B activation elicits an increase in adenylate 
cyclase activity (Layland et al., 2014). In some cells, A2B receptors can also activate PLC and 
mitogen-activated protein kinases (MAPK) signalling pathways (Cohen et al., 2010). The four 
membrane receptors of the P1 family share an average sequence homology of 47%, although this 
rises to approximately 57% homology when only the transmembrane domains are considered 
(Jacobson et al., 2012). 
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Activation and overexpression of A2B receptors is associated with stimulation of osteogenic 
differentiation in MSCs, whereas adipogenic differentiation is related to an increase in expression 
of A1 and A2A receptors (Gharibi et al., 2011, 2012). In addition, signalling via P1 receptors has an 
established role in white adipocytes. Adenosine is known to have an anti-lipolytic effect (Fredholm 
et al., 1977; Ohisalo, 1981; Johansson et al., 2008), which, as mentioned earlier in Section 1.7.2, is 
exerted by inhibiting the accumulation of intracellular cAMP. A1 receptor knockout mice display 
increased fat mass and impaired insulin sensitivity (Faulhaber-Walter et al., 2011), whereas mice 
overexpressing A1 receptors are protected from obesity-induced insulin resistance (Dong et al., 
2001).  
 
1.13 P2X receptors  
P2X receptors are ATP-sensitive gated ion-channels (Figure 1.6). There are seven P2X subunits, 
named P2X1-7. All seven subunits share a common basic structure that consists of intracellular N- 
and C-termini, two transmembrane domains and a large extracellular ectodomain (Dal Ben et al., 
2015). P2X receptors are trimeric receptors that are formed of either homomeric or heteromeric 
combinations of the seven P2X subunits (Surprenant and North, 2009; Evans, 2010). Upon 
interaction with ATP a conformational change occurs that facilitates the entry of cations, such as 
Na+, K+ and Ca2+, into the cells via lateral fenestrations (Kawate et al., 2011), thus initiating 
depolarisation of the cell and induction of downstream signalling pathways (Dal Ben et al., 2015). 
Some P2X receptors are also capable of allowing larger molecules through the cell membrane after 
prolonged periods of activation (North, 2002). Signalling via these receptors has already been 
implicated in processes ranging from cell proliferation and death to inflammation (Dal Ben et al. 
2015).  
 
Very few studies have investigated the role of P2X receptors in human adipose-tissue derived 
adipocyte progenitor cells. However, a study conducted by Zippel et al. (2012), identified that P2X5, 
P2X6 and P2X7 were all expressed at the protein level in AD-MSCs. Furthermore, ATP elicits a 
functional Ca2+ response, which is blocked by the generic P2 antagonist, suramin and non-specific 
concentrations (100 μM) of the selective P2X1 antagonist, NF279 (Zippel et al., 2012). Taken 
together, these data indicate that P2X receptors are expressed in AD-MSCs and these cells have a 
functional purinergic response. However, this study only used cells isolated from three donors, so 
there is currently a need for more comprehensive investigations into the role of P2X receptors in 
human AD-MSCs. However, additional functional studies in MSCs derived from other tissues, for 
example dental pulp, demonstrate a role for P2X7 receptors in cell proliferation and migration 
(Peng et al., 2016). Most studies conducted in cells from mice or bone marrow, suggest that P2X7 
receptors are central for driving osteogenesis and suppressing adipogenesis (Noronha-Matos et al., 
2014; Li et al., 2015). However, a study using human AD-MSCs suggests P2X7 receptor expression 
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is actually downregulated during osteogenesis in human AD-MSCs. Instead, there is an upregulation 
of P2X6 receptor expression during adipogenesis and a downregulation of expression of the 
receptor during osteogenesis (Zippel et al., 2012). Both findings correlate well with previous data 
that suggests ATP treatment increases mouse preadipocyte responsiveness to adipogenic hormone 
stimulation (Omatsu-Kanbe et al., 2006).  
 
Like AD-MSCs, very little is currently known about the role of P2X receptors in human adipocytes. 
However, expression of P2X3-7 mRNA has been detected in human adipocytes (Zippel et al., 2012) 
and electrophysiological evidence of ATP-evoked responses in white adipocytes isolated from rats 
(Lee and Pappone, 1997) suggests that there are functional purinergic receptors present in white 
adipocytes. Studies investigating the physiological roles of P2X receptors in white adipocytes have 
focused on P2X7 receptors. P2X7 receptor activity appears to mediate inflammatory responses 
within adipose tissue (Yu and Jin, 2010). Similar findings have been determined in humans where 
activation of P2X7 receptors leads to enhanced release of inflammatory cytokines, IL-6 and TNFα, 
and acute phase reactants, such as plasminogen activator inhibitor-1 (PAI-I). These effects are 
sensitive to antagonism of P2X7 receptors and/or gene silencing (Madec et al., 2011). However, the 
P2X7 knockout mouse appears to be heavier and display ectopic lipid deposition, which suggests 
P2X7 activity may also protect against adipose tissue dysfunction (Beaucage et al., 2014). 
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Figure 1.6 Schematic diagram of P2X and P2Y receptors, including downstream signalling 
pathways. Activation of ionotropic P2X receptors initiates a conformational change in the receptor 
which enables the opening of lateral fenestrations to allow entry of calcium (Ca2+) and sodium (Na+) 
ions, whereas activation of metabotropic P2Y receptors leads to different downstream effects 
depending on which G-protein the receptor is coupled to. P2Y1, P2Y2, P2Y4 and P2Y6 are all primarily 
coupled to Gq proteins, thus activation of these receptors activates phospholipase C (PLC), which 
generates diacylglycerol (DAG) and inositol triphosphate (IP3). IP3 then binds to receptors on the 
surface of the endoplasmic reticulum (ER) to initiate release of Ca2+ from the ER into the cytosol.  
P2Y11 receptors are Gs-coupled, thus activation of P2Y11 stimulates adenylate cyclase (AC) and leads 
to an accumulation of intracellular cyclic AMP (cAMP). Finally, P2Y12, P2Y13 and P2Y14 are Gi-coupled 
receptors, thus their activation leads to inhibition of AC and prevents accumulation of cAMP.
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1.14 P2Y receptors  
The second major class of P2 receptors are the P2Y receptors (Figure 1.6), which are metabotropic 
receptors. P2Y receptors, like P1 and P2X receptors, are widely distributed throughout the body 
and are implicated a huge variety of cellular processes, such as platelet aggregation, inflammation 
and epithelial cell hydration (Boeynaems et al., 2012). Unlike other class A GPCRs, P2Y receptors 
display limited sequence homology, which may explain the subtype variation in agonist preference 
and G protein coupling (Conroy et al., 2016) (Table 1.3). However, coupled with phylogenetic 
information, the sequence homology between the receptor subtypes is sufficient to categorise the 
eight members of this family of receptors into two groups: P2Y1-like or P2Y12-like receptors. P2Y1, 
P2Y2, P2Y4, P2Y6 and P2Y11 are all Gαq/11-coupled receptors and consequently activate phospholipase 
C-β, whereas P2Y12, P2Y13 and P2Y14 are Gαi/o-coupled receptors which inhibit adenylate cyclase and 
regulate ion channels (Yegutkin 2008) (Figure 1.6 and Table 1.3). P2Y11 receptors can also couple to 
Gs proteins, which means they can activate either adenylate cyclase or phospholipase C-β. In 
addition, P2Y2 and P2Y4 receptors can couple to both Gq and Gi proteins (Erb and Weisman, 2012).  
 
 
 
Table 1.3 P2Y receptor agonist preferences and G-protein coupling. Table adapted from (Jacobson 
et al., 2012).  
Receptor subtype Preferred agonists (pEC50, human) G-protein coupling 
P2Y1 ADP (5.90) Gq 
P2Y2 ATP (7.07) = UTP (8.10) Gq, Gi 
P2Y4 UTP (5.60) Gq, Gi 
P2Y6 UDP (6.52) Gq 
P2Y11 ATP (4.77) Gq, Gs 
P2Y12 ADP (7.22) Gi 
P2Y13 ADP (7.94) Gi 
P2Y14 UDP (6.80), UDP-glucose (6.45) Gi 
 
 
 
Unlike P2X receptors, which are exclusively activated by ATP, both purine and pyrimidine 
nucleotides are capable of activating P2Y receptors. Although each subtype displays their own 
agonist preference (Table 1.3). In brief, P2Y1, P2Y12, and P2Y13 receptors are all preferentially 
activated by ADP, P2Y2 and P2Y4 are both UTP receptors, while P2Y6 and P2Y14 receptors are 
activated by UDP and P2Y2 and P2Y11 are ATP receptors (Boeynaems et al. 2012). P2Y14 is also a 
receptor for UDP-glucose and other nucleotide sugars. Like other GPCRs, P2Y receptors share a 
basic general structure that consists of an extracellular N-terminus, seven transmembrane domains 
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that contains the ligand binding pocket, three intracellular loops that enable G-protein coupling and 
an intracellular C-terminus (Erb et al., 2012).  
 
Gene expression analysis indicates that all eight P2Y receptor subtypes are expressed in primary 
human AD-MSCs and white adipocytes (Zippel et al., 2012). The literature regarding the role of P2 
receptor mediated signalling in human AD-MSCs and mature adipocytes is limited, with the vast 
majority of the data surrounding these cell two types being derived from rodent models and/or 
bone marrow derived (BM) MSCs. However, studies indicate that P2Y1, P2Y2, P2Y4 and P2Y11 may 
positively regulate adipogenesis in BM- or AD-MSCs (Kawano et al., 2006; Zippel et al., 2012; 
Ciciarello et al., 2013; Li et al., 2015). In addition, inhibition of Gi-signalling pathways with pertussis 
toxin (Katada et al., 1983) prevents ATP-induced increases in PPARγ, a major transcription factor 
involved in adipogenesis (Ciciarello et al., 2013). It is possible that these Gi-mediated effects are 
achieved via P2Y13 receptor activation, as data from P2Y13 knockout mouse models indicate that 
BM-MSCs isolated from these mice display earlier expression of adipogenic markers, faster lipid 
droplet formation and augmented numbers of adipocytes within the bone marrow, while also 
demonstrating a decrease in the development of osteogenic markers in the presence of osteogenic 
stimuli (Biver et al., 2013). In addition, P2Y6 receptors have been shown to promote osteogenesis 
in BM-MSCs (Noronha-Matos et al., 2012) and this receptor has also been implicated in increasing 
IL-6 expression (Satrawaha et al., 2011). It has been suggested that IL-6 is important for maintaining 
the immunoprivilege stasis of MSCs (Li et al., 2013), so if P2Y6 receptors are involved in IL-6 
secretion, P2Y6 receptors may be a valuable target for prolonging MSC viability for therapeutic use. 
However much more additional work is required to clarify both the molecular mechanism and 
functional role of P2Y6 receptor activation in these cells.   
 
Currently there are very few studies that have investigated the molecular basis of the role of P2Y 
receptors in primary human adipocytes, but data gathered from rodent models suggests P2Y 
receptors may play a role in key adipocyte functions. For example, activation of P2Y6 receptors has 
been shown to enhance GLUT4 translocation to the membrane and increase glucose uptake in 
primary mouse white adipocytes. This effect was reversed by selective inhibition of P2Y6 receptors 
(Balasubramanian et al., 2014). In addition, selective inhibition of P2Y1 receptors or deleting P2Y1 
receptor expression leads to a decrease in leptin production (Laplante et al., 2010), whereas P2Y4 
knockout mice display augmented secretion of adiponectin (Lemaire et al., 2017).  
 
Despite the limited scope of the research into the role of P2 receptors in human adipocytes and 
their progenitor cells, progress has been made in targeting P2 receptor-mediated signalling 
pathways in other cell types. Purinergic receptors are attractive drug targets and success has 
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already been attained in disrupting P2Y receptor activity for therapeutic gain (as discussed in 
further in Section 1.14.1 and 1.14.2).  
 
1.14.1 P2Y1 and P2Y12 receptors 
The crystal structures of both P2Y1 and P2Y12 receptors have been published and this revealed that 
P2Y1 has two distinct agonist binding sites (Zhang, Gao, et al., 2015), whereas P2Y12 requires large 
scale receptor rearrangement to enable agonist binding (Zhang et al., 2014). Both receptors are 
preferentially activated by ADP, but as mentioned in the previous Section, P2Y1 receptors are Gq 
coupled, whereas P2Y12 receptors are Gi-coupled and thus they activate distinct downstream 
signalling pathways. Both P2Y1 and P2Y12 receptors play important roles in platelet aggregation 
(Jagroop et al., 2003). Activation of P2Y1 receptors leads to a change in platelet shape and an 
initiation of platelet aggregation (Jin et al., 1998), and then P2Y12 receptor activity sustains platelet 
aggregation post-initiation (Dorsam and Kunapuli, 2004). Anti-thrombotic drugs are currently the 
only widely approved therapeutic drug that selectively targets P2Y receptors. Despite the fact that 
inhibition of P2Y1 receptors significantly decreases platelet aggregation and effectively decreases 
arterial thrombosis (Fabre et al., 1999; Léon et al., 2001; Lenain et al., 2003), all available 
therapeutic anti-aggregation treatments specifically target P2Y12 receptors (Conroy et al., 2016). 
Selective antagonists of P2Y12 receptors, such as Ticagrelor, are routinely used clinically for the 
prevention of atherothrombotic events in acute coronary syndrome patients (Wallentin et al., 
2009).  
Although, there are currently no reports indicating P2Y12 receptors may be involved in adipocyte 
biology, studies using P2Y1 knockout mice have identified that P2Y1 is involved in leptin secretion 
(Laplante et al., 2010). Upon comparison to wild type mice, preadipocytes and adipocytes isolated 
from knockout mice secreted less leptin when agonised with ADP despite similarities in mature cell 
size, lipid content and lipolytic activity between the two model animals. The suppression of leptin 
secretion could also be mimicked in wildtype cells by incubating them with MRS2500 (a selective 
P2Y1 antagonist) for 48 hours. A decrease in the plasma concentration of leptin was also noted 
within the knockout models, but this decrease was overcome when these mice were put on a high 
fat diet suggesting that when the demand for leptin increases the effects of P2Y1 receptor mediated 
secretion of leptin are overcome by other compensatory mechanisms. An elevation in cytoplasmic 
calcium was seen in response to ADP even in the P2Y1 knockout mice, suggesting the contribution 
of other P2 receptors (Laplante et al., 2010). 
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1.14.2 P2Y2 receptors 
P2Y2 receptors are equipotently activated by both ATP and UTP, and they are able to couple to Gq, 
Go and G12 proteins, although Go and G12-coupling requires interaction with αv integrins (Bagchi et 
al., 2005; Liao et al., 2007). An agonist for P2Y2, Diquafosol, has been approved for therapeutic use 
as an ophthalmic solution under the trade name Diquas™ (Santen Pharmaceutical Co, Ltd, Osaka, 
Japan) by the regulatory bodies in Japan and Korea for the clinical treatment of dry eye. However, 
DiquasTM has not been approved for use in other countries (Lau et al., 2014). In addition, it has been 
identified that activation of P2Y2 receptors increases the secretion of Cl-, water and mucin into the 
trachea in ex vivo models (Yerxa et al., 2002), which suggests that P2Y2 receptors could be a 
potential drug target in cystic fibrosis patients, who exhibit faulty Cl- secretion. Despite promising 
results in rodent models (Yerxa et al., 2002) and in Phase II trials (Deterding et al., 2005), the results 
from early Phase III clinical trials and longer term studies did not display statistically significant 
improvements in cystic fibrosis patients (Accurso et al., 2011; Ratjen et al., 2012) and consequently 
this drug was not pursued further. 
It has recently been suggested that the P2Y2 receptor may play a role in driving BM-MSC 
adipogenesis while suppressing osteogenesis, without effecting the rate of cell proliferation (Li et 
al., 2015). It may be that P2Y2 receptors are involved in a similar role in AD-MSCs. If this was the 
case, this could provide an opportunity to develop pharmacological tools to target P2Y2 receptors 
specifically to drive MSCs towards/away from an adipogenic phenotype in vivo, thus providing a 
route to control the number of new adipocytes present in adipose tissue and potentially regulate 
weight gain. P2Y2 receptor-mediated signalling has also been implicated in the proliferation of 
keratinocytes (Dixon et al., 1999) and carcinoma cells (Xie et al., 2014; Qiu et al., 2018), as well as 
neutrophil migration (Chen et al., 2006). Both cell proliferation and migration are key functions of 
MSCs, so investigating whether P2Y2 receptors play a role in either of these functions in human AD-
MSCs would be of significant clinical and physiological interest.  
P2Y2 is also a potentially interesting target to investigate within white adipocytes as well, as P2Y2 
knockout mice are resistant to diet-induced obesity and display improved glucose tolerance. These 
effects have been attributed to enhanced metabolic rates in P2Y2 knockout mouse models (Kishore 
et al., 2016). As adipocytes play a vital role in systemic metabolism, this could be indicative of a role 
for P2Y2 receptors in white adipocytes.  
1.15 Project aims  
The global rise in the incidence of obesity has initiated a surge in research into adipose biology to 
enable attempts to identify novel drug targets that can be of use in the fight against obesity. 
Purinergic receptors represent a very attractive drug target and they have been successfully 
targeted in other cell types for therapeutic gain. However, purinergic signalling in adipose tissue 
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remains a largely unexplored area of research. Through this project, I hope to identify the molecular 
basis of nucleotide-evoked responses in primary human adipose derived mesenchymal stromal cells 
(Chapter 3) and in in vitro differentiated adipocytes (Chapter 4) and then attempt to uncover the 
physiological role of these receptors (Chapter 5). Very little is currently known about the role of P2 
receptors in both cell types and it is hoped that this study will provide a solid foundation to begin 
to unpick the complex role of purinergic signalling in cells within human adipose tissue.    
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Chapter 2: Materials and Methods 
2.1 Materials 
Chemical reagents used throughout this study were purchased from Sigma Aldrich. In instances 
where materials from other suppliers were used, the company’s name is provided within the text. 
A list of commonly used products is provided in the following passage (2.1.1) and in Tables 2.1, 2.2 
and 2.3.  
2.1.1 Cell culture 
Unless otherwise stated, this study was conducted exclusively using primary human adipose-
derived mesenchymal stromal cells (MSCs) and primary human in vitro differentiated adipocytes. 
All cells were maintained in uncoated tissue culture flasks or multi-well plates (Thermo Fisher 
Scientific) in a humidified incubator at 37 oC in the presence of 5% CO2. Both cell types were 
maintained in Dulbecco’s Modified Eagles medium (DMEM) containing 4.5 g/L glucose, 0.6 g/L L-
glutamine and 0.1 g/L sodium pyruvate (Lonza), supplemented with 10% (v/v) foetal bovine serum 
(FBS) (GE Healthcare), 50 IU/ml penicillin and 50 µg/ml streptomycin (Gibco). This combination will 
be referred to as culture media throughout this thesis. Any subsequent reference to DMEM 
henceforth will denote to DMEM containing 4.5 g/L glucose, L-glutamine and sodium pyruvate 
(Lonza).  
Table 2.1 Nucleotides and subtype-selective agonists. 
Agonist Target Supplier Purity Concentration Reference 
ATP P2X, P2Y2, 
P2Y11 
Abcam > 99% 0.01 – 300 μM Burnstock, 2007 
ADP P2Y1, P2Y12, 
P2Y13 
Sigma Aldrich ≥ 95% 0.01 – 300 μM Chhatriwala et al., 
2004 
MRS2365 P2Y1 Tocris 99.6% 0.1 μM Bourdon et al., 2006 
UTP P2Y2, P2Y4 Abcam > 98% 0.01 – 300 μM Burnstock, 2007 
UDP P2Y6, P2Y14 Sigma Aldrich > 96% 0.01 – 300 μM Burnstock, 2007 
UDP-
glucose 
P2Y14 Abcam > 98% 0.01 – 600 μM Abbracchio et al., 
2003 
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Table 2.2 Subtype-selective purinergic receptor antagonists.  
Antagonists Target Supplier Concentration Vehicle Reference 
PSB-12062 P2X4 Tocris 0.003 – 30 μM DMSO Hernandez-Olmos et al., 2012 
A438079 P2X7 Tocris 0.003 – 10 μM DMSO Nelson et al., 2006 
MRS2500 P2Y1 Tocris 0.0001 – 1 μM Water Kim et al., 2003 
AR-
C118925XX 
P2Y2 Tocris 0.003 – 30 μM DMSO Meghani, 2002; Rafehi et al., 
2017 
MRS2578 P2Y6 Tocris 0.003 – 10 μM DMSO Mamedova et al., 2004 
NF340 P2Y11 Tocris 0.003 – 10 μM Water Meis et al., 2010 
PSB-0739 P2Y12 Tocris 0.003 – 10 μM Water Hoffmann et al., 2009 
Ticagrelor P2Y12 Cayman 0.3 μM DMSO Zech et al., 2012 
MRS2211 P2Y13 Tocris 0.003 – 10 μM Water Kim et al., 2005 
DMSO Dimethylsulfoxide 
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Table 2.3 Other inhibitors and enzymes. 
Antagonists Target Supplier Concentrat
ion 
Vehicle Reference 
Apyrase Nucleotides Sigma Aldrich 0.5-4 U/ml Water Kettlun et al., 1982 
BRL50481 PDE7 Sigma Aldrich 1 μM DMSO Smith et al., 2004 
Cilostramide PDE3 Sigma Aldrich 1 μM DMSO Hidaka et al., 1979 
IBMX PDE Sigma Aldrich 10 μM DMSO Morgan et al., 1993 
Pertussis toxin Gi, Go, Gt Tocris 100 ng/ml Water Carbonetti, 2010 
PF-05180999 PDE2 Sigma Aldrich 10 μM DMSO Helal et al., 2012 
Rolipram PDE4 Sigma Aldrich 10 μM DMSO MacKenzie & 
Houslay, 2000 
SQ22,536 AC Tocris 1 μM DMSO Emery et al., 2013 
Thapsigargin SERCA Santa cruz 3 μM DMSO Lytton et al., 1991 
U-73122 PLC Santa cruz 10 μM DMSO Bleasdale & Fisher, 
1993 
Vinpocetine PDE1 Sigma Aldrich 10 μM DMSO Dunkern & 
Hatzelmann, 2007 
AC Adenylate cyclase; DMSO Dimethylsulfoxide; IBMX 2-isobutyl-1-methylxanthine; PDE 
Phosphodiesterase; PLC Phospholipase C; SERCA Sarcoendoplasmic reticulum calcium transport 
ATPase 
 
2.2 Tissue donation  
Ethical approval for this study was obtained from the London-Stanmore Research Ethics Committee 
(152093) and the Research and Development department at the Norfolk and Norwich University 
Hospital (NNUH) (2014EC03L). This permitted the recruitment of 51 healthy female volunteers 
undergoing elective delayed deep inferior epigastric perforator (DIEP) flap operations at the NNUH. 
Informed consent was obtained from all volunteers prior to their participation in the study. All 
recruited patients were prior breast cancer sufferers who required mastectomies as part of the 
cancer treatment. A DIEP flap operation involves the removal of subcutaneous abdominal tissue to 
allow autologous tissue breast reconstruction (Hamdi and Rebecca, 2006). The nature of this 
operation means that there is often surplus subcutaneous abdominal adipose tissue that can be 
utilised for research purposes.   
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All volunteers were screened to exclude diabetics, patients with current infections or active 
malignancy and patients on anti-inflammatory medication. Where available, additional information 
regarding the donors’ age, weight, body mass index (BMI), blood pressure and whether they were 
pre- or post-menopausal was also noted to further characterise the recruited population. All 
average data is presented as mean ± SEM. Recruited donors had an average age of 56 ± 1.4 years 
(N=48, range 38-75 years), average weight of 73.1 ± 1.3 kg (N=38, range 59-89 kg) and mean body 
mass index (BMI) value of 27.5 ± 0.5 kg/m2 (N=37, range 23-35 kg/m2). The average BMI value 
includes nine donors with a healthy BMI of between 18 and 24, 21 overweight donors (BMI 25-29 
kg/m2) and seven obese donors (BMI 30-39 kg/m2). The BMI data was not available for 14 donors. 
Donors were largely normotensive with an average mean arterial pressure of 98.5 ± 1.6 mmHg 
(N=46, range 76-132 mmHg). Information about the donors’ menopausal status was only available 
for 21 of the recruited tissue donors, of which only four were pre-menopausal.  
 
2.3 Primary human mesenchymal stromal cell (MSC) isolation 
Fresh human subcutaneous abdominal adipose tissue was transported immediately from the 
operating theatre to the laboratory and the cell isolation protocol was commenced without delay. 
The tissue samples were dissected to remove blood vessels, fibrous tissue and skin. The samples 
were then further minced and enzymatically digested with collagenase from Clostridium 
histolyticum (Sigma Aldrich) and bovine pancreatic DNase I (Biomatik) for 30 minutes at 37 oC with 
regular mixing by inversion. The digested tissue samples were then passed through a 70 μm cell 
strainer and centrifuged for 5 minutes at 450 x g, which separated the sample into a floating fraction 
containing mature adipocytes and a pellet containing multipotent mesenchymal stromal cells 
(MSCs) and other cell types. The mature adipocytes were discarded and the MSC fraction was 
treated with a red cell lysis buffer, washed and then resuspended in fresh culture media. The cells 
were then left in a T175 flask overnight in a humidified incubator at 37 oC with 5% CO2. The following 
day, the cells were washed twice with phosphate-buffered saline (PBS) (Lonza) to remove any non-
adherent cells or debris, and then left in fresh culture media until the cells were close to confluence, 
at which point they were detached from the bottom of the flask using tryspin EDTA (Lonza) and 
seeded for experimental use. For experimentation, isolated MSCs were plated at an initial seeding 
density of 2x104 cells/well in 96-well plates, unless otherwise indicated. The cells were then 
maintained in a humidified environment at 37 oC with 5% CO2 for 48 hours and either directly used 
for experimentation or allowed to grow to hyper-confluence over the next two days and then 
differentiated (Section 2.6). MSCs were passaged a maximum of eight times for direct experimental 
use.   
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2.4 Cryopreservation and thawing of MSCs 
Early passage, most commonly the first passage post-cell isolation, MSCs that were not required for 
immediate experimental use were stored in liquid nitrogen for future use. This was achieved by 
detaching MSCs from their culture flasks using trypsin ETDA and then centrifuging the cells at 450 
x g for 5 minutes. The MSC pellet was then resuspended in cryopreservation media, which consisted 
of 45% (v/v) DMEM, 45% (v/v) FBS and 10% (v/v) DMSO. The cells were then immediately 
transferred to cryovials at a density of 1x106 cells/vial. The cryovials were then placed in a Mr 
FrostyTM freezing container (Thermo Fisher Scientific) containing isopropanol to slow the cooling 
rate to 1 oC/min while the cells were stored at -80 oC overnight. The following day, the cells were 
transferred to a liquid nitrogen tank (-196 oC) for longer term storage.    
 
When these cells were required for experimental use, they were removed from the liquid nitrogen 
and rapidly defrosted in a 37 oC waterbath. The defrosted cells were then immediately diluted with 
culture media and centrifuged at 450 x g for 5 minutes. Next, the cells were washed once, 
resuspended in fresh culture media and placed in a culture flask overnight at 37 oC in 5% CO2. The 
following morning the culture media was removed and the cells were washed with PBS. Fresh 
culture media was then added and the cells were incubated at 37 oC until they were nearly 
confluent, at which point, they were passaged and seeded for experimental use.  
 
2.5 Cell surface marker characterisation of MSCs by flow cytometry 
Since the discovery of the existence of MSCs, there have been numerous groups working in this 
field, with different groups adopting different methods of characterising these cells. In an attempt 
to standardise the characterisation of MSCs, the International Society for Cellular Therapy proposed 
a set of minimum criteria for defining human MSCs (Dominici et al., 2006): 
1. MSCs must be plastic-adherent under standard culture conditions.  
2. MSCs must be able to differentiate to adipocytes, osteoblasts and chondroblasts in vitro. 
3. MSCs must express CD73, CD90 and CD105, but lack CD45, CD34, CD14 or CD11b, CD79α 
or CD19 and HLA-DR surface molecules.  
All the cells used throughout this study were plastic-adherent and the differentiation capacity of 
these cells was tested in Section 2.6. To address the third criteria, the cell surface marker expression 
profile was assessed by flow cytometry using an adapted version of a panel of markers outlined by 
The International Society for Cellular Therapy. To do this, MSCs were trypsinised and centrifuged at 
450 x g for 5 minutes. The cells were then resuspended in PBS at a density of 2x106 cells/ml and 
100 μl of cells was placed in individual Eppendorf tubes for each marker and control required. The 
cells were then incubated with 5 μg/ml of human BD Fc blockTM (BD Pharmingen) for 10 minutes. 
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Next, PE-conjugated antibodies (1:33) were added to detect cell surface expression of CD14, CD45, 
CD73, CD90 and CD105 (Table 2.4) and the cells were incubated in the dark for a further 30 minutes. 
An isotype control (1:33) and an unstained control was also run alongside these markers. The cells 
were then washed once with PBS and resuspended in 200 μl of fresh PBS. Samples were analysed 
using a Beckman Coulter CytoFLEX flow cytometer. Living cells were gated according to their 
forward and side scatter and histograms were plotted to compare the fluorescence signal for each 
marker versus the isotype control using CytExpert 1.2.11 software (Beckman Coulter). A total of 
10,000 events was collected for each marker and control. Flow cytometry was performed on cells 
isolated from six independent donors. MSCs from all six donors were strongly positive for the 
expected cell surface markers CD73 (90.2 ± 2.5% positivity), CD90 (89.8 ± 2.9% positivity) and CD105 
(83.7 ± 3.3% positivity), while the expression of CD14 (10.0 ± 4.0% positivity) and CD45 (11.8 ± 4.3% 
positivity) was low (Figure 2.1). 
 
 
Table 2.4 Phycoerythrin-conjugated anti-human primary antibodies for flow cytometry. 
Target Manufacturer Product code Host species 
IgG1 κ isotype control Biolegend 400113 Mouse 
CD14 Biolegend 367103 Mouse 
CD45 Biolegend 368509 Mouse 
CD73 Biolegend 344003 Mouse 
CD90 Biolegend 238109 Mouse 
CD105 Biolegend 323205 Mouse 
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Figure 2.1 Phenotypic characterisation of human adipose-derived mesenchymal stromal cells by 
flow cytometry. Differential Interference Contrast microscopy of mesenchymal stromal cells in 
culture. The scale bar represents 200 μm. Flow cytometric analysis of cell surface marker expression 
in human mesenchymal stromal cells of known positive (CD73, CD90, CD105) and negative (CD14 
and CD45) markers. Grey histogram indicates the isotype control (PE-conjugated anti-IgG1) and the 
black histogram shows the surface antigen expression level. This experiment was conducted on 
cells from six independent donors, but the data shown here is for one representative donor and 
the percentages displayed correspond specifically to this one donor.  
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2.6 Differentiation of primary human MSCs to adipocytes or osteoblasts  
MSCs extracted from human adipose tissue can be induced to differentiate in vitro by incubating 
the cells with specific hormone cocktails for two weeks. The ability of MSCs to differentiate 
diminishes when the cells have undergone multiple passages (Chen et al., 2012; Lee et al., 2014), 
so in this study only early passage MSCs (P1-4) were differentiated. Freshly isolated mature 
adipocytes were not used, because they are technically challenging to work with, as they cannot be 
maintained in culture for extended periods and they are non-adherent. In this study, as is common 
practice in the field, in vitro differentiated adipocytes were utilised.   
MSCs were seeded onto plastic or glass-bottom plates/flasks and grown to hyper-confluency by 
maintaining the cells in a humidified incubator at 37 oC for four days. The culture media was then 
removed and replaced with adipogenic or osteogenic media. Adipogenic media consists of culture 
media supplemented with insulin, dexamethasone, indomethacin and 3-isobutyl-1-methylxanthine 
(IBMX), whereas osteogenic media consisted of culture media supplemented with sodium β-
glycerophosphate, L-ascorbic acid-2-phosphate and dexamethasone (Table 2.5). In both cases, the 
cells were left in the presence of the adipogenic or osteogenic media for two weeks. During this 
period the media was replaced every four days. After two weeks in the presence of adipogenic or 
osteogenic media, the media was removed and exchanged to culture media for three days to allow 
the cells to habituate. After which, the cells were ready for experimentation. In all instances where 
in vitro differentiated adipocytes (or osteoblasts) are mentioned in this study, they are cells that 
have undergone the full differentiation and habituation protocol. Only populations of cells that 
displayed >90% differentiation were deemed adequate for experimental use. There are clear 
morphological changes that occur that make it easy to distinguish between non-differentiated and 
mature cells using a microscope, such as the formation of lipid droplets within adipocytes. 
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Table 2.5 Components of adipogenic and osteogenic differentiation media.  
Components Purpose Concentration 
(μM) 
Reference 
Adipogenic media:   
Dexamethasone Activates transcription of adipocyte-
specific genes 
1 Scott et al., 2011 
IBMX Non-selective PDE inhibitor 500 Scott et al., 2011 
Indomethacin Upregulate C/EBPβ and PPARγ2 
expression 
200 Styner et al., 2010 
Insulin Mimics IGF-1, the main adipogenic 
inducer, by interacting with the IGF-
1 receptor 
0.1 Petersen et al., 
2008 
Osteogenic media:   
Dexamethasone Activates transcription of 
osteoblast-specific genes and 
increase alkaline phosphatase 
activity 
0.01 Lee et al., 2009 
L-ascorbic acid-2-
phosphate 
Increased secretion of collagen type 
I/ increased Col1/α2β1 integrin-
mediated intracellular signalling 
172.7 Langenbach and 
Handschel, 2013 
Sodium β-
glycerophosphate 
Source of phosphate 10,000 Langenbach and 
Handschel, 2013 
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2.6.1 Oil red O staining of mature adipocytes 
The cells were washed with PBS once and then fixed with 4% paraformaldehyde (PFA) for 5 minutes 
at room temperature. The cells were then washed once with distilled water and incubated with 
60% isopropanol. The isopropanol was removed and replaced with oil red O dye. A working solution 
of oil red O dye was generated less than two hours before initiating the staining protocol. This was 
achieved by mixing 30 ml of 3 mg/ml oil red O (dissolved in 99% (v/v) isopropanol) with 20 ml 
deionised water. The diluted oil red O was passed through filter paper to remove any clumps of 
dye. The cells were incubated with the dye for 5 minutes at room temperature. The dye was then 
removed, and the cells were washed with PBS and visualised using an Olympus CKX41 inverted 
microscope. Oil red O is a neutral lipid stain (Lillie and Ashburn, 1943), which provides an effective 
method of identifying adipocytes via staining lipid droplets within the cells. MSCs were 
differentiated in the presence of adipogenic media or incubated with culture media (control cells) 
and stained with oil red O to confirm the presence of triglyceride-filled lipid droplets within the 
mature adipocytes that were absent from the non-differentiated control cells (Figure 2.2).  
2.6.2 Alizarin red S staining of mature osteoblasts 
The cells were washed with PBS lacking Ca2+ and Mg2+ and then fixed with 4% PFA for 15 minutes at 
room temperature. Then the cells were washed with deionised water once and incubated with 
alizarin red S dye (pH 4.1) for 45 minutes at room temperature in the dark. The dye was then 
removed and the cells were washed four times with deionised water and imaged using an Olympus 
CKX41 inverted microscope. Red staining indicated the presence of calcium deposition and 
mineralisation. MSCs were differentiated with osteogenic media to osteoblasts and stained with 
alizarin red S to detect the presence of calcium deposits in mature osteoblasts, which were not 
detected in non-differentiated control cells (Figure 2.2).  
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Figure 2.2 Primary human adipose-derived mesenchymal stromal cells can be induced to 
differentiate to adipocytes and osteoblasts. Cells were cultured in the presence of culture media 
(controls, left column), adipogenic media (top right) or osteogenic media (bottom right) for two 
weeks and then the cells shown in the top row (MSCs and adipocytes) were stained with Oil Red O 
and the cells in the bottom row (MSCs and osteoblasts) were stained with Alizarin Red S. Images 
shown are for one representative donor, but cells from three independent donors were treated in 
the same manner to produce nearly identical results. Scale bar represents 150 μm.
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2.7 Total RNA extraction 
Up to 1x106 cells were lysed with 1 ml of TRI-reagent and transferred into an Eppendorf tube. The 
lysed cells were then treated with 100 μl 1-bromo-3-chloropropane and centrifuged to partition 
the sample. The top aqueous phase was then carefully transferred into a fresh tube and the RNA 
was precipitated with 100% isopropanol and washed with ice-cold 75% (v/v) ethanol. The RNA was 
then centrifuged at 12,000 x g for 10 minutes. The supernatant was removed and the RNA pellet 
was air dried. The resultant RNA was then resuspended in molecular grade water and heated to    
65 oC for 5 minutes to ensure the RNA was fully dissolved. Potential genomic DNA contamination 
was removed using a DNA-freeTM DNA removal kit (Thermo Fisher Scientific) as per the 
manufacturer’s instructions. In brief, the RNA was incubated with 0.1 volume of 10x DNase I buffer 
and 1 μl of rDNase I for 30 minutes at 37 oC. Then 0.1 volume of DNase inactivation reagent was 
added and the mixture was incubated at room temperature for two minutes with regular mixture. 
Finally, the mixture was centrifuged at 10,000 x g for 90 seconds and the RNA was transferred to a 
fresh Eppendorf tube, taking extra care not to disturb the waste pellet at the bottom of the tube. 
The purity and quantity of RNA was assessed using a Nanodrop 2000 (Thermo Fisher Scientific). An 
absorbance ratio (260/280 nm) value of 2.0 was regarded as a pure RNA sample. RNA was stored 
at -80 oC until required.   
2.8 Complementary DNA (cDNA) synthesis 
Messenger RNA (mRNA) must be converted to complementary DNA (cDNA) by reverse 
transcriptase, to enable amplification via a polymerase chain reaction (PCR). To do this, 500 ng of 
RNA for each sample was primed with 100 ng random hexamer primers (Bioline) by heating the 
mixture to 70 oC for 10 minutes. Each sample was then incubated with 250 μM dNTPs (Bioline), 30 
U RNasin ribonuclease inhibitor (Promega), 0.01 M DTT, first strand buffer and 200 U Superscript III 
reverse transcriptase (RT) (Thermo Fisher Scientific) for 1 hour at 42 oC. A duplicate sample with no 
RT was run alongside to control for genomic DNA contamination. The reaction was terminated by 
heating the samples to 70 oC for 10 minutes. cDNA samples were then stored at -20 oC.  
2.9 Non-quantitative reverse transcription PCR (RT-PCR) 
RT-PCR was used to assess the mRNA expression of human P1 adenosine receptors, adenylate 
cyclase isoforms and to determine whether functional or non-functional P2X5 receptors were 
expressed.  
2.9.1 Primer design 
Primer sequences provided in Table 2.6 were either obtained from previously published sources or 
designed using the Primer Designing Tool on the National Center for Biotechnology Information 
(NCBI) website. The primer sequences for the human P2X5 receptor were acquired from Kotnis et 
al. (2010). These primers yield products of varying lengths: 461 bp represents the exon 10-
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containing functional P2X5 receptor, whereas the 395 bp product represents the exon 10-less non-
function receptor. All the primer sequences for human adenylate cyclase isoforms were obtained 
from Xu et al. (2001), excluding isoforms 4, 5 and 6, which were manually designed. For manual 
primer design, accession numbers for mRNA transcript sequences for each gene of interest (GOI) 
were identified using the Uniprot website. Primer pairs for each GOI were selected using the 
following criteria:  
1. Located within the coding DNA sequence of the GOI.  
2. Targets all variants of the GOI. 
3. Limited recognition of unintended genes.   
4. Spanning exon-exon junctions (where possible).  
5. Optimal melting temperature (Tm) of 60 oC. 
All primers were acquired from Thermo Fisher Scientific in a lyophilised form. The primers were 
reconstituted to 100 μM stocks with nuclease-free water, and subsequently diluted further to 10 
μM working solutions for experimental use. Both the 100 μM stocks and 10 μM working solutions 
were stored at -20 oC. Primer sequences for human P1 adenosine receptors were manually designed 
by a previous PhD student, Dr Hinnah Campwala.  
2.9.2 Polymerase chain reaction (PCR) 
cDNA or no RT control samples (1 μg) was mixed with 25 μl of ReadyMix™ Taq PCR Reaction Mix, 
0.2 μM forward primers, 0.2 μM reverse primers and water to achieve a total volume of 50 μl. This 
was done for each of the primer sequences disclosed in Table 2.6. The following PCR conditions 
were employed for each GOI: Initial denaturation at 94 oC for 1 minute, then 35 cycles of 94 oC for 
30 seconds, variable annealing conditions according to GOI and 72 oC for 1 minute to allow robust 
amplification of the cDNA, followed by 5 minutes at 72 oC for the final extension. The annealing 
conditions were 55 oC for 30 seconds for all primer sequences outlined in Table 2.6, excluding 
ADCY2, ADCY3, ADCY8 and ADCY9 which had an annealing temperature of 52 oC for 1 minute and 
ADCY7 which had an annealing temperature of 45 oC for 1 minute. These adjustments were made 
to gain optimum specific product amplification for each GOI. Commercially available human brain 
mRNA was transcribed to cDNA (according to the protocol outlined in Section 2.8) and run for each 
GOI as a positive control. The PCR products were stored at -20 oC until needed. 
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Table 2.6 Primer sequences for human P1 adenosine receptors (ADORA), human P2X5 receptor 
and human adenylate cyclase isoforms (ADCY).  
Gene Accession number Primer sequence (5’→3’) Product size 
(bp) 
ADORA1 NM_000674 F: GTGCGAGTTCGAGAAGGTCA 
R: GGATGCGGAAGGCATAGACA 
374 
ADORA2A NM_000675 F: CTACCGTATCCGCGAGTTCC 
R: GCTAAGGAGCTCCACGTCTG 
295 
ADORA2B NM_000676.2 F: CAGAACCCTGGGATGGAACC 
R: CAGCACAGGGCAAAAATCCC 
277 
ADORA3 NM_001081976 F: CTGGTGCCGAGGCTATTTCC 
R: CCTTGCGGACAACTTTGGGA 
302 
P2RX5 NM_001204520.1 F: CACTATTCTTTTAGCCGTCTGGAC 
R: TTCTGACTGCTGCTTCCACGCTTC 
395/461 
ADCY1 L05500 F: CAT GAC CTG CGA GGA CGA T 
R: ACA GGA GAC TGC GAA TCT GAA 
446 
ADCY2 X74210 F: GGG GCT GCG TTT CTC T 
R: CAG GAA CAC GGA ACA GGA TA 
369 
ADCY3 NM_004036 F: CAC GGG ACC CAG CAA T 
R: GCT CTA AGG CCA CCA TAG GTA 
263 
ADCY4 NM_139247.3 F: TCC AAG CTC CCA ATG TGT CC 
R: CTT GTC CAG AGG TGG CAT TT 
753 
ADCY5 U65473.1 F: TCT GGT CTA ACG ATG TCA CGC 
R: TCT TTC CGC TTC TGG GTG C 
202 
ADCY6 AB007882 F: GGC ATT GAT GAT TCC AGC AAA GAC 
R: TGC AGG GCC TTA GGG AAC AGA 
380 
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ADCY7 NM_001114.4 F: CCA GTC TGG ATG CAC AGG AG 
R: AGC CTC CCA TCA AAG AAC CG 
746 
ADCY8 NM_001115 F: CGG GAT TTG GAA CGC CTC TA 
R: CCG GTC TGA CAG GTA ACT GAT AA 
543 
ADCY9 NM_001116 F: CAC CGC AAA ATA CTT AGA TGA CG 
R: CCT TCT CCT GCA AGA TCT CAC AC 
497 
 
2.9.3 Agarose gel electrophoresis 
Agarose gel electrophoresis was utilised to separate DNA fragments according to their size (and 
charge). A 2% (w/v) agarose gel was prepared by dissolving 2 g of agarose (Melford Labs) in 100 ml 
of 1x Tris-acetate-EDTA (TAE) buffer (Thermo Fisher Scientific). This mixture was heated to ensure 
the agarose was fully dissolved and 4 μl ethidium bromide (final concentration 0.4 ug/ml) was 
added. Ethidium bromide intercalates with double stranded DNA and fluorescences under UV light, 
thus enabling visualisation of DNA fragments separated in an agarose gel. The agarose and ethidium 
bromide mixture was carefully poured into a gel mould containing a 15 well comb. Any bubbles 
were removed while the agarose was still molten and then the agarose was left to set for 30 minutes 
at room temperature. Meanwhile, the PCR products for each GOI, including the no RT controls, 
were mixed with 6x gel loading dye (New England Biolabs) at a ratio of 6:1 (total volume 20 μl). 
Once the gel had set, the comb was removed and the gel was placed in an electrophoresis tank 
containing TAE buffer. More TAE was added until the wells in the gel were filled. Next, the PCR 
products were carefully loaded into each well. At least one well on each gel was loaded with a       
100 bp ladder (New England Biolabs) to enable deduction of the DNA fragment lengths. When all 
the samples (and ladder) were loaded, electrophoresis was initiated by passing an electrical current 
at 90 volts through the gel for 90 minutes. DNA is negatively charged and therefore moves towards 
the anode, with larger fragments travelling at a slower rate than smaller fragments. When the 
electrophoresis was complete, the DNA fragments were visualised under a UV lamp using a 
ChemiDoc™ XRS visualizer (Bio-Rad).   
2.10 Quantitative real time-PCR (qRT-PCR) 
Quantitative RT-PCR was used to characterise the expression of P2 purinergic receptors in human 
MSCs and in vitro differentiated adipocytes. This enabled comparison of relative receptor 
expression in the two cell types, as well as validation of RNA interference (RNAi) techniques. In qRT-
PCR, the primers are tagged with a fluorescent probe to enable real time monitoring of the 
amplification process.  
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cDNA or no RT control samples (10 ng) were mixed with 10 μl TaqManTM fast universal PCR master 
mix (Applied Biosystems) and 1 μl 20x TaqManTM gene expression assay primers and probes 
(Applied Biosystems) for each GOI (Table 2.7) in a total volume of 20 μl. No template control wells 
were also prepared by substituting cDNA for nuclease-free water to control for DNA contamination 
of the reagents. Each sample and control was then amplified in a sealed MicroAmp fast optical 96-
well reaction plate (Applied Biosystems) using a TaqManTM 7500 PCR cycler (Applied Biosystems). 
The following protocol was utilised to amplify DNA: 20 seconds at 50 oC then 10 minutes at 95 oC 
(initial denaturation), followed by 40 cycles of denaturing the DNA double helix by heating the 
samples to 95 oC for 15 seconds and cooling to 60 oC for 1 minute to allow primer annealing and 
DNA amplification.  
All TaqManTM minor groove binder (MGB) probes are tagged with an FAMTM reporter dye at the 5’ 
end and a non-fluorescent quencher (NFQ) at the 3’ end. When the primer-probe complex is intact, 
the NFQ ensures that the fluorescence emitted by FAM is quenched due to fluorescence resonance 
energy transfer (FRET). However, when the primers anneal successful to the DNA and Taq 
polymerase begins to create new DNA fragments, the exonuclease activity of Taq polymerase leads 
to a permanent physical separation of the reporter dye and the NFQ, which prevents the quenching 
effect and allows a fluorescent signal to be detected. Therefore, the fluorescence signal is directly 
proportional to primer cleavage and PCR product formation.  
The threshold cycle (CT) values were extracted from amplification plots on the 7500 software 
(Applied Biosystems) and converted to ∆CT values by normalising to the expression of endogenous 
reference gene, ribosomal protein lateral stalk subunit P0 (RPLP0):  
∆CT = CT(GOI) - CT(reference gene) 
For relative comparison analyses, the 2-∆∆CT method was employed (Livak and Schmittgen, 2001), 
which converts the CT values to a fold-change in gene expression normalised to an endogenous 
reference gene and a calibrator.   
2-∆∆CT = 2-(∆CT(sample) - ∆CT(calibrator)) 
For comparing the relative expression of P2 receptors in adipocytes versus MSCs, the calibrator was 
the ∆CT value for MSCs, whereas for validating shRNA knockdown, the calibrator was the ∆CT for 
the scrambled control cells.   
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Table 2.7 Assay identification codes for TaqManTM gene expression assay primers and probes. 
All primers were minor groove binder (MGB) probes are tagged with an FAMTM reporter dye at 
the 5’ end and a non-fluorescent quencher (NFQ) at the 3’ end. 
Gene Assay ID 
P2RX1 Hs00175686_m1 
P2RX2 Hs04176268_g1 
P2RX3 Hs01125554_m1 
P2RX4 Hs00602442_m1 
P2RX5 Hs01112471_m1 
P2RX6 Hs01003997_m1 
P2RX7 Hs00175721_m1 
P2RY1 Hs00704965_s1 
P2RY2 Hs04176264_s1 
P2RY4 Hs00267404_s1 
P2RY6 Hs00366312_m1 
P2RY11 Hs01038858_m1 
P2RY12 Hs01881698_s1 
P2RY13 Hs03043902_s1 
P2RY14 Hs01848195_s1 
RPLP0 Hs99999902_m1 
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2.11 Immunocytochemistry  
Confirmation of the P2 receptor expression profile was achieved by performing 
immunocytochemistry. MSCs were seeded onto glass coverslips and incubated at 37 oC for 48 hours 
or differentiated on the coverslips. All subsequent steps were conducted at room temperature 
unless otherwise stated. Culture media was gently aspirated off the cells and the cells were washed 
with PBS. They were subsequently fixed with 4% PFA for 15 minutes and permeabilised with 0.25% 
Triton X-100 for 10 minutes. Non-specific binding was blocked with 1% bovine serum albumin (BSA) 
and then the cells were incubated with the appropriate primary antibody (1:200 dilution in 1% BSA) 
(Table 2.8) overnight at 4 oC. Cells incubated without primary antibodies were used as controls for 
non-specific secondary antibody staining. The excess primary antibody was removed and successful 
binding was detected using rabbit anti-goat (Abcam) or goat anti-rabbit (Thermo Fisher Scientific) 
Alexa Fluor 488-conjugated secondary antibodies (1:1000 dilution in 1% BSA). Finally, cells were 
mounted onto glass slides using VectaShield containing 1.5 µg/ml DAPI (Vector Laboratories), 
sealed with clear nail varnish and visualised using a Zeiss AxioPlan 2ie epifluorescent microscope 
(Carl Zeiss Ltd.). Exposure settings for the green (AF488) and blue (DAPI) channels remained 
constant throughout the imaging.  
2.12 Immunohistochemistry 
Fresh human subcutaneous adipose tissue was cut into 1 cm2 pieces and washed with PBS to 
remove excess blood. The tissue was then submerged in 4% ice-cold PFA for four hours, then 
washed with PBS for 30 minutes twice and left overnight at 4 oC in PBS. The samples were then 
sequentially submerged in increasing concentrations of ethanol (30, 50, 70, 90, 95 and 100%) for 
one hour each to dehydrate the tissue. Next, the tissue was submerged in histo-clear (National 
Diagnostic) for one hour and embedded into paraffin by placing the tissue in molten paraffin for 
two hours twice. The embedded tissue was placed in a mould, encased in paraffin and left overnight 
at 4 oC to set. The tissue blocks were then removed from their moulds and cut into 6 μm sections 
using a Microm HM355S automatic microtome (Thermo Fisher Scientific) and mounted onto (3-
aminopropyl)triethoxysilane coated glass slides and allowed to dry.  
The tissue was now ready for staining. To do this, the sections were dewaxed with histo-clear (five 
minutes twice) and rehydrated by sequentially submerging the slides in decreasing concentrations 
of ethanol (100, 95, 80, 70, 50 and 30% for 1 minute each), followed by distilled water for 1 minute. 
The sections were then stained using an Anti-rabbit or Anti-goat HRP-DAB Cell & Tissue Staining Kit 
purchased from R and D systems as per the manufacturer’s instructions. All steps were conducted 
at room temperature unless otherwise stated. In brief, the rehydrated samples were treated with 
peroxidase blocking reagent for five minutes and then washed with buffer for five minutes. The 
sections were then blocked for 15 minutes with the appropriate serum reagent (rabbit or goat) 
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depending on the kit being used. Excess serum was drained off the slides and avidin blocking 
reagent was added for 15 minutes. The slides were then rinsed with buffer and biotin blocking 
reagent was added for 15 minutes. Again, the slides were rinsed with buffer and subsequently the 
sections were incubated with primary antibodies for P2Y1, P2Y2 or P2Y12 (1:200 in PBS with 1% BSA; 
Table 2.8) or PBS with 1% BSA alone overnight at 4 oC. The slides were then washed with buffer 
three times for 15 minutes, drained and incubated with biotinylated secondary antibodies for one 
hour. The secondary antibody was removed and the slides were washed with buffer three time (15 
minutes for each wash). Next, the sections were incubated with high sensitivity streptavidin 
conjugated to horseradish peroxidase (HSS-HRP) for 30 minutes. The slides were then washed with 
buffer three times (two minutes each) and incubated with 3,3' Diaminobenzidine (DAB) chromogen 
for up to 20 minutes. The sections were monitored closely during this incubation period and 
incubation was terminated early if the appropriate intensity of staining was achieved. However, the 
same incubation time was maintained for both the primary antibody treated and no primary 
antibody treated sections. When appropriate, the DAB chromogen was removed and the sections 
were rinsed and washed with distilled water for five minutes. Subsequently, the sections were 
dehydrated again by rapidly dipping the slides in increasing concentrations of ethanol, and then 
histo-clear for 10 minutes and finally mounted with DPX mountant. Once the mountant was dry, 
images of stained sections and no primary antibody controls were taken using an Olympus CKX41 
inverted microscope.  
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Table 2.8 Polyclonal anti-human primary antibodies for the detection of P2 purinergic receptors. 
Target Manufacturer Product code Host species Application 
P2X1 Santa cruz Sc-31491 Goat ICC 
P2X4 Alomone APR-002 Rabbit ICC 
P2X5 Santa cruz Sc-15192 Goat ICC 
P2X7 Alomone Sc-20123 Rabbit ICC 
P2Y1 Santa cruz Sc-20123 Rabbit IHC 
P2Y1 Alomone APR-009 Rabbit ICC 
P2Y2 Santa cruz Sc-20124 Rabbit IHC 
P2Y2 Abcam Ab10270 Rabbit ICC 
P2Y4 Alomone APR-006 Rabbit ICC 
P2Y6 Alomone APR-011 Rabbit ICC 
P2Y11 Alomone APR-015 Rabbit ICC 
P2Y12 Santa cruz Sc-27152 Goat IHC 
P2Y12 Alomone APR-020 Rabbit ICC 
P2Y13 Alomone APR-017 Rabbit ICC 
ICC immunocytochemistry; IHC immunohistochemistry; 
 
2.13 Calcium mobilisation experiments 
For detection of changes in intracellular calcium upon purinergic receptor activation calcium (Ca2+) 
mobilisation experiments were performed by loading cells with a fluorescent ratiometric Ca2+ dye, 
fura-2 acetoxymethyl (AM) ester (Abcam) (Grynkiewicz et al., 1985). The AM moiety allow fura-2 to 
traverse the cell membrane to the cytosol, where the AM group is cleaved by cellular esterases, 
which prevents fura-2 from leaving the cell. The peak excitation wavelength of fura-2 varies 
according to whether it is bound to Ca2+ or not, from 362 nm in Ca2+-free states to 335 nm in Ca2+-
bound states, but the emission wavelength remains constant (510 nm). Measurement of 
fluorescence at 510 nm using two excitation wavelengths, 340 nm and 380 nm respectively, enables 
calculation of a fluorescence ratio (340/380). Calculating a ratio limits the effects of photobleaching 
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and neutralises variables, including cell thickness and differing local fura-2 concentrations, thus 
increases the accuracy and reproducibility of results.      
To perform Ca2+ mobilisation assays, cells were seeded at 2x104 cells/well in black glass bottom 96 
well plates (Molecular Devices, California, USA) and incubated at 37 oC in 5% CO2 for 48 hours or 
differentiated in vitro. When the cells were ready for experimentation, the growth media was 
aspirated off and the cells were gently washed with salt buffered solution (SBS), containing 130 mM 
sodium chloride, 5 mM potassium chloride, 1.2 mM magnesium chloride, 1.5 mM calcium chloride, 
8 mM D-(+)-Glucose, 10 mM hydroxyethyl piperazineethanesulfonic acid (HEPES). The cells were 
then loaded with 2 μg/ml fura-2AM in SBS supplemented with 0.01% (w/v) pluronic acid for 1 hour 
at 37 oC while being protected from light. The fura-2 loading buffer was then removed and the cells 
were washed twice with SBS. Where applicable, the cells were incubated for a further 30 minutes 
with antagonists or calcium-free SBS (SBS lacking 1.5 mM calcium chloride, but containing 2 mM 
EGTA; pH 7.4). Finally, the cells were challenged with nucleotides administered by a FlexStation III 
microplate reader (Molecular Devices), which also recorded the fluorescence (excitation 340nm 
and 380nm, emission 510nm) every three seconds to provide Fratio values. Fratio values at every time 
point, peak Fratios and area under the curve data were extracted using SoftMax Pro 5.4.5 software 
(Molecular Devices). Data was analysed using Origin Pro 2018 software (Origin Lab). All dose 
response data was normalised to the maximal response and all antagonist data was normalised to 
their respective vehicle controls. Dose response curves were fitted using a modified Hill equation 
(DoseResp function on Origin) via the following formula:  
𝑦 = 𝐴1 +  
𝐴2 − 𝐴1
1 + 10(𝐿𝑜𝑔𝑥0−𝑥)𝑝
 
Where A1 is the bottom asymptote (minimum response on the y axis), A2 is the top asymptote 
(maximum response on the y axis), Logx0 is the centre (EC50) and p is the hill slope.  
Analysis of the decay kinetics, τ, was performing using the ExpDecay1 function, which uses the 
following formula:  
𝑦 = 𝑦0 +  𝐴1 x 𝑒𝑥𝑝 (− 
𝑥 − 𝑥0
𝑡1
) 
Where y0 is the offset, A1 is the amplitude and t1 is the ‘time’ constant.  
2.13.1 Calcium mobilisation experiments using pertussis toxin 
Pertussis toxin (PTx) is a exotoxin produced exclusively by Bordetella pertussis, the causative agent 
of Whooping cough (Carbonetti, 2010). PTx is transported across the cell membrane to the cytosol, 
where it hydrolyses cellular NAD to allow transfer of the released ADP-ribose to cysteine residues 
on the alpha subunit of heterotrimeric Gi-proteins (Katada et al., 1983), which consequently 
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terminates any Gi-mediated signalling pathways. In this study, PTx was used to assess whether Gi-
proteins were involved in nucleotide-evoked calcium responses in human adipocytes. As the target 
of PTx is intracellular, it requires a longer incubation time to facilitate entry into the cell and have 
its an effect, so the calcium mobilisation assay protocol was slightly amended to accommodate this. 
Cells were seeded and grown in 96-well plates as per the normal protocol (Section 2.13). When the 
cells were ready for experimentation, instead of directly loading the cells with fura-2 AM, the 
culture media was removed and replaced with culture media containing 100 ng/ml PTx or vehicle 
control. The cells were then incubated at 37 oC with 5% CO2 for 4 hours. Then the cells were 
removed from the incubator and the calcium mobilisation assays was conducted as normal (Section 
2.13).   
2.13.2 Calcium calibration assay 
In vitro differentiated adipocytes were loaded with fura-2AM as per the calcium mobilisation 
experiment protocol (Section 2.13) and then incubated with SBS or Ca2+ free SBS for 30 minutes at 
37 oC prior to challenging the cells with 2 μM ionomycin and recording the changes in intracellular 
calcium levels using a Flexstation III microplate reader. The Grynkiewicz formula (Grynkiewicz et al., 
1985) was then utilised to convert Fratio values from calcium mobilisation assays to intracellular 
calcium concentrations: 
[Ca2+]i = KD x β x (R-Rmin)/(Rmax-R) 
Where KD is the KD for fura2-AM at 37 oC which is 224 nM, β is the (maximum fluorescence signal at 
380 nm for ionomycin in the absence of calcium)/(the minimum fluorescence at 380 nm for 
ionomycin in the presence of calcium), Rmin is the minimum Fratio value for ionomycin in absence of 
calcium and Rmax is the maximum Fratio value for ionomycin in the presence of calcium and R is the 
Fratio value that needs to be converted. β, Rmax and Rmin were calculated by averaging the data from 
three independent donors.  
2.14 Lactate dehydrogenase cytotoxicity assay  
Lactate dehydrogenase (LDH) is a cytosolic enzyme, which is released into the supernatant when 
the cell membrane integrity is compromised due to cell damage or death, therefore the amount of 
LDH in the supernatant equates to the level of cytotoxicity. To exclude the possibility that the 
pharmacological effects observed with selective antagonism were not due to cytotoxicity, an LDH 
cytotoxicity assay (Cayman) was performed as per the manufacturer’s instructions. In brief, cells 
were seeded in 96-well plates and treated in the same manner as they are for pharmacological 
studies (calcium mobilisation and functional studies). MSCs and adipocytes were washed once with 
SBS and then 200 μl/well SBS was added to each well. An additional 20 μl/well of each antagonist 
(maximal concentration) or vehicle was added to duplicate wells, including two wells per donor that 
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contained 10% (v/v) triton X, and the cells were incubated for 30 minutes at 37 oC. The protocol 
was adjusted slightly for AR-C118925XX in adipocytes to account for the longer incubation times 
used in the functional studies. For AR-C118925XX, the cells were washed with PBS once and then 
DMEM was added, in place of SBS, and the cells were incubated with the antagonist for three hours, 
rather than 30 minutes. When the respective antagonist incubation times had elapsed, the plates 
were centrifuged at 400 x g for five minutes and 100 μl/well of supernatant was removed and 
placed in a fresh 96-well plate. Then 100 μl/well of LDH reaction solution was added to every well 
and the plate was incubated at 37 oC for 30 minutes on an orbital shaker. Finally, the absorbance 
was read at 490 nm using a Flexstation III microplate reader and the percentage cytotoxicity was 
calculated using the following formula: 
% Cytotoxicity = ((A490Antagonist – A490Vehicle) / (A490Triton X – A490Vehicle)) x 100 
Maximal concentrations of AR-C11892XX, MRS2578 and U73122 did not cause an increase in 
extracellular LDH levels for MSCs. In addition, treatment of in vitro differentiated adipocytes with 
maximal concentrations of AR-C118925XX, MRS2500, PSB0739, U73122 and Ticagrelor also failed 
to increase levels of LDH in the supernatant. These results suggested that these antagonists did not 
cause cytotoxicity in MSCs or adipocytes (Figure 2.3).  
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Figure 2.3 Assessment of whether maximal concentrations of antagonists induce cytotoxicity in 
primary human adipose-derived mesenchymal stromal cells and in vitro differentiated 
adipocytes. Cytotoxicity was determined via measurement of lactate dehydrogenase levels in the 
supernatants of (A) primary human adipose-derived mesenchymal stromal cells and (B) primary 
human in vitro differentiated adipocytes. Values are normalised to their own vehicle controls and 
10% triton X (positive control). Data presented is the mean ± SEM of cells from three independent 
donors. *p<0.05 and *** p <0.001 versus vehicle control.     
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2.15 Cell proliferation assay 
To ascertain whether activation or inhibition of purinergic signalling influenced proliferation of 
primary human AD-MSCs, proliferation of AD-MSCs was measured in the presence and absence of 
nucleotides and subtype selective antagonists. A CellTiter 96® Aqueous one solution cell 
proliferation assay kit was purchased from Promega and performed as per the manufacturer’s 
instructions. MSCs were diluted to 1x104 cells/ml and 100 μl of cells was added to each well. This 
lower initial seeding density was selected to provide sufficient space for the MSCs to proliferate 
within each well. The cells were incubated overnight in humified environment at 37 oC with 5% CO2 
and the following morning, a further 100 μl/well of culture media containing vehicle, nucleotide or 
antagonist was added to every well and the cells were incubated for 30 minutes at 37 oC. Next, 10 
μl of CellTiter 96® Aqueous one solution (MTS reagent) was added to duplicate wells (control and 
nucleotide/antagonist treated cells) and the cells were incubated for four hours with the reagent 
at 37 oC. Then the absorbance was measured at 490 nm (4.5-hour reading). The cells were then 
placed back in the incubator (37 oC) for a further six days, with MTS reagent being added four hours 
before the absorbance was read at each timepoint (24, 48, 72, 96, 120 and 144 hours). All values 
were normalised to the absorbance values for the vehicle control at the 144 hour timepoint. The 
MTS tetrazolium compound is bioreduced by metabolically active cells to produce a coloured 
formazan product, thus altering the absorbance of culture media. As this reaction can only occur in 
the presence of viable cells, it is possible to use the formation of formazan as a measure of the 
number of viable cells present. The number of viable cells, and consequently the amount of 
formazan produced, should increase as the cells proliferate.  
2.16 Cell migration assay (transwell) 
Another important function of AD-MSCs is their ability to migrate towards chemotactic agents. To 
investigate whether nucleotides may play a role in chemotaxis, a transwell assay was performed. 
MSCs were trypsinised and resuspended at a density of 4x105 cells/ml in Roswell Park Memorial 
Institute (RPMI) culture media containing HEPES (Lonza), but no FBS or antibiotics. The cells were 
then incubated for 1 hour at 37 oC in the dark in the presence of 1.5 μM calcein-AM to fluorescently 
label the cells. A range of concentrations of ATP (0.1, 1, 30 and 100 μM) and a positive control 
containing 10% FBS (a known chemoattractant) were prepared in RPMI containing HEPES.                
200 μl/well of each potential chemotactic agent was placed in the lower clear plate of a Corning 
FluoroblokTM 96-multiwell insert system, whereas 50 μl/well of calcein-loaded primary human MSCs 
were carefully added to the upper wells (black plate). The upper plate was very gently lowered into 
the lower plate containing the chemotactic agents, avoiding the formation of any bubbles between 
the two plates. The two-plate structure was then immediately transferred to a Flexstation III 
microplate reader (maintained at 37 oC) and the fluorescence (excitation 485 nm/emission 530 nm) 
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was read from the bottom of each well every five minutes for four hours. Corning FluoroBlok 
multiwell inserts are specifically designed with a polyethylene terephthalate (PET) membrane that 
efficiently blocks the transmission of wavelengths between 400 and 700 nm, therefore when light 
is passed through the bottom of the plate, only fluorescence in the lower plate is detected, whereas 
the cells within the upper plate are protected. Initially the lower plate should be devoid of 
fluorescence, but the fluorescence signal should increase as the calcein-loaded cells from the upper 
plate migrate through the PET membrane to the lower plate. Although some cells will 
spontaneously migrate to the lower plate, the rate of migration should be enhanced in the presence 
of true chemotactic agents.  
2.17 Lentiviral shRNA knockdown 
RNA interference techniques are an effective and widely used tool for exploiting cellular microRNA 
processing mechanisms to reduce expression of a target gene (Cullen, 2005). Short hairpin RNA 
(shRNA) strategies are often used to produce highly potent and sustained knockdown of a gene of 
interest (GOI), with minimal off-target effects (Rao et al., 2009). Lentiviral particles based on the 
human immunodeficiency virus (HIV-1) can be harnessed to effectively deliver plasmids containing 
shRNA constructs into both dividing and non-dividing cells. When the plasmids enter the cell, they 
are transported to the nucleus, where the plasmid DNA is transcribed into a single stranded RNA 
sequence and the complementary regions of the RNA interact to form a stem-loop structure 
(hairpin) with a two nucleotide 3’ overhang (H. Zhang et al., 2002). This pre-shRNA molecule is then 
transported into the cytoplasm, where the loop region is removed by an enzyme known as DICER. 
The two strands of the mature shRNA molecule then disassociate, and one strand (the guide strand) 
is incorporated into the RNA-interfering silencing complex (RISC), where it is used to mediate a 
conformational change or cleavage of target gene’s mRNA, thus preventing the translation of the 
target gene (Cullen, 2004). The plasmid DNA remains within the nucleus for the lifespan of the cell, 
which ensures stable production of shRNA and consequently enduring reduction of target gene 
expression.     
 
In this study, lentiviral particles were used to deliver plasmids containing shRNA constructs capable 
of knocking down the expression of P2Y2 to further explore the functional role of P2Y2 in primary 
human MSCs and in vitro differentiated adipocytes.  
 
2.17.1 Preparation of plasmid DNA for lentiviral production 
Bacterial glycerol stocks of pLKO.1-puro vectors carrying Mission® non-target shRNA control 
sequences or shRNA sequences that target P2Y2 receptor mRNA were purchased from Sigma-
Aldrich (Table 2.9). The base pLKO.1-puro vector (Figure 2.4) was developed as part of the RNAi 
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consortium at the Broad Institute (Stewart et al., 2003), and it enables antibiotic selection of 
successfully transduced cells due to the presence of a puromycin-resistance gene within the vector.  
 
In addition to plasmids containing the control and target shRNA sequences, additional plasmids 
containing viral transgenes are required to facilitate viral particle formation. Bacterial stocks of 
psPAX2 (viral packaging plasmid) and pMD2.G (viral envelope plasmid) were purchased from 
Addgene (Trono Lab, unpublished data). All plasmids were purchased in ampicillin-resistant 
bacteria. Each plasmid DNA sequence was amplified by streaking a small amount of the bacterial 
stocks on Luria Bertani (LB) agar plates, containing 100 μg/ml ampicillin, and were left at 37 oC 
overnight. The following day individual colonies from each agar plate were transferred to tubes 
containing LB broth (with 100 μg/ml ampicillin) and the tubes were incubated at 37 oC overnight 
under constant agitation at 225 rpm. Multiple colonies were inoculated for each plasmid. The 
plasmid DNA was then purified using an E.Z.N.A Plasmid Mini Kit II (Omega Bio-Tek), performed as 
per the manufacturer’s instructions. The quantity and purity of the resultant DNA was then 
assessed using a Nanodrop 2000 (Thermo Fisher Scientific). A value of 1.8 for the ratio of 
absorbance at 260 and 280 nm was regarded as a pure DNA sample.  
 
 
Table 2.9 Short hairpin RNA plasmid DNA sequences purchased from Sigma-Aldrich. 
 Product code Sequence 
Non-
mammalian 
shRNA 
control 
SHC002V CCGGCAACAAGATGAAGAGCACCAACTCGA 
GTTGGTGCTCTTCATCTTGTTGTTTTT 
 TRC number Clone ID Sequence 
P2Y2 target 
shRNA 
TRCN0000009481 
 
NM_176072.1-
1505s1c1 
CCGGGCAGAGGATAGAAGATGTGTTCT 
CGAGAACACATCTTCTATCCTCTGCTTTTT 
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Figure 2.4 Map of an empty pLKO.1-puro vector acquired from the Sigma Aldrich website. 
https://www.sigmaaldrich.com/life-science/functional-genomics-and-rnai/shrna/library-
information/vector-map.html. Last accessed 15.5.18. 
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2.17.2 Generation of lentiviral particles  
Self-inactivating viral particles can be generated via co-transfection of lentiviral genes (psPAX2 and 
pMD2.G) and shRNA constructs in packaging cells (HEK293T) (Song and Yang, 2010). HEK293 cells 
are a cell line derived from human embryonic kidney cells that were transformed with adenovirus 
type 5 DNA (Graham et al., 1977). Transfection of the simian virus 40 large T-antigen and a 
neomycin resistance gene transformed HEK293 cells to HEK293T cells (DuBridge et al., 1987). 
HEK293T cells were purchased from the European Collection of Authenticated Cell Cultures 
(ECACC). HEK293T cells were maintained in culture in the same manner as primary human AD-MSCs 
(Section 2.1.1). HEK293T cells (9x106) were seeded in 150 mm petri dishes and left at 37 oC overnight 
in culture media (DMEM with 10% [v/v] FBS, 50 IU/ml penicillin and 50 µg/ml streptomycin). The 
following morning, the culture media was exchanged for 20 ml of viral collection media (DMEM 
supplemented with 1% [v/v] FBS and no antibiotics) and the plasmids were prepared for 
transfection under sterile conditions. Two tubes each containing 1.2 ml serum-free OPTIMEM 
media (Life Technologies) were prepared: 36 μl LipofectamineTM 2000 transfection reagent (Life 
Technologies) was added to one tube, while plasmid DNA was added to the other tube. The 
following concentrations of plasmid DNA were used: 9 μg of lentiviral vector containing pLKO.1-
puro P2Y2 (target) or pLKO.1-puro non-target shRNA (scrambled), 12 μg psPAX2 and 3 μg pMD2.G. 
Both tubes were then incubated at room temperature for five minutes. The contents of the two 
tubes were then mixed and incubated for a further 20 minutes at room temperature. The 
plasmid/transfection reagent mixture was then added drop-wise to the HEK293T cells and the cells 
were incubated for 6 hours at 37 oC in 5% CO2. The media was then replaced with fresh viral 
collection media and the cells were left to incubate at 37 oC for 72 hours, with the media being 
collected (and stored at 4 oC) and replaced with fresh viral collection media every 24 hours. After 
72 hours had lapsed, the virus-containing media was passed through a 0.45 μm filter to remove cell 
debris and then the virus was concentrated using Lenti-X concentrator solution (Clontech) as per 
the manufacturer’s instructions. The resulting concentrated virus was then immediately aliquoted 
and stored at -80 oC until required. This process was performed in duplicate to produce lentiviral 
particles containing pLKO.1-puro P2Y2 (target) or pLKO.1-puro non-target (scrambled) shRNA.  
2.17.3 Calculation of the Multiplicity of Infection (MOI) using a p24 ELISA 
A p24 enzyme-linked immunosorbent assay (ELISA) was performed using a QuickTiterTM Lentivirus 
Titer Kit (Cell Biolabs Inc) to determine the number of lentiviral particles present for both the 
scrambled control and P2Y2 target shRNA lentiviruses. These values were then used to ensure that 
equivalent amounts of control and target lentivirus were used for the subsequent experiments. The 
QuickTiterTM Lentivirus Titer Kit was designed to specifically detect lentivirus associated HIV-1 p24 
core protein, not free p24, thus providing an accurate measurement of the viable viral titre. The 
assay has a sensitivity limit of 1 ng/ml HIV p24. The assay was performed as per the manufacturer’s 
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instructions. In brief, samples of both the scrambled and P2Y2-shRNA lentiviruses were diluted 1:50 
in 1 ml of DMEM and 10 μl ViraBindTM Lentivirus Reagent A and B were added to each tube 
sequentially with mixing by inversion after each reagent was added. The tubes were then incubated 
at 37 oC for 30 minutes to inactivate the virus and then centrifuged at 12,000 x g for 5 minutes. The 
supernatant was removed and the pellet was vortexed to resuspend the inactivated virus in 250 μl 
of sample diluent. 100 μl/well of inactivated lentivirus or p24 antigen standard was added to an 
anti-p24 antibody coated 96-well plate and the plate was incubated at 4 oC overnight. The next 
morning, the supernatants were discarded and the wells were washed three times with 1x wash 
buffer and thoroughly dried. FITC-conjugated anti-p24 monoclonal antibody (100 μl/well) was 
added to every well and plate was incubated at room temperature on an orbital shaker for one 
hour. The wells were then emptied and washed three times with 1x wash buffer. Again, the wells 
were dried and 100 μl/well of substrate solution was added to each well. The plate was incubated 
on an orbital shaker at room temperature for up to 30 minutes. The colour change reaction was 
monitored closely to prevent saturation and the reaction was terminated by adding 100 μl/well 
stop solution. The absorbance was then read at 450 nm using a Flexstation III microplate reader. 
The p24 standard curve was used to calculate the concentration of virus-associated p24 (ng/ml). 
This concentration was then converted to a p24 titre (ng/ml) using the following equation: 
p24 titre (virus associated p24, ng/ml) = p24 (ng/ml) x dilution factor x (0.25 ml/1.0 ml) 
The p24 titre was subsequently converted to the number of lentiviral particles, as 1 ng/ml p24 
equates to 1.25x107 lentiviral particles. In turn, this value was then used to calculate the Multiplicity 
of Infection (MOI) for each lentivirus. The MOI is the ratio between the number of viral particles 
and the number of cells being infected. It was calculated via the following equation: 
Multiplicity of Infection (MOI) = Volume of virus (ml) x Number of lentiviral particles  
                                                                Number of cells transfected 
2.17.4 Puromycin kill curve for primary human MSCs 
As mentioned previously in Section 2.17.1, the vectors containing the non-target and target shRNA 
sequences both have a puromycin-resistance gene, which enables selection of successfully 
transduced cells with puromycin. In order to determine the correct concentration of puromycin to 
use for selection, a puromycin kill curve was performed. MSCs (2x104 cells/well) were seeded in 96 
well plates and incubated overnight at 37 oC. The following morning, different concentrations of 
puromycin were added to quadruplet wells (0, 0.1, 0.3, 1, 3 and 10 μg/ml). Immediately after the 
puromycin was added (day 0), 10 μl/well of CellTiter 96® AQueous One Solution Reagent (MTS 
reagent) (Promega) was added to half of the cells and then all the cells were incubated at 37 oC for 
four hours. Next, the absorbance was read at 490 nm for all the wells containing MTS. All the cells 
were then placed back in the incubator for five days. On the fifth day, 10 μl/well MTS reagent was 
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added to the remaining wells and the cells were again incubated at 37 oC for four hours. The 
absorbance was then read at 490 nm for the remaining well and these values were normalised to 
the day 0 readings. In primary human MSCs, the absorbance value decreased as the concentration 
of puromycin increased (Figure 2.5). Little or no effect was observed using ≤ 0.3 μg/ml puromycin, 
but concentrations of 1 μg/ml and above were sufficient to kill all the cells in the well after five 
days. Thus 1 μg/ml puromycin was used to select for successful transduction in primary human 
MSCs.  
 
2.17.5 Direct transfection of primary human in vitro differentiated adipocytes 
To partially reduce the expression of P2Y2 receptors in primary human in vitro differentiated 
adipocytes, the cells were differentiated and habituated in 96-well plates (Section 2.6). The cells 
were then washed once with PBS and 200 μl/well of fresh culture media (DMEM with 10% [v/v] 
FBS, 50 IU/ml penicillin and 50 µg/ml streptomycin) containing 8 μg/ml of hexadimethrine bromide 
was added to each well. Then lentiviral particles containing either scrambled control or P2Y2 shRNA 
were added to each well and the cells were incubated for 18 hours at 37 oC in 5% CO2. A range of 
different MOIs (1, 10, 100, 500 and 1000) were used in order to identify the optimal MOI for 
maximum knockdown of P2Y2 receptor expression. The following day, the virus-containing media 
was removed and replaced with fresh culture media and the cells were incubated for a further four 
days at 37 oC in 5% CO2 before they were ready for experimental use. The cells were then lysed with 
TRI reagent and RNA extraction, cDNA synthesis and quantitative PCR was performed as described 
in Sections 2.7, 2.8 and 2.10 respectively. The fold-change in P2Y2 mRNA expression was determined 
using the 2-∆∆CT method, where each value was compared to a scrambled control produced using 
the same MOI used to knockdown P2Y2 receptor expression. A value of 1 represents no change, but 
values below 1 represent a decrease in expression (Figure 2.6). From this experiment it was 
determined that an MOI of at least 500 was required to achieve significant knockdown of P2Y2 
expression, however an MOI of 1000 produced the greatest reduction in receptor expression, thus 
an MOI of 1000 was used for all subsequent experiments in which knockdown of P2Y2 receptor 
expression was required. Where possible, qPCR was performed to confirm successful shRNA-
mediated knockdown of P2Y2 in all subsequent experiments.  
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Figure 2.5 Puromycin kill curve for primary human MSCs (N=3). Cells were treated with puromycin 
for five days and then cell viability was tested by measuring changes in absorbance at 490 nm due 
to the production of formazan. Absorbance values are normalised to readings taken immediately 
after puromycin was added on day 0.     
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Figure 2.6 Change in P2Y2 receptor mRNA expression in primary human in vitro differentiated 
adipocytes when cells are treated with an increasing number of lentiviral particles (N=3). Data 
was normalised to expression of the endogenous control gene, RPLP0, and then comparisons were 
made between the ∆CT values for cells treated with lentivirus containing scrambled non-target 
control shRNA and lentivirus containing the P2Y2 target shRNA using the 2-∆∆CT method. ** p <0.005 
and *** p <0.001.    
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2.17.5 Transfection of primary human MSCs (spinoculation)  
For primary human MSCs it was necessary to adopt a spinoculation protocol to the increase the 
likelihood of successful transfection (and transduction) of the scrambled and target shRNA 
sequences (O’Doherty et al., 2000). This involved diluting 2x105 MSCs in 2 ml of culture media 
containing 8 μg/ml hexadimethrine bromide. Viral particles (control and target; MOI of 1000) were 
then added to the cells and the mixture was centrifuged at 1,400 x g at 32 oC for 60 minutes. The 
supernatant was then carefully aspirated off without disturbing the pellet of cells at the bottom of 
each tube. The pellet was then gently resuspended in culture media and transferred to a T25 flask. 
The cells were then incubated at 37 oC for 48 hours prior to replacing the culture media with fresh 
culture media containing 1 ug/ml puromycin. The cells were maintained under puromycin selection 
until they reached confluence. The media was replaced every four days. The puromycin-resistant 
cells were then expanded and used for experimentation.   
2.18 BODIPY staining 
In vitro differentiated adipocytes which were transfected with scrambled control or P2Y2 shRNA 
lentiviral particles were stained with BODIPY 493/503 lipid dye (Thermo Fisher Scientific) to quantify 
any changes in total lipid content due to a reduction of P2Y2 receptor expression. To do this, the 
culture media was removed and replaced with 100 μl/well DMEM (no FBS or antibiotics) and a 
further 100 μl/well of DMEM containing 2 μM BODIPY 493/503 dye was added and immediately 
mixed thoroughly by gently pipetting. The cells were then incubated for 30 minutes at 37 oC in the 
dark. The excess dye was then removed and the cells were washed twice with PBS and then the 
fluorescence at 493/503 nm (excitation/emission) was measured using a Flexstation III microplate 
reader. Each experiment was normalised for background fluorescence, by measuring and 
subtracting the fluorescence values for cells in the absence of the dye.  
2.19 Lipid droplet quantification 
Images of human in vitro differentiated adipocytes that had been treated with both scrambled and 
P2Y2 shRNA lentiviral particles were taken using an Olympus CKX41 inverted microscope for 12 
independent donors. These images were then anonymised and given to an independent member 
of the laboratory for analysis to eliminate operator bias. The number of lipid droplets in 15 
individual cells from each image were quantified using the counter plugin on Image J (National 
Institutes of Health). Once all the counting was complete, the values were sorted according to 
whether they were calculated from an image of scrambled or P2Y2 knockdown adipocytes to 
perform statistical analyses.   
84 
 
2.20 Quantification of intracellular cyclic AMP 
Cyclic AMP (cAMP) is an important secondary messenger molecule that mediates numerous cellular 
processes. Increases in intracellular cAMP are mediated by adenylate cyclase (AC), which 
synthesizes cAMP from ATP. Activation of Gs and Gi-coupled receptors leads to stimulation or 
inhibition of AC respectively (Reddix and Pacheco, 2007). P2Y12 is an Gi-coupled receptor, so 
quantification of cAMP is a useful method of assessing P2Y12 activity (von Kügelgen and Hoffmann, 
2016).  
2.20.1 CatchPoint cAMP assay 
To investigate the functional activity of P2Y12, a CatchPoint cAMP Fluorescent Assay Kit was 
purchased from Molecular Devices and performed as per the manufacturer’s instructions. In brief, 
culture media was gently aspirated off in vitro differentiated adipocytes and the cells were washed 
with Krebs-Ringer Bicarbonate buffer containing 120 mM sodium chloride, 4.6 mM potassium 
chloride, 0.5 mM magnesium chloride, 0.7 mM dibasic sodium phosphate, 1.5 mM monobasic 
sodium phosphate, 10 mM D-glucose and 15 mM sodium bicarbonate (KRBG; pH 7.4). The cells 
were then incubated with vehicle or antagonists (diluted in KRBG; 50 μl/well) for 30 minutes at       
37 oC. An additional 50 μl/well of KRBG containing vehicle or agonist was added to each well and 
the cells were incubated at 37 oC for 5 minutes. Finally, a further 50 μl/well of KRBG containing       
60 μM forksolin (20 μM final concentration) was added and the cells were incubated for 15 minutes 
at 37 oC. The supernatant was then removed and the cells were lysed with 50 μl/well of lysis buffer 
for 10 minutes on a plate shaker. Then 40 μl of each lysed sample was transferred immediately to 
a goat anti-rabbit IgG coated microplate and 40 μl/well of rabbit anti-cAMP antibody was also 
added, excluding two wells where the antibody was replaced with buffer to serve as no antibody 
control wells. The plate was then placed on a shaker for 5 minutes to mix the lysates and antibody. 
Next, 40 μl/well of HRP-cAMP conjugate was added to every well and the plate was sealed and 
placed on an orbital mixer for two hours at room temperature. The supernatant was then removed 
from all wells and the wells were washed with wash buffer four times. Finally, 100 μl/well Stoplight 
red substrate was added to each well and the plate was protected from light and incubated at room 
temperature for 10 minutes, and then the fluorescence intensity (excitation 530 nm/emission 590 
nm) was measured. A cAMP standard curve was run on each plate to facilitate conversion of 
fluorescence intensity readings to intracellular cAMP concentrations. There is an inverse 
relationship between the fluorescence intensity and concentration of cAMP, because cAMP in the 
lysates competitively decreases the binding of HRP-cAMP conjugates, consequently decreasing the 
measured HRP activity. 
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2.20.2 Cyclic AMP XP® Assay Kit 
Measuring intracellular cAMP can also be a useful method of determining intracellular mechanisms. 
In vitro differentiated adipocytes were washed once with PBS and then incubated with 100 μl/well 
DMEM (no FBS/antibiotics) for two hours at 37 oC and then 1 μl/well vehicle or antagonist was 
added to each well and the cells were incubated for a further 30 minutes at 37 oC. DMEM alone or 
agonist (50 μl/well) was added to each well and the cells were incubated for a further 15 minutes 
at 37 oC. The cells were then washed twice with ice-cold PBS and lysed on ice with 100 µl/well 1x 
cell lysis buffer containing 1 mM phenylmethylsulfonyl fluoride. The amount of cAMP in the cells 
was then quantified using a Cyclic AMP XP® Assay Kit (Cell Signalling Technology). The protocol and 
methodology for this kit is very similar to the CatchPoint cAMP assay described in 2.15.1. In brief, 
50 μl/well of the cell lysates and 50 μl/well cAMP-HRP conjugates were placed in microwells coated 
with anti-cAMP rabbit monoclonal antibodies and incubated at room temperature on an orbital 
mixer for three hours. The supernatants were then removed and the wells were washed four times 
with wash buffer. Next, 100 μl/well 3,3’,5,5’-Tetramethylbenzidine (TMB) substrate was added to 
each well and the formation of a coloured product was monitored for up to 30 minutes to prevent 
saturation. The reaction was terminated by adding stop solution to all the wells and then the 
absorbance was measured at 450 nm using a Flexstation III microplate reader. A standard curve 
was run with each experiment. 
  
2.21 ATP quantification assay 
An ATP Bioluminescence Assay Kit HS II was purchased from Roche and performed as per the 
manufacturer’s instructions. Luciferase from Photinus pyralis (American firefly) catalyses the 
breakdown of D-luciferin in the presence of ATP and a by-product of this reaction is green light 
emitted at 562 nm. 
ATP + D-luciferin + O2 → oxyluciferin + PPi + AMP + CO2 + light 
At low concentrations of ATP (CATP), the Michaelis-Menten constant (Km) is much greater than the 
concentration of ATP, therefore the Michaelis equation for the reaction (Light intensity = (Vmax x 
CATP)/(Km + CATP)) can be simplified to: 
Light intensity = Vmax x CATP/Km 
The amount of light produced by the reaction is directly proportional to the concentration of ATP 
and dependent on the amount of luciferase (Vmax) present. The working range of the assay is 
between 10-5 and 10-12 M ATP. 
In vitro differentiated adipocytes were washed once with warm PBS and then incubated with            
50 μl/well DMEM (no FBS or antibiotics) for 1 hour at 37 oC. Next, 1 μl vehicle or antagonist was 
86 
 
added directly to each well and the cells were incubated for a further 1 hour at 37 oC with 5% CO2. 
The supernatant was then carefully removed, taking care not to disturb the cells, and placed in a 
white 96-well plate alongside ATP standard curve samples diluted in DMEM. The plate was then 
immediately placed in a Flexstation III (Molecular Devices), which automatically added 50 μl 
luciferase/luciferin reagent to each well and measured the bioluminescence of each well. An 
integration time of 1 second was used. An ATP standard curve was produced every time the assay 
was run and this was used to convert the luminescence values to ATP concentrations (nM). Blank 
DMEM samples were also run to control for background luminescence.  
2.22 Glycerol quantification assay 
Lipid droplets within white adipocytes are filled with triglyceride molecules, which are composed 
of three fatty acids (FA) attached to a glycerol backbone. During times of nutrient shortage, 
triglycerides are hydrolysed to their component parts in a process known as lipolysis (Ahmadian et 
al., 2010). FA molecules are rapidly reabsorbed and recycled, but glycerol molecules are not 
metabolised to a significant extent (Vaughan, 1962), which means quantifying glycerol release is a 
more stable measure of lipolysis. To assess whether purinergic signalling may play a role in lipolysis, 
glycerol release was measured in the presence and absence of nucleotides and subtype selective 
antagonists. To do this, in vitro differentiated adipocytes were washed once with PBS and then 
incubated with 100 μl/well DMEM (no serum or antibiotics) for two hours at 37 oC with 5% CO2. 
Immediately following this incubation period, 1 μl/well vehicle or antagonist was added directly to 
each well and the cells were incubated for a further 30 minutes at 37 oC with 5% CO2. Next, a further 
50 μl/well DMEM containing vehicle or agonists was added to the cells. For the time series assays, 
a supernatant sample was collected immediately after the agonist was added by pipetting gently 
up and down twice and then transferring 100 μl of supernatant to a fresh 96-well plate. Samples 
were kept on ice for the duration of the experiment. The cells were incubated at    37 oC between 
sample intervals. The initial samples were labelled ‘0 minutes’, and then samples were taken after 
20, 40, 60, 120 and 180 minutes had lapsed. Alternatively, for all non-time series glycerol 
experiments, samples were taken three hours after vehicle/agonist was added. After the final 
sample was collected, all the samples were stored at -80 oC or used immediately for the glycerol 
quantification assay.  
A glycerol assay kit was purchased from Sigma-Aldrich and was performed as per the 
manufacturer’s instructions. The glycerol concentration is determined via the induction of a series 
of reactions catalysed by glycerol kinase and glycerol phosphate oxidase resulting in the formation 
of a fluorometric product proportional to the concentration glycerol present. In brief, 10 μl of each 
supernatant sample, no cell control or glycerol standard was placed in a glass bottom black 96-well 
plate. A master reaction mix containing 100 μl assay buffer, 2 μl enzyme mix, 1 μl dye reagent and 
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1 μl ATP was prepared. These amounts were multiplied by the number of wells required. 100 μl/well 
of master reaction mix was added to each well and the plate was briefly placed on a plate shaker 
to allow the reagents to mix well with the samples and then the plate was incubated at room 
temperature for 20 minutes. The fluorescence was then measured (excitation 535 nm/emission 587 
nm) using a Flexstation III microplate reader. A standard curve was run on each plate. The 
fluorescence intensity (RFU) was converted to a glycerol concentration using the gradient of the 
linear standard curve: 
[Glycerol] (μM) = (RFUsample – RFUno cell control) / gradient of the standard curve 
 Due to variation in basal glycerol levels between donors, the data was normalised to the amount 
of glycerol produced under the control conditions after 3 hours.  
 
2.23 Measuring glycerol release in primary human subcutaneous adipose 
tissue ex vivo 
To investigate whether observations made in in vitro differentiated adipocytes were representative 
of the effects ex vivo, an experiment was designed to stimulate adipose tissue ex vivo with AR-
C118925XX. To do this, two 1 cm2 pieces of fresh human subcutaneous abdominal adipose tissue 
were dissected and washed three times with PBS to remove excess blood and lipid. Attempts were 
made to avoid large blood vessels and areas of fibrous tissue when selecting tissue pieces. The 
pieces of tissue were then weighed individually. All the tissue pieces used weighed approximately 
500-600 mg. Each piece of tissue was then attached to a hook and suspended within a beaker 
containing 15 ml of gassed DMEM (pH 7.4) for one hour. The DMEM was gassed with a mixture of 
5% CO2 and 95% air). The DMEM was kept at 37 oC by incubating the beakers in a 37 oC water bath 
for the duration of experiment. The contents of each beaker were under constant, but gentle, 
agitation throughout the experiment. After the first hour had elapsed, baseline samples were taken 
every 20 minutes for 1 hour. Samples were taken in duplicate (20 μl per sample) and kept on ice. 
When a sample was taken, equivalent amounts of DMEM were replaced in each beaker to maintain 
a total volume of 15 ml. At the 1 hour timepoint, 15 μl of AR-C118925XX (final concentration 10 
μM) was added to one beaker and 15 μl of vehicle (DMSO) was added to other beaker prior to 
immediately taking the 1 hour sample. Subsequent samples were taken every 20 minutes for two 
hours for both conditions. Next at the 3 hour timepoint, isoprenaline (final concentration 1 μM) 
was added to both beakers and the tissue was left for another hour. The final samples were taken 
one hour later and then the concentration of glycerol in each of the samples was determined using 
a glycerol assay kit (Section 2.22). Both the vehicle and antagonist treated samples were normalised 
to their respective initial baseline values (0 minutes).  
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2.24 Protein array 
Adipocytes secrete a wide range of adipokines that are capable of regulating adipocyte metabolism 
in an autocrine/paracrine manner, as well as adipokines that can control systemic metabolism (Kim 
and Moustaid-moussa, 2000). In order to determine whether purinergic signalling may be involved 
in adipokine secretion, a protein array was conducted. In vitro differentiated adipocytes were 
washed once with PBS and then incubated with 100 μl/well DMEM (no serum or antibiotics) for 
two hours at 37 oC in 5% CO2. Next, 1 μl/well of vehicle (DMSO) or AR-C118925XX (10 μM final 
concentration) was added to each well and the cells were incubated for a further 30 minutes at     
37 oC in 5% CO2. Then, 1 μl/well of vehicle or ATP (100 μM final concentration) was added to each 
well and supernatant samples (75 μl/well) were collected immediately for the 0 hour timepoint by 
gently pipetting up and down. The samples were placed in a fresh 96-well plate and kept on ice for 
the duration of the experiment. Subsequent samples were taken in the same manner after 3 hours, 
6 hours and 24 hours. All the samples were stored at -80 oC until required.  
A Human Obesity Array Q3, which is a multiplexed sandwich ELISA-based quantitative array 
platform, that has the capacity to detect 40 human adipokine simultaneously (Figure 2.7), was 
purchased from RayBiotech. The protein array was performed as per the manufacturer’s 
instructions. In brief, supernatant samples and protein array slides coated with adipokine-specific 
antibodies (16 identical arrays per slide) were equilibrated to room temperature. All subsequent 
steps were conducted at room temperature, unless otherwise indicated. Each incubation or wash 
step was conducted on an orbital shaker. Non-specific binding was blocked by adding 100 μl/well 
of sample diluent to each well for 30 minutes. The sample diluent was then removed and 100 
μl/well of undiluted supernatant samples or cytokine standards were added to each well and the 
array was incubated at 4 oC overnight to encourage maximum detection. The following morning, 
the samples/standards were decanted and each well was washed five times with 1x wash buffer I 
and twice with 1x wash buffer II (five minutes for each wash). The wash buffer was removed, and 
the arrays were incubated with 80 μl/well of biotin-labelled detection antibodies for two hours, 
which should create a sandwich complex if the adipokine was present in the sample. Next, the 
excess antibodies were removed and again, the arrays were washed five times with wash buffer I 
and twice with wash buffer II. Next, each well was incubated with Cy3 equivalent dye-conjugated 
streptavidin (80 μl/well) for one hour while being protected from light. The wells were then washed 
five times with wash buffer I and twice with wash buffer II. The device holding the array was 
disassembled and the glass slide containing all 16 arrays was carefully transferred to a slide washer 
tube filled with 1x wash buffer I for 15 minutes. Wash buffer I was removed and the slide was 
washed with wash buffer II for five minutes. Finally, the slides were dried and sent back to the 
manufacturer for analysis. Positive adipokine detection was detected using a laser scanner 
equipped with a Cy3 wavelength. Each adipokine was arrayed in quadruplet for each sample. The 
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median fluorescence values were used for adipokine quantification analysis and a heat map was 
generated by normalising the average adipokine concentrations to the vehicle control.  
 
2.25 Statistical analysis 
Data were analysed, including statistical analyses, using Origin Student 2018 software (Origin Lab). 
Data were expressed as mean ± SEM of experiments performed in duplicate using cells from a 
minimum of three independent donors. However, in most cases cells from six independent donors 
were used. Throughout this thesis, N refers to the number of biological repeats (independent 
donors). As primary human cells were used throughout this study, unsurprisingly there was often 
donor-to-donor variation between absolute values, so values were normalised to their respective 
vehicle controls to minimise the effects of this variation. Data were assessed for normality using a 
Shapiro-Wilk test. Normally distributed data were assessed using a paired Student’s t-test or a 
repeated measures one-way ANOVA with post hoc Tukey test, whereas non-normally distributed 
data were assessed by paired sample Wilcoxon signed rank test or Friedman ANOVA with post hoc 
Dunn’s test.  
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Figure 2.7 Array map acquired from the Ray Biotech website displaying all 40 adipokines in the 
array. https://www.raybiotech.com/files/images/Maps/QAH-ADI-3.jpg Last accessed 19.5.18 
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Chapter 3: Characterisation of the 
purinergic receptor profile in primary 
human adipose-derived mesenchymal 
stromal cells 
 
3.1 Introduction 
Adipose tissue is an abundant and easily accessible source of mesenchymal stromal cells (MSCs) in 
adult humans. MSCs are multipotent plastic-adherent cells that can be isolated from bone marrow 
and other tissues, including adipose (Dominici et al., 2006). These cells exhibit the ability to 
differentiate into various cell types, such as adipocytes, osteoblasts, chondrocytes, myocytes and 
neurons (Ning et al., 2006; Uccelli et al., 2008; Karantalis et al., 2015). In adult adipose tissue, a pool 
of omnipresent MSCs serve to replace approximately 10% of mature adipocytes annually via 
adipogenesis (Spalding et al., 2008). Both adipogenesis and hypertrophic mechanisms are 
important for the expansion of adipose tissue and body buffering of glucose and free fatty acids. 
Lower rates of adipogenesis are associated with increased visceral obesity, adipocyte hypertrophy 
and higher fasting blood glucose (Lessard et al., 2014). This suggests that efforts to improve the 
adipogenic potential of MSCs may oppose metabolically unhealthy phenotypes.  
In addition to the physiological function of MSCs in vivo, adipose-derived (AD)-MSCs have been 
clinically evaluated for use in regenerative medicine to repair damaged tissue (Thesleff et al., 2011; 
Houtgraaf et al., 2012; Jo et al., 2014). The initial results suggest that MSCs exert their beneficial 
effects by migrating to the site of injury and utilising their regenerative capacity as well as having 
an immunomodulatory effect at the injury site (Cho et al., 2009; Feisst et al., 2015). Despite some 
promising results in tissue regeneration studies, MSC senescence and induced inflammation are 
common drawbacks to therapy (Turinetto et al., 2016; Kim et al., 2017). A greater understanding of 
how MSCs respond to their environment via cell surface receptors will therefore delineate MSC 
function.  
Signalling via extracellular nucleotides has been implicated in cell migration, proliferation, 
differentiation and inflammation (Burnstock and Verkhratsky, 2010; Yegutkin, 2014). Receptor-
mediated intracellular calcium (Ca2+) signals are known to be important for cellular proliferation 
and differentiation, and studies have demonstrated stem cell sensitivity to extracellular ATP (Tonelli 
et al., 2012). However, current work has primarily focused on rodent models and bone marrow-
derived MSCs (BM-MSC) or has failed to report the molecular basis of purinergic responses (Ferrari 
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et al., 2011; Jiang, Hao, et al., 2017). For example, extracellular nucleotides elicit reorganisation of 
actin filaments and cell migration in 3T3-L1 mouse adipocyte precursors (Omatsu-Kanbe et al., 
2006), and ATP promotes adipogenic and osteogenic differentiation in BM-MSCs (Ciciarello et al., 
2013). This Chapter focuses on the molecular identity of the P2 receptors in human AD-MSCs 
utilised to respond to physiologically relevant extracellular nucleotides, while also attempting to 
identify the downstream cellular functions mediated by P2 receptors in these cells.  
 
3.2 Purinergic receptor expression profile in primary human MSCs as 
determined by analysis of mRNA transcripts  
In order to fully identify the profile of purinergic receptors expressed in primary human AD-MSCs, 
mRNA transcript expression was explored using a mixture of non-quantitative and quantitative PCR.  
Although this project primarily focuses on the role of P2 purinergic receptors, for completeness the 
expression of P1 receptors was confirmed using non-quantitative PCR. Analysis of mRNA transcripts 
revealed that primary human MSCs expressed all of the known P1 receptor subtypes: A1, A2A, A2B 
and A3 (N=3; Figure 3.1A). P1 receptors are activated by adenosine, which is a product of ATP and 
ADP cell surface hydrolysis (Yegutkin, 2014), thus it is important to be mindful that exogenous 
application of nucleotides may indirectly activate P1 receptors, as well as P2 receptors. 
For characterising the profile of P2 receptors quantitative PCR was employed, therefore the data 
are expressed as average cycle threshold (CT) values (Table 3.1) or relative 1/∆CT values (Figure 3.1B) 
where the expression has been normalised to the expression of an endogenous reference gene, 
RPLP0, and inverted for analytical ease. Genes with a CT value of below 35 (or 1/∆CT > 0.06) were 
deemed to be present, whereas genes that were not detected or had CT values of above 35 (or 
1/∆CT < 0.06) were considered absent. Using these principles, it was determined that P2X1, P2X4, 
P2X5, P2X6, P2X7, P2Y1, P2Y2, P2Y4 and P2Y6 receptors were all present in MSCs, whereas P2X2 and 
P2X3 receptors were not expressed in any of the donors tested (N=6; Figure 3.1B; Table 3.1). It was 
also identified that there was some heterogeneity in the expression of P2Y11, P2Y12, P2Y13, and P2Y14 
receptors, as some donors had CT values above 35 for these receptors (Table 3.1). In the case of the 
P2Y12 receptor, only two of the six donors tested had CT values below 35, with even these donors 
displaying average CT values of 34.1 and 34.7 respectively, which indicates very low expression. On 
average the 1/∆CT for P2Y12 was below the cut-off of 0.06.  
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Table 3.1 Average cycle threshold (CT) values for each P2 receptor in primary human adipose-
derived mesenchymal stromal cells per donor (N=6). Only genes with CT values of <35 were 
considered present. ND indicates no amplification detected within 40 PCR cycles.  
Gene  
CT values  
Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6 
P2RX1 31.3 31.5 30.1 31.1 29.7 28.9 
P2RX2 ND ND ND ND ND ND 
P2RX3 37.3 38.5 37.5 ND 36.9 38.6 
P2RX4 24.8 26.7 26.5 25.3 26.4 25.2 
P2RX5 24.3 31.2 32.5 31.2 33.2 31.4 
P2RX6 31.8 32.4 33.5 34.4 33.8 31.6 
P2RX7 31.6 32.2 31.3 32.3 31.0 31.4 
P2RY1 28.9 30.0 31.9 28.7 28.7 26.0 
P2RY2 32.7 31.7 33.0 31.3 31.0 29.9 
P2RY4 30.6 31.8 32.8 30.8 30.3 29.3 
P2RY6 31.8 29.8 29.3 30.3 29.0 26.0 
P2RY11 35.3 35.3 32.0 32.5 31.7 29.3 
P2RY12 35.3 35.6 36.9 35.6 34.1 34.7 
P2RY13 35.6 33.5 33.8 34.2 32.8 30.9 
P2RY14 33.1 32.4 33.8 35.2 33.9 31.0 
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Figure 3.1 Messenger RNA expression profile of purinergic receptors in primary human adipose-
derived mesenchymal stromal cells. (A) Non-quantitative RT-PCR analysis of P1 receptor 
expression showing bands detected for ADORA1 (374 bp), ADORA2A (295 bp), ADORA2B (277 bp) 
and ADORA3 (302 bp). RT’ indicates the no reverse transcriptase control samples. Results are 
representative of the data for three independent donors. (B) Quantitative real time PCR analysis of 
the P2 receptor expression profile. Cycle threshold (CT) values have been normalised to the 
expression of an endogenous reference gene, RPLP0. The dashed line represents the CT cut-off, 
where receptors that had an average 1/∆CT value of below 0.06 are classified as not expressed 
(N=6). * indicate variability in expression (above and below the threshold) between donors. 
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3.3 Protein expression profile of P2 purinergic receptors in MSCs 
The protein level expression of the P2 receptors consistently detected at the mRNA level (Section 
3.2) were readily confirmed using immunocytochemistry. Immunofluorescence for P2X1, P2X4, 
P2X5, P2X7, P2Y1, P2Y2, P2Y4 and P2Y6 receptors were all consistently detected in three independent 
donors. Representative images of the positive staining observed for each receptor are shown in 
Figure 3.2A. In addition, the heterogeneity in mRNA transcript detection for both the P2Y11 and 
P2Y13 receptors was mirrored at the protein level, with positive protein staining detected in only a 
proportion of the three donors tested (Figure 3.2B). In the donor that P2Y13 was detected, the 
staining is particularly faint, but positive immunofluorescence above the no primary antibody 
control was evident under the microscope. No staining was observed for the P2Y12 receptor (N=3). 
Cells were not stained for P2X2, P2X3, P2X6 or P2Y14 either due to lack of mRNA expression or lack 
of available antibody.  
Immunocytochemistry not only confirmed that the mRNA expression profile (Section 3.2) was 
representative of the protein level expression of P2 receptors in primary human AD-MSCs, it also 
provided an insight into the cellular localisation and distribution of each receptor. However, it is 
difficult to definitively distinguish whether the receptors are located intracellularly or on the cell 
surface, because the cells were permeabilised for staining, cells were not counterstained with a 
membrane marker and the cells themselves are very flat. Overall, the immunocytochemical staining 
(Figure 3.2) revealed that P2X4, P2X5, P2Y4 and P2Y6 receptors, as well as P2Y11 and P2Y13 receptors 
when they were detected, were distributed relatively uniformly throughout the cytoplasm/cell 
membrane, although the staining was very faint for P2X5 and P2Y13 receptors. The 
immunofluorescence for P2Y2 receptors displayed a punctate distribution throughout the cell, 
whereas P2X1 receptors appeared to be particularly pronounced at the edges of the cell. Although 
immunofluorescence for both P2X7 and P2Y1 receptors was detected throughout the cells, 
unusually the staining appeared to be particularly intense in the nuclear/perinuclear regions. It was 
not possible to compare the relative protein expression level of each receptor due to differing 
antibody affinities. 
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Figure 3.2 Analysis of P2X and P2Y receptor immunofluorescence in human adipose-derived 
mesenchymal stromal cells (MSCs). (A) Immunocytochemical staining for P2X1, P2X4, P2X5, P2X7, 
P2Y1, P2Y2, P2Y4, P2Y6 and P2Y12 receptors. Images presented are representative of cells from three 
independent donors. (B) Immunocytochemical staining for P2Y11 and P2Y13 receptors showing 
heterogeneity between cells extracted from three independent donors. Images were taken with a 
63x objective on a Zeiss AxioPlan 2ie epifluorescent microscope of permeabilised MSCs labelled 
with primary antibodies against receptor targets and visualized with an Alexa Fluor 488-conjugated 
secondary antibody (green). Cells are counterstained with DAPI to visualise nuclei (blue). The 
exposure and camera settings remained consistent across all the images taken for each donor. 
Images are representative of at least ten fields of view for cells from three independent donors. 
Scale bar represents 30 μm.
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3.4 Nucleotide-evoked calcium responses in primary human MSCs 
Activation of P2 receptors leads to a transient elevation of intracellular Ca2+ levels due to direct Ca2+ 
entry from the extracellular space via ionotropic P2X receptors or release of Ca2+ from intracellular 
stores due to activation of metabotropic P2Y receptors. To ascertain whether the P2 receptors 
expressed in MSCs were functionally active, exogenous nucleotides were applied and real-time 
changes in intracellular Ca2+ levels were monitored.  
In the presence of extracellular Ca2+, exogenous application of ATP, ADP and UTP elicited 
concentration-dependent increases in intracellular Ca2+ in all donors tested (N=7-9) (Table 3.2; 
Figure 3.3A,C,E). Nucleotides had a rank order of potency ADP (EC50 1.25±1.0μM) > ATP (EC50 
2.2±1.1μM) = UTP (EC50 3.2±2.8μM). All three nucleotides elicited an initial rapid response that 
decayed to approximately 25% above baseline intracellular Ca2+ levels within the recording period 
of 250 seconds (Figure 3.3B,D,F). Between nucleotides the magnitude of responses and net Ca2+ 
movement were comparable at maximal concentrations (Table 3.2), though responses to ADP 
decayed significantly faster than responses elicited by ATP or UTP (p<0.05, N=7-9; Table 3.2).  
 
Table 3.2 Characteristics of the calcium responses evoked by maximal concentrations of 
nucleotides (30 μM) in primary human adipose-derived mesenchymal stromal cells. Mean ± SEM. 
Nucleotide Peak magnitude 
(F ratio) 
Net calcium movement 
(area under the curve) 
Decay time, τ 
(s) 
EC50 (μM) 
ATP (N=9) 0.422 ± 0.05 53.7 ± 5.9 73.4 ± 230.2 2.24 ± 1.1 
ADP (N=8) 0.385 ± 0.05 39.6 ± 6.2 35.3 ± 6.3a 1.25 ± 1.0 
UTP (N=7) 0.334 ± 0.06 41.9 ± 7.8 122.4 ± 4447.5 3.24 ± 2.8 
a Decay time was significantly faster for the ADP-evoked calcium response vs ATP (p<0.005) and UTP (p<0.005) as 
determined by Kruskal-Wallis ANOVA with post hoc analysis using a Dunn's Test. 
 
Changes in intracellular calcium were not detected in response to application of 30 μM UDP or 
below (N=6) (Figure 3.4A,B). However, responses were consistently detected in the presence of   
300 μM UDP (N=6), with some donors displaying very small responses (peak Fratio 0.12 ± 0.04, N=3 
of 6 donors) with the addition of 100 μM UDP. Agonist concentrations of above 30 μM UDP are not 
likely to be representative of physiological nucleotide concentrations, so it is unlikely that these 
results show true activation of UDP-sensitive receptors. It is possible that these responses are 
instead due to ATP, ADP or UTP contamination of the UDP used, which was the manufacturer states 
is >96% pure. Similarly, exogenous application of UDP-glucose elicited a Ca2+ response in some 
donors (N=3 of 9 donors) (Figure 3.4C,D), but these responses were only evident at very high agonist 
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concentrations of greater than 100 μM (N=1) or 300 μM (N=2). No response was detected for 30 
μM UDP-glucose (N=9). Furthermore, six out of a nine donors tested did not display a response to 
UDP-glucose at any concentration tested (up to 600 μM) (data excluded from Figure 3.4C,D). The 
EC50 values for both UDP and UDP-glucose could not be accurately calculated as the ‘responses’ had 
not plateaued within the range of concentrations tested. 
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Figure 3.3. ATP, ADP and UTP elicited intracellular calcium responses in human adipose-derived 
mesenchymal stromal cells. Concentration response curves for the peak magnitude of intracellular 
Ca2+ responses elicited by (A) ATP (N=9), (C) ADP (N=8) and (E) UTP (N=7). Ca2+ responses were 
normalized to the maximal response observed in the majority of donors, which was the response 
to 30 μM ATP, ADP and UTP respectively. Averaged time-resolved intracellular Ca2+ responses 
elicited by (B) 30 μM ATP (N=9), (D) 30 μM ADP (N=8) and (E) 30 μM UTP (N=7). Traces were 
normalised to the maximal response within a donor, and averaged across donors. Data points are 
mean ± SEM. 
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Figure 3.4 Physiological concentrations of UDP and UDP-glucose did not elicit consist intracellular 
calcium responses in human adipose-derived mesenchymal stromal cells. Concentration response 
curves for the magnitude of intracellular Ca2+ responses elicited by (A) UDP (N=6) and (C) UDP-
glucose (N=3). Ca2+ responses were normalized to the maximal response observed in the majority 
of donors, which was the response to 300 μM UDP and 600 μM UDP-glucose respectively. Average 
data for donors that responded to nucleotide stimulation are shown. Data for donors that did not 
respond to nucleotide stimulation were excluded. Averaged time-resolved intracellular Ca2+ 
responses elicited by (B) 30 μM UDP (N=6) and (D) 30 μM UDP-glucose (N=3). Traces were 
normalised to the maximal response within a donor, and averaged across donors. Data points are 
mean ± SEM. 
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3.5 Nucleotide-evoked calcium responses persisted despite multiple 
passaging of primary human MSCs 
During this study, MSCs were passaged up to eight times for experimental use, so it was important 
to establish whether the nucleotide-evoked calcium responses remained consistent irrespective of 
passage number. To do this, the response to super-maximal concentrations of ATP, ADP and UTP 
were monitored across eight passages. This revealed that all three nucleotides evoked functional 
calcium responses from passage 1 to 8 and although there were slight fluctuations in the magnitude 
of the response across the different passages (Figure 3.5), these changes were not significant, 
suggesting the purinergic response in these cells is not altered by passage.  
 
3.6 Nucleotide-evoked calcium responses persisted, but were significantly 
diminished in the absence of extracellular calcium 
The responses elicited by maximal ATP, ADP and UTP concentrations persisted, but were decreased 
by 82.7±3.5% (N=6, p<0.001), 92.0±4.2% (N=3, p<0.05) and 81.8±4.0% (N=4, p<0.001; Figure 
3.6B,D,F; Table 3.3) respectively following removal of Ca2+ from the extracellular solution with             
2 mM EGTA. This suggests the magnitude of the nucleotide responses are heavily reliant on 
extracellular calcium, which may indicate P2X receptor activity. However, the fact that there are 
concentration-dependent responses to ATP, ADP and UTP (N=6; Figure 3.6A,C,E) in the absence of 
extracellular calcium suggests that nucleotide-evoked calcium responses are at least in part 
mediated by metabotropic P2Y receptors. If the response was entirely mediated by P2X ion 
channels, then you would expect the response to be abolished in the absence of extracellular 
calcium. The small transient increase in intracellular calcium observed with higher concentrations 
of each agonist must be due to release of calcium from intracellular stores. It is possible that the 
reduced magnitude of the nucleotide-evoked responses may be due to partial emptying of the 
intracellular stores due to cellular efforts to maintain intracellular calcium homeostasis in the 
absence of extracellular calcium. 
The nucleotide-evoked responses also all returned to baseline Ca2+ levels within the sampling 
period when extracellular Ca2+ was removed, instead of remaining approximately 25% above 
baseline. In addition, in the absence of extracellular calcium, ATP-evoked responses decayed faster 
(τ 31.2±5.4 seconds without Ca2+ vs τ 55.0±3.6 seconds with Ca2+, p<0.005; N=6). Although the 
responses to ADP and UTP displayed the same trend, the respective alterations in the decay times 
were not statistically significant (Table 3.3). Also, despite the appearance of a rightward shift in the 
concentration response curves, particularly for ADP (Figure 3.6C), variation between donors meant 
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that the EC50 values were not significantly altered for any of the nucleotides when extracellular 
calcium was removed (Table 3.3).  
 
Table 3.3 Changes in the magnitude, decay kinetics and potency of nucleotide-evoked calcium 
responses in primary human adipose-derived mesenchymal stromal cells in the presence and 
absence of extracellular calcium, [Ca2+]e. Mean ± SEM. 
Nucleotide Peak magnitude  
(F ratio)a 
Decay time, τ (s) EC50 (μM) 
 + [Ca2+]e - [Ca2+]e + [Ca2+]e - [Ca2+]e + [Ca2+]e - [Ca2+]e 
30 μM ATP (N=6) 0.68±0.1 0.11±0.03 55.0±3.6 31.2±5.4b 0.9±0.4 5.7±2.6 
100 μM ADP (N=3) 1.08±0.1 0.17 ± 0.1 30.3±1.4 22.5±72.4 0.8±0.6 28.3±62.1 
30 μM UTP (N=4) 0.57±0.04 0.12±0.02 59.7±27 41.2±5.9 8.3±1.4 7.8±2.8 
a The peak magnitude was significantly decreased when extracellular calcium is removed for ATP (p<0.001), ADP 
(p<0.05) and UTP (p<0.001) as determined by paired T tests or Wilcoxon signed rank test. 
b The decay time was significantly faster for the ATP-evoked calcium response in the absence of extracellular calcium 
(p<0.005) as determined by a paired T test. 
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Figure 3.5 Effect of multiple passage of primary human mesenchymal stromal cells on the 
magnitude of the response to (A) 100 μM ATP, (B) 100 μM ADP and (C) 100 μM UTP.
104 
 
 
Figure 3.6 Removing extracellular calcium leads to a reduction in the magnitude of the response 
evoked by ATP, ADP and UTP in primary human adipose-derived mesenchymal stromal cells. 
Concentration-response curves in the presence (closed circles) and absence (open circles) of 1.5 
mM extracellular calcium for (A) ATP (N=6), (C) ADP (N=3) and (E) UTP (N=4). All responses were 
normalised to the response to maximal concentrations of each agonist (30 μM ATP and UTP and 
100 μM ADP respectively) in the presence of extracellular calcium. Average time-resolved traces 
showing the response elicited by (B) 30 μM ATP (N=6), (C) 100 μM ADP (N=3) and (D) 30 μM UTP 
(N=4) in the presence (closed circles) and absence (open circles) of extracellular calcium (N=6). Data 
points represent the mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 versus response to equivalent 
agonist concentration in the presence of extracellular calcium. 
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3.7 Nucleotide-evoked calcium responses in primary human MSCs are 
mediated by phospholipase C activation and downstream release of calcium 
from the intracellular store 
Inhibition of phospholipase C (PLC), which is part of the downstream signalling pathway instigated 
by Gq-coupled P2Y receptor activation, with 10 μM U73122 abolished the responses to ATP (N=6), 
ADP (N=4) and UTP (N=3) (Figure 3.7). These results suggest a predominance of metabotropic P2Y 
receptor involvement in the nucleotide-evoked Ca2+ responses in primary human AD-MSCs, with 
little or no contribution from P2X receptors. This hypothesis is supported by the fact that the 
nucleotide-evoked calcium responses persist in the absence of extracellular calcium (Section 3.6). 
Furthermore, depleting the endoplasmic reticulum Ca2+ stores by inhibiting sarco-endoplasmic 
reticulum Ca2+-ATPases (SERCA) with 5 μM thapsigargin abolishes the response to ATP (N=6) (Figure 
3.8). Together these data suggest that the nucleotide responses in human AD-MSCs are mediated 
primarily by metabotropic P2Y receptors. These results may also indicate that the diminished 
nucleotide-evoked calcium responses observed in the absence of extracellular calcium (Figure 3.6) 
are likely to be due to partial emptying of the stores and/or the lack of store-operated calcium entry 
post-P2Y receptor activation, rather than P2X involvement. However, as the reductions in the 
magnitudes of the responses are so pronounced (Figure 3.6), it is also possible that P2X receptors 
act downstream of P2Y receptors and they may be responsible for potentiating the nucleotide-
evoked responses in the presence of extracellular calcium.  
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Figure 3.7 Inhibition of phospholipase C with 10 μM U73122 abolishes the response to ATP,            
30 μM ADP and 30 μM UTP in primary human adipose-derived mesenchymal stromal cells. (A) 
ATP concentration response curve in the presence (open circles) and the absence (closed circles) of 
10 μM U73122. Responses were normalised to the response to 30 μM ATP in the absence of 
U73122. Average time-resolved traces showing the response elicited by (B) 30 μM ATP (N=6), (C) 
30 μM ADP (N=4) and (D) 30 μM UTP (N=4) in the presence (open circles) and absence (closed 
circles) of 10 μM U73122. Data points represent the mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 
versus response to equivalent concentrations of ATP in the absence of U73122. 
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Figure 3.8 Inhibition of sarcoendoplasmic reticulum calcium transport ATPase (SERCA) with 5 μM 
thapsigargin completely abolishes the response to ATP in primary human MSCs (N=6). (A) ATP 
dose-response curve under control conditions (closed circles) or following sarco-endoplasmic 
reticulum Ca2+-ATPases inhibition induced emptying of the intracellular Ca2+ stores with 5μM 
thapsigargin (open circles) (N=6). (B) Average time-resolved traces for the response to 30 μM ATP 
under control conditions (closed circles) and following thapsigargin pre-treatment (open circles) 
(N=6). Data points represent mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 versus the response to 
equivalent concentrations of ATP in absence of thapsigargin. 
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3.8 P2X receptors are not involved in the ATP-evoked calcium responses in 
primary human MSCs 
Almost all known purinergic receptor subtypes respond to ATP, either directly or via ATP breakdown 
products, such as ADP or adenosine, however certain subtypes, P2X1-7, P2Y2 and P2Y11 receptors, 
display greater affinity for ATP above other physiological agonists (Burnstock, 2007). All of the 
known P2X receptor subtypes, excluding P2X2 and P2X3 receptors, were detected in primary 
human AD-MSCs (Section 3.3 and 3.4). However, only three of the five detected P2X receptors are 
known to commonly form functional receptors in humans: P2X1, P2X4 and P2X7 receptors. Current 
evidence suggests both P2X5 and P2X6 receptors are non-functional in humans (Torres et al., 1999; 
Ormond, 2006; Kotnis et al., 2010). In addition, the response to the P2X1 receptor rapidly 
desensitises, so it is unlikely to be detected with the equipment used in this study. This narrows the 
possible P2X receptor candidates to just P2X4 and P2X7 receptors. MSCs were preincubated with 
selective antagonists for the P2X4 receptor (PSB12062) or the P2X7 receptor (A438079) to see 
whether either receptor had any effect on the response to ATP. It is important to note that super-
maximal concentrations of ATP were used, as P2X receptors, particularly P2X7 receptors, typically 
require much higher concentrations of ATP to be activated (Gorini et al., 2013), so the agonist 
concentrations have been adjusted accordingly to facilitate P2X receptor activation. Despite 
elevating the concentration of agonist, both antagonists failed to significantly alter the response to 
ATP in these cells (N=6; Figure 3.9A-D, Table 3.4), suggesting that neither receptor is involved in the 
ATP-evoked calcium response. The lack of functional evidence of P2X4 and P2X7 receptor 
involvement in the response to ATP is in agreement with the evidence put forward in Sections 3.6 
and 3.7, which strongly suggests a predominance of metabotropic P2Y receptors.  
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Figure 3.9 Selective antagonism of P2X4, P2X7 and P2Y11 receptors had no inhibitory effect on the 
ATP-evoked calcium response in primary human mesenchymal stromal cells (N=6). (A) The 
response to 100 μM ATP antagonised with increasing concentrations of the selective P2X4 receptor 
antagonist, PSB12062. (C) The response to 1 mM ATP antagonised with increasing concentrations 
of the selective P2X7 receptor antagonist, A438079. (E) The response to 30 μM ATP antagonised 
with increasing concentrations of the selective P2Y11 receptor antagonist, NF340. Time-resolved 
traces showing the response to ATP in the presence (open circles) and absence (closed circles) of 
(B) 10 μM PSB12062, (D) 10 μM A438079 or (F) 10 μM NF340. All data points are normalised to 
their respective peak agonist response in the presence of vehicle only. Data points are expressed 
as mean ± SEM. * p<0.05 versus the agonist response in the presence of vehicle only.
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3.9 ATP and UTP-evoked calcium responses are mediated by P2Y2 receptors 
in primary human MSCs  
In addition to P2X receptors, P2Y2 and P2Y11 receptors also display a preference for ATP, so selective 
antagonists for both receptors were utilised to identify whether either of these receptors were 
involved in the ATP-evoked Ca2+ responses in AD-MSCs. The response to maximal and EC50 
concentrations of ATP was not inhibited by selective antagonism of P2Y11 using NF340 (N=6; Figure 
3.9E,F; Table 3.4). Although, oddly very low concentrations of NF340 (≤10 nM) caused significant 
potentiation of the response to ATP. It is unclear what the reason for this may be. Antagonism of 
other P2Y receptors that display lower affinities for ATP, such as P2Y1 (Figure 3.12A,B), P2Y12 and 
P2Y13 receptors (Table 3.4), also failed to have an inhibitory effect on the response to ATP (N=6). 
However, the response to ATP was significantly and dose-dependently inhibited in the presence of 
a P2Y2 receptor selective antagonist, AR-C118925XX (Figure 3.10A,B). It caused concentration-
dependent inhibition of the peak response to ATP (IC50 1.1±0.8μM, N=7), reaching a plateau 
inhibition of 73.0±8.5% on average in the presence of 10 μM antagonist (N=7; Figure 3.10A,B). Net 
elevation in intracellular Ca2+ in response to ATP, as calculated by the area under the curve, was 
inhibited by 81.5±3.3% with maximal concentrations of AR-C118925XX (N=5). Although AR-
C118925XX had an inhibitory effect on the ATP response in all donors tested, there was some 
variation between donors. In three of the seven donors tested, the response to ATP was abolished 
in the presence of 3 μM antagonist, although on average there appears to be a residual response 
of approximately 20% of the response in the presence of vehicle only. Furthermore, AR-C118925XX 
abolished UTP-evoked responses with the same potency as the ATP response (IC50 1.6±0.6μM, N=6) 
(Figure 3.10C,D).  Together with the observation that ATP and UTP are equipotent agonists in MSCs 
(Section 3.4), these data strongly suggest that the ATP and UTP responses are mediated primarily 
by P2Y2 receptor activation.   
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Figure 3.10 Selective antagonism of the P2Y2 receptor with AR-C118925XX has an inhibitory effect 
on the response to ATP and abolishes the response to UTP in primary human mesenchymal 
stromal cells. AR-C118925XX inhibition response curves for the response to (A) 30 μM ATP (N=7) 
and (C) 30 μM UTP (N=6). (B) Time-resolved traces showing the response to ATP in the presence 
(open circles) and absence (closed circles) of 10 μM AR-C118925XX (N=7). (D) Time-resolved traces 
showing the response to UTP in the presence (open circles) and absence (closed circles) of 30 μM 
AR-C118925XX (N=6). All data points are normalised to their respective agonist responses in the 
presence of vehicle control. Data points are expressed as mean ± SEM. * p<0.05, ** p<0.005, *** 
p<0.001 versus the agonist response in the presence of vehicle only.
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Table 3.4 The effect of P2 subtype selective antagonism on the nucleotide-evoked calcium responses in primary human adipose-derived mesenchymal stromal cells. 
The number of independent donor cells used (N number) is indicated within round brackets in the maximum inhibition and IC50 columns.  
Selective 
antagonist 
Receptor 
target 
Nucleotide 
[concentration, μM] 
 Antagonist range, 
μM 
Maximum inhibition (%)a 
[antagonist concentration, μM] 
IC50, μMa 
 
PSB-12062 P2X4 ATP [100] 0.003 – 30 NS - 
A438079 P2X7 ATP [1000] 0.003 – 10 NS - 
MRS2500 P2Y1 ATP [3] 1 NS - 
  ATP [30] 0.0001 – 1 NS - 
  ADP [1] 1 NS - 
  ADP [30] 0.0001 – 1 NS - 
AR-C118925XX P2Y2 ATP [30] 0.003 – 30 73.0 ± 8.5 [10] (7) 
81.5  3.3 [10] (5) 
1.1 ± 0.8 (7) 
2.9 ± 1.1 (5) 
 ADP [30] 0.003 - 30 18.2  6.6 [30] (6) 
53.9  5.1 [30] (6) 
0.64 ± 0.4 (6) 
9.6 ± 1.6 (6) 
 UTP [30] 0.003 - 30 100 [30] (6) 
100 [30] (6) 
1.6 ± 0.6 (6) 
0.84 ± 0.5 (6) 
MRS2578 P2Y6 ADP [30] 0.003 - 10 79.4  9.6 [10] (6) 0.44 ± 0.1 (6) 
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 166.9  27.3 [10] (6) 0.29 ± 0.1 (6) 
NF340 P2Y11 ATP [3] 10 NS - 
  ATP [30] 0.003 - 10 NS - 
  ADP [1] 10 NS - 
  ADP [30] 0.003 – 10 NS - 
PSB-0739 P2Y12 ATP [30] 0.003 – 10 NS - 
  ADP [30] 0.003 – 10 NS - 
MRS2211 P2Y13 ATP [30] 0.003 – 10 NS - 
  ADP [30] 0.003 – 3 NS - 
aIC50 values and max % inhibition values were calculated with the peak magnitude values (top) and area under the curve data (bottom) for each agonist/antagonist combination. ns 
indicates no significant inhibition with any concentration of antagonist tested. 
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3.10 shRNA-mediated knockdown on P2Y2 receptor expression leads to loss 
of AR-C118925XX sensitivity in primary human MSCs 
In an attempt to confirm the pharmacological findings presented in Section 3.9, P2Y2 receptor 
expression was knocked down in primary human AD-MSCs using shRNA. This method was able to 
successfully decrease the mRNA expression of P2Y2 by 45.4±22% (N=3; Figure 3.11E). The 
expression of P2Y2 was decreased in all three donors, however, as indicated by the large standard 
error of the mean associated with the percentage decrease value, there was variability in the 
amount of knockdown achieved in cells isolated from different donors, ranging from 15.8% to 
88.2% knockdown depending on the donor. This variation in the level of knockdown translated to 
variation in the effects observed, which made it difficult to observe statistically significance.   
Surprisingly, knocking down P2Y2 receptor expression lead to a significant increase in the magnitude 
(Figure 3.11B) and net movement of calcium (Figure 3.11C) of the response to 30 μM ATP, which 
directly contradicts the results obtained by pharmacologically inhibiting P2Y2 receptors with AR-
C118925XX. However, interestingly the P2Y2 knockdown cells were no longer sensitive to AR-
C118925XX, whereas AR-C118925XX was able to decrease the peak and area under the curve of the 
response to ATP in the scrambled cells. In the time-resolved traces (Figure 3.11A), AR-C118925XX 
appears to accelerate the decay of the response to ATP in the knockdown cells, but this effect was 
only observed in the donor with the lowest level of P2Y2 receptor knockdown (15.8% knockdown 
versus scrambled control), which skewed the data. Thus, when the change in net calcium was 
quantified this effect was not statistically significant. The lack of sensitivity to AR-C118925XX in the 
knockdown cells indicates that the increase in the magnitude and net movement of calcium in 
response to ATP in these cells is not mediated by P2Y2 receptors. Instead, it is likely that the reason 
that the response to ATP increases when P2Y2 receptor expression is knocked down is that 
redundancy mechanisms are engaged to preserve the response to ATP in AD-MSCs. Although it is 
unclear what the molecular basis of this heightened response to ATP is, as mentioned in the 
previous Section (3.7 and 3.8), there are other receptors which are preferentially activated by ATP 
(P2X receptors and P2Y11), so it is likely that the cells engage these alternative receptors to maintain 
the response to ATP.  
Although there appear to be mechanisms in place to preserve the ATP-evoked calcium response, 
there does not seem to be the same protection for the UTP response. The response to UTP 
decreased when P2Y2 receptor expression was knocked down, although this decrease was not 
statistically significant due to variation between donors in the level of decrease in response 
magnitude. Again, the donor that showed limited P2Y2 receptor knockdown (15.8%) skewed the 
data. This donor displayed a very small/no effect on the response to UTP in the knockdown cells 
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versus the scrambled counterparts, which means the decrease in the response to UTP in the 
knockdown cells was not statistically significant.  
Overall, although these data are difficult to interpret due to the variation between donors and the 
apparent redundancy mechanisms that activate upon receptor knockdown, the results appear to 
largely support the pharmacological data as the UTP response was decreased, albeit non-
significantly, and the ATP response was no longer sensitive to pharmacological inhibition of P2Y2 
receptors.    
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Figure 3.11 shRNA-mediated knockdown of P2Y2 receptors in primary human mesenchymal 
stromal cells causes a loss of sensitivity to pharmacological inhibition of P2Y2 receptors (N=3). (A) 
Time-resolved traces showing the elevation in intracellular calcium in response to 30 μM ATP in 
scrambled control cells (closed symbols) versus P2Y2 receptor knockdown cells (open symbols) in 
the presence (circles) and absence (squares) of 10 μM AR-C118925XX. (B) The peak magnitude data 
and (C) area under the curve data for the ATP-evoked Ca2+ response in the presence (grey bars) and 
absence (black bars) of 10 μM AR-C118925XX. (D) Response to 30 μM UTP in the scrambled control 
cells (closed circles) and P2Y2 receptor knockdown cells (open circles). Responses are normalised to 
the respective responses to 1 μM ionomycin in each cell type to control for variation in cell number. 
(E) Relative fold-change in P2Y2 receptor mRNA transcript expression quantified using quantitative 
PCR. Values were normalised to the expression of an endogenous reference, RPLP0 (N=3).  
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3.11 ADP-evoked calcium responses in primary human MSCs are mediated 
by P2Y6 receptors 
Like ATP, some P2 receptors are preferentially activated by ADP: P2Y1, P2Y12 and P2Y13 receptors. 
Of these receptors only P2Y1 receptors are Gq-coupled and therefore expected to directly affect 
calcium levels via activation of PLC and release of Ca2+ from intracellular stores. However, although 
P2Y1 receptors were detected at the mRNA and protein level, selective antagonism of P2Y1 
receptors using MRS2500 had no significant effect on the response to maximal and EC50 
concentrations of ADP (N=6; Figure 3.12B/C; Table 3.4). In addition, application of a selective P2Y1 
receptor agonist, MRS2365, did not elicit a detectable change in intracellular calcium levels (N=3; 
Figure 3.12E). Taken together these data strongly suggests that P2Y1 receptors are not functionally 
active in primary human AD-MSCs under the conditions used in this study. Furthermore, selective 
antagonism of P2Y12 receptors and P2Y13 receptors with PSB0739 and MRS2211 respectively had no 
significant effect on the response to ADP (N=6; Figure 3.13). These results are perhaps less 
surprising, as P2Y12 receptors were not detected at the protein level (Figure 3.2) and there was 
heterogeneity in the expression of P2Y13 receptors between donors (Table 3.1), whereas the 
response to ADP was present in all donors. In addition, P2Y13 receptors are Gi-coupled, so activation 
of P2Y13 may instead lead to changes in intracellular cAMP levels that are independent of calcium.   
Interestingly, the only subtype-selective antagonists to have an effect were AR-C118925XX and 
MRS2578 (P2Y6 receptor antagonist). MRS2578 in particular displayed potent antagonism (IC50 
437±133nM; N=6) of the ADP response and inhibited the peak response elicited by maximal ADP 
concentrations by >80% (N=6; Figure 3.14A,B). Antagonism of P2Y6 receptors also caused the 
concentration of intracellular Ca2+ to drop below baseline Ca2+ post agonist stimulation. ADP has 
been shown to elicit a calcium response in 1321N1 astrocytoma cells over-expressing P2Y6 
receptors, but its effects are much less potent than the preferred agonist of P2Y6 receptors, UDP 
(Communi et al., 1996), so it was surprising that MRS2578 abolished the response to ADP in MSCs, 
when these cells lack a UDP-elicited Ca2+ response (N=6; Section 3.4). The ADP-evoked calcium 
responses were also affected by selective antagonism of P2Y2 receptors with AR-C118925XX. 
Although, AR-C118925XX (≤10μM) did not affect the magnitude of the response, it altered the 
decay kinetics which attributed to a decrease in the net movement of Ca2+ by 37.3±5.8% (p<0.001, 
N=6) (Figure 3.14C,D). ADP is not the preferred agonist for P2Y2 receptors, so these results may 
indicate indirect activation of the P2Y2 receptor via ADP-induced release of ATP (Jiang, Mousawi, et 
al., 2017). Alternatively, this effect may be due to a small amount ATP contamination of the ADP 
(Mahaut-Smith et al., 2000). The manufacturers state that the ADP utilised in this study is ≥95% 
pure. 5% ATP contamination would amount to approximately EC50 concentrations of ATP being 
present when a maximal concentration of ADP (30 μM) is applied to the cells. 
118 
 
 
Figure 3.12 P2Y1 receptors do not appear to be functionally active in primary human 
mesenchymal stromal cells. Effect of increasing concentrations of MRS2500 (a P2Y1 receptor 
antagonist) on the response to (A) 30 μM ATP (N=6) and (C) 30 μM ADP (N=6). Time-resolved traces 
showing the effect of 1 μM MRS2500 on the response to (B) 30 μM ATP (N=6) and (D) 30 μM ADP 
(N=6). All data points are normalised to their respective agonist responses in the presence of vehicle 
control. (E) Non-normalised data showing no detectable change in intracellular calcium upon 
exogenous application of 100 nM MRS2365 (a P2Y1 receptor agonist) (N=3). Data points are 
expressed as mean ± SEM. 
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Figure 3.13 The ADP-evoked calcium response in primary human mesenchymal stromal cells is 
insensitive to selective antagonism of P2Y12 and P2Y13 receptors with PSB0739 and MRS2211 
respectively (N=6). Effect of increasing concentrations of (A) PSB0739 (a P2Y12 receptor antagonist) 
or (C) MRS2211 (a P2Y13 receptor antagonist) on the response to 30 μM ADP (N=6). Time-resolved 
traces showing the effect of (B) 10 μM PSB0739 or (D) 10 μM MRS2211 on the response to 30 μM 
ADP (N=6). All data points are normalised to their respective agonist responses in the presence of 
vehicle only. Data points are expressed as mean ± SEM. 
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Figure 3.14 Selective antagonism of P2Y2 and P2Y6 cause concentration-dependent inhibition of 
the ADP-evoked calcium response in primary human mesenchymal stromal cells (N=6). (A) Effect 
of increasing concentrations of MRS2578 (a P2Y6 receptor antagonist) on the peak magnitude of 
the response to 30 μM ADP (N=6). (C) Effect of increasing concentrations of AR-C118925XX (a P2Y2 
receptor antagonist) on the net movement of calcium in response to stimulation with 30 μM ADP 
(N=6).  Time-resolved traces showing the effect of (B) 3 μM MRS2578 or (D) 10 μM AR-C118925XX 
on the response to 30 μM ADP (N=6). All data points are normalised to their respective agonist 
responses in the presence of vehicle only. Data points are expressed as mean ± SEM. *p<0.05, 
**p<0.005, ***p<0.001 versus the agonist response in the presence of vehicle only.
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3.12 Investigating possible downstream functions mediated by purinergic 
signalling in primary human MSCs 
In recent years there has been growing interest in human AD-MSCs, both in research to tackle the 
growing problem of obesity and for use in regenerative medicine. These cells are able to proliferate 
to maintain a pool of omnipresent multipotent cells, which are capable of maintaining or expanding 
adipose tissue via adipogenesis (Spalding et al., 2008). MSCs can migrate to areas where they are 
required to regenerate adipose tissue post cell death. These homing capabilities can be exploited 
for use in regenerative medicine, where several chemokines and growth factors have been shown 
to induce chemotaxis of MSCs to the site of injury and subsequently differentiate to replenish the 
damaged tissue (Eseonu and De Bari, 2015; Feisst et al., 2015). Although, this technique has been 
successfully employed in some patients (Feisst et al., 2015), little is known about the molecular 
mechanisms that underline these functions. Better understanding of these mechanisms could 
result in a more tailored approach that is able to increase the success rate of these procedures, as 
well as providing insight into the normal systems that are in place to regenerate and expand adipose 
tissue, so that we are able to design pharmacological interventions capable of controlling adipose 
tissue expansion to assist in the fight against the global epidemic of obesity.  
Calcium signalling has previously been implicated in the initiation of cell proliferation and migration 
(Tonelli et al., 2012; Jiang, Mousawi, et al., 2017). As demonstrated earlier in this Chapter, 
activation of both P2Y2 and P2Y6 receptors in primary human MSCs leads to a transient elevation in 
intracellular calcium. Thus, these receptors are candidates for mediating calcium signalling 
pathways controlling cell proliferation and migration within AD-MSCs. The following sections detail 
the attempts made to identify the functional role of P2Y2 and P2Y6 receptors in primary human 
MSCs.  
 
3.12.1 Cell proliferation 
In comparison to bone marrow derived MSCs, AD-MSCs have an increased capacity to proliferate 
(Yu et al., 2015), this feature, coupled with the fact that AD-MSCs are more accessible, makes them 
the ideal resource for regenerative medicine. To test whether purinergic signalling may be involved 
in cell proliferation, cells were grown in the presence of nucleotides or subtype-selective 
antagonists and cell proliferation was measured using an MTS assay. As expected the data revealed 
that MSCs are capable of proliferating in vitro. The absorbance steadily increased over the first 72 
hours as the cells proliferated and then plateaued due to contact inhibition. However, the results 
also suggested that a single application of maximal concentrations of ATP, ADP or UTP had no effect 
on the rate of cell proliferation in primary human AD-MSCs (N=3; Figure 3.15). In addition, selective 
antagonism of P2Y2 and P2Y6 receptors also had no effect on cell proliferation (Figure 3.16). Taken 
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together these results imply nucleotide-evoked Ca2+ responses are not involved in cell proliferation. 
However, it is important to note that an MTS assay was used to measure cell proliferation in this 
study and although the reagent is marketed a ‘cell proliferation assay kit’, the MTS assay is in fact 
a measure of mitochondrial metabolic activity, which is an indirect indicator of the proportion of 
viable cells present. In some cases, mitochondrial activity does not accurately reflect proliferation 
(Wang et al., 2010), so it would be more accurate to draw the conclusion that these results suggest 
that purinergic signalling does not affect mitochondrial metabolic activity in primary human AD-
MSCs. Additional experiments are necessary conclusively determine whether purinergic signalling 
is involved in MSC proliferation.  
 
3.12.2 Chemotaxis 
Chemotaxis of MSCs facilitate normal tissue morphogenesis, homeostasis and repair. Previous 
studies suggest that regulation of adult stem cell migration is mediated by Ca2+ signalling pathways 
(Jiang, Mousawi, et al., 2017). To investigate whether P2 receptor-mediated changes in intracellular 
Ca2+ are implicated in inducing/enhancing MSC migration, a transwell assay was performed. MSCs 
migrated towards 10% FBS, a known chemotactic agent (Figure 3.17), however exogenous ATP, at 
all concentrations tested, had no significant effect on MSC migration. It is unclear what caused the 
slight dip in the fluorescence after approximately one hour for the cells in the presence of ATP, 
because the fluorescence would be expected to progressively increase as more cells travel through 
the PET membrane towards the chemotactic agents. A dip suggests a decrease in the number of 
cells in the bottom chamber, which may suggest the cells were migrating back into the upper 
chamber against the ATP gradient or possibly that there was some cell death. Although the MSCs 
appear to display a slightly reduced capacity to migrate in the presence of ATP (due to this dip), this 
reduction was not statistically significant and the fact that the effect doesn’t demonstrate any 
concentration-dependence, suggests that this is likely to be artefactual. These results suggest MSCs 
do not migrate towards ATP, which suggests ATP-evoked calcium responses do not initiate cell 
migration.  
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Figure 3.15 Maximal concentrations of exogenous nucleotides have no effect on the rate of cell 
proliferation in primary human mesenchymal stromal cells over seven days (N=3). The 
absorbance was measured at 490 nm to monitor the formation of a coloured formazan product as 
an indirect indicator of the number of viable cells present after a single application of (A) 30 μM 
ATP, (B) 30 μM ADP or (C) 30 μM UTP (N=3). Data is normalised to the 144 hour reading for the 
vehicle control for each respective nucleotide. Data is expressed as mean ± SEM.  
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Figure 3.16 Subtype selective antagonism of P2Y2 and P2Y6 receptors have no effect on the rate 
of cell proliferation in primary human mesenchymal stromal cells over seven days (N=3). 
Absorbance measured at 490 nm to monitor the production of a coloured formazan product as an 
indirect indicator of the number of viable cells present after a single application of (A) 10 μM AR-
C118925XX (P2Y2 receptor antagonist) or (B) 10 μM MRS2578 (P2Y6 receptor antagonist) (N=3). 
Data is normalised to the 168 hour reading for the vehicle control for each antagonist. Data is 
expressed as mean ± SEM.  
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Figure 3.17 Effect of exogenous ATP on primary human mesenchymal stromal cell migration over 
four hours (N=4). Data represents the fluorescence signal (excitation 485nm/emission 530nm) from 
MSCs labelled with calcein, which have migrated through a polyethylene terephthalate membrane 
towards the chemotactic agents over time (A) or after 4 hours. 10% foetal bovine serum (FBS) was 
used as a positive control. Data are normalised to control conditions. *p<0.05 versus control 
conditions. 
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3.13 Summary  
Primary human AD-MSCs express all the known subtypes of P2 receptors, excluding P2X2, P2X3 and 
P2Y12, although there is some heterogeneity in the expression of P2Y11, P2Y13 and P2Y14 across 
donors. In addition, functional evidence of purinergic receptor activation was also acquired, 
whereby changes in intracellular calcium were detected in response to ATP, ADP and UTP. The 
nucleotide responses were remarkably consistent across donors and after multiple passages. The 
ATP response was even resistant to shRNA-mediated knockdown of P2Y2 receptor expression.  
Although AD-MSCs appear to express almost all known P2X receptor subtypes, the evidence 
presented in this Chapter demonstrates a clear predominance of metabotropic Gq-coupled P2Y 
receptors in the nucleotide-evoked calcium responses. This was demonstrated by the fact that the 
nucleotide responses persisted (albeit significantly diminished) in the absence of extracellular 
calcium and were abolished when PLC and SERCA were inhibited. In addition, subtype-selective 
antagonism of P2X4 and P2X7 receptors had no effect on the response to ATP in these cells. Taken 
together these data suggest the nucleotide-evoked calcium responses in primary human AD-MSCs 
are mediated by activation of P2Y receptors, with little/no contribution from the ionotropic P2X 
receptors present. Although, it is possible that P2X receptors may act downstream of P2Y receptor 
activation to potentiate the responses, which may explain why the magnitude of the nucleotide-
evoked responses is substantially reduced in the absence of extracellular calcium.   
All of the known P2Y receptors, excluding P2Y12 receptors, were detected at both the mRNA and 
protein level in primary human MSCs in at least four of the six donors tested. As mentioned 
previously there was some heterogeneity in the expression of P2Y11, P2Y13 and P2Y14 receptors, 
however subtype selective antagonism of P2Y11 and P2Y13 receptors revealed that neither receptor 
plays a functional role in the nucleotide-evoked calcium responses in these cells. In addition, no 
response was detected for UDP-glucose, the preferred agonist for P2Y14 receptors, suggesting that 
this receptor was not functionally active either. All of the known Gq-coupled P2Y receptors (P2Y1, 
P2Y2, P2Y4 and P2Y6 receptors) were consistently detected in primary human MSCs, although 
subtype-selective antagonism revealed that only P2Y2 and P2Y6 receptors appear to play a 
functional role in the nucleotide-evoked calcium responses in these cells. P2Y2 receptors mediate 
the ATP and UTP response in these cells, as evidenced by the equipotent effects of ATP and UTP 
and the fact that selective antagonism of P2Y2 receptors reduced the response to ATP and abolished 
the response to UTP. Interestingly, P2Y6 receptors appear to mediate the ADP-evoked calcium 
response, despite the fact that no response was detected for UDP, the preferred agonist for P2Y6 
receptors.  
Unfortunately, although the pharmacological evidence presented in this Chapter clearly 
demonstrates a functional purinergic response in these cells, the downstream functions of these 
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purinergic signalling pathways were not deciphered during this project. Exogenous nucleotides 
and/or selective antagonism of P2Y2 or P2Y6 receptors had no effect on the rate of proliferation or 
chemotaxis in these cells. However, it must be acknowledged that this is far from an exhaustive list 
of MSC functions, there are many functions that were not explored within the scope of this study. 
In addition, it is not known whether additional assays or amending assay protocols may have altered 
these outcomes. Regardless, additional work is required to ascertain the role of purinergic signalling 
in primary human MSCs, although this study provides a good foundation to build upon.  
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Chapter 4: Characterisation of the 
purinergic receptors in primary 
human in vitro differentiated 
adipocytes 
 
4.1 Introduction 
Adipose tissue is the primary site of long-term energy storage in mammals. The tissue contains a 
wide variety of cell types, but the predominant cell type is white adipocytes. White adipocytes are 
highly dynamic cells, capable of safely storing excess nutrients as triglycerides in lipid droplets, 
while also being able to hydrolyse triglycerides to free fatty acids and glycerol in response to a 
nutrient deficit caused by prolonged fasting or strenuous exercise (Rutkowski et al., 2015). Storage 
and release of energy was long considered to be the only function of adipose tissue, however 
approximately 20 years ago it was discovered that adipose tissue is also an endocrine organ that is 
capable of regulating systemic metabolism via the secretion of a wide variety of adipokines 
(Barinaga, 1995; Ahima and Flier, 2000). This discovery, in combination with the rise in obesity in 
society, has fuelled an exponential increase in adipocyte research.  
Obesity is defined as the excessive or abnormal expansion of adipose tissue beyond the healthy 
limits. A crude, but widely used, measurement of obesity are body mass index (BMI) values, which 
are calculated from an individual’s height and weight (Poirier, 2007). A BMI of greater than 25 kg/m2 
indicates that an individual is overweight, whereas a BMI of greater than 30 kg/m2 denotes obesity. 
Over the past four decades, there has been an large increase in the number of overweight and 
obese individuals in the world (Ng et al., 2014). According to the World Health Organisation, in 2016 
more than 1.9 billion adults and 380 million children were classified as overweight, of these people 
more than 30% were obese (WHO, 2018). Being overweight or obese is associated with numerous 
severe comorbidities, such as cardiovascular disease, diabetes and cancer (Kahn et al., 2006; Van 
Gaal et al., 2006; Ungefroren et al., 2015), and it is estimated that in 2010 3.4 million deaths 
occurred due to obesity (Lim et al., 2012). Consequently, the global obesity crisis represents a major 
clinical and economic problem.  
Greater understanding of the molecular mechanisms underlying both healthy white adipocyte 
functioning, as well as dysfunction of adipocytes during obesity, is required to inform efforts to 
combat the global obesity crisis. Purinergic signalling has been implicated in a wide range of 
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physiological processes, including a role for P1 receptors and adenosine in inhibiting triglyceride 
hydrolysis in adipocytes (Fredholm and Hjemdahl, 1976; Ohisalo, 1981; Johansson et al., 2008). 
However, thus far limited research has been conducted on the role of P2 receptors in human 
adipocytes (Tozzi and Novak, 2017). This Chapter outlines my efforts to identify the molecular basis 
of the P2 purinergic response in primary human in vitro differentiated adipocytes (referred to as 
adipocytes throughout this Chapter) with a view to form a solid foundation for investigating the 
role of P2 receptors in downstream adipocyte functions.  
 
4.2 Purinergic receptor expression profile in primary human in vitro 
differentiated adipocytes as determined by analysis of mRNA transcripts  
Non-quantitative analysis of mRNA transcripts revealed that adipocytes expressed all of the known 
P1 receptor subtypes: A1, A2A, A2B and A3. No bands were detected in the no RT control lanes 
suggesting the PCR products were derived from cDNA and not genomic DNA (N=3; Figure 4.1A).  
Quantitative PCR was used to assess the expression of P2 receptors in primary human adipocytes. 
Data are expressed as average cycle threshold (CT) values (Table 4.1) or relative 1/∆CT values (Figure 
4.1B) where the expression has been normalised to the expression of an endogenous reference 
gene, RPLP0, and inverted for analytical ease. Genes with a CT value of 35 or below (or 1/∆CT > 
0.062) were deemed to be present, whereas genes with CT values exceeding 35 (or 1/∆CT < 0.062) 
were considered absent. Applying these parameters revealed consistent expression of P2X4, P2X6, 
P2Y1, P2Y2, P2Y4, P2Y12 and P2Y13 receptors, whereas P2X2 and P2X3 receptors were not expressed 
in any of the donors tested (N=6; Table 4.1; Figure 4.1B). Near consistent mRNA expression of P2X5, 
P2X7 and P2Y6 receptors was also observed with only one donor displaying an average CT values of 
above 35 for each receptor. Similarly, CT values of above 35 were recorded for five out of six donors 
for P2X1 and P2Y14 receptors, and on average the 1/∆CT values for both receptors falls below the 
0.062 cut-off. The most variation was observed in the expression of P2Y11 receptors, with expression 
being detected in three of the six donors tested, and on average, the 1/∆CT value for P2Y11 falls 
below the 0.062 cut-off. Unfortunately, the sample size used in this study is too small to draw 
conclusions about population level heterogeneity or correlate the variation observed between 
donors with specific donor traits, such as age, weight or menopausal status.  
P2X5 was detected in the majority of donors tested (Table 4.1), but previous studies have elucidated 
that a single nucleotide polymorphism (SNP) resulting in the substitution of thymine with a guanine 
at the 3’ splice site of exon 10 in the gene for the human P2X5 receptor can result in the exclusion 
of exon 10 during translation, which renders the receptor non-functional (Kotnis et al., 2010). Non-
quantitative PCR, revealed that human adipocytes express the exon-10 less variant of the receptor, 
indicating that P2X5 is not functional in these cells (Figure 4.1C). This is line-in with the findings 
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presented by Kotnis et al. (2010), which demonstrated a predominance of the exon-10 less non-
functional P2X5 receptor variant in humans  
 
Table 4.1 Average cycle threshold (CT) values for each P2 receptor in primary human in vitro 
differentiated adipocytes per donor (N=6). Only genes with CT values of <35 were considered 
present. ND indicates no amplification detected within 40 PCR cycles.  
Gene  
CT values  
Donor 1 Donor 2 Donor 3 Donor 4 Donor 5 Donor 6 
P2RX1 35.9 35.1 35.9 37.3 34.6 35.4 
P2RX2 ND ND ND ND ND ND 
P2RX3 36.1 37.9 38.5 ND 37.4 37.3 
P2RX4 25.1 27.3 26.6 29.4 26.8 26.3 
P2RX5 30.7 29.4 30.4 35.6 30.9 30.3 
P2RX6 30.9 29.4 27.6 34.3 30 29.5 
P2RX7 31.8 30.9 29.9 36.9 33.2 32.8 
P2RY1 28.8 29.3 30.6 29.4 28.2 26.5 
P2RY2 33.4 33.6 34.4 31.9 33.7 30.8 
P2RY4 31.4 31.4 33 31.6 31.4 29.4 
P2RY6 32.8 32.8 35.7 31.4 28.7 26.6 
P2RY11 39.9 36.5 34.9 37.8 33.9 33.7 
P2RY12 31.4 30.9 30.3 29.1 28 26.5 
P2RY13 35 33.9 33.5 34.4 32.6 29.4 
P2RY14 35.5 35.2 35.7 36.6 ND 32.1 
 
131 
 
 
Figure 4.1 Messenger RNA expression profile of purinergic receptors in primary human in vitro 
differentiated adipocytes. (A) Non-quantitative RT-PCR analysis of P1 receptor expression showing 
bands detected for ADORA1 (374 bp), ADORA2A (295 bp), ADORA2B (277 bp) and ADORA3 (302 
bp). RT’ indicates the no reverse transcriptase control samples. Results are representative of the 
data from three independent donors. (B) Quantitative real time PCR analysis of the P2 receptor 
expression profile. Cycle threshold (CT) values have been normalised to the expression of an 
endogenous reference gene, RPLP0. The dashed line represents the CT cut-off, where receptors that 
had an average 1/∆CT value of below 0.062 are classified as not expressed (N=6). *near the tick 
labels for each receptor indicate variability in expression between donors. (C) Non-quantitative RT-
PCR analysis of P2X5 receptor transcript variants in three independent donors showing bands for 
either exon-10 less non-functional P2X5 receptor (395 bp) or exon-10 containing functional P2X5 
receptor transcript (461 bp). RT’ indicates the no reverse transcriptase control samples.  
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4.3 Protein expression profile of P2 purinergic receptors in primary human 
in vitro differentiated adipocytes 
Immunocytochemistry was used to confirm that the P2 receptor profile detected at the mRNA level 
(Section 4.2) correlated well with protein expression. Immunofluorescence for P2X4, P2X5, P2X7, 
P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12 and P2Y13 receptors were all consistently detected in three 
independent donors. Representative images of the positive staining observed for each receptor are 
shown in Figure 4.2A. The three donors used for immunocytochemistry were selected at random 
and do not appear to demonstrate the heterogeneity detected at the mRNA level. Cells were not 
stained for P2X1, P2X2, P2X3, P2X6 or P2Y14 either due to lack of mRNA expression or lack of 
antibody.  
The immunofluorescence for each receptor also provided an insight into the cellular localisation 
and distribution of each receptor. However, as the cells were permeabilised for staining and not 
counterstained with membrane or organelle markers, it is not possible to definitively determine 
the localisations of each receptor. Immunofluorescence was detected for all the receptors 
investigated and the staining appears to be uniformly distributed throughout the cells. Adipocytes 
are large cells with a very distinct morphology as the cells are packed with round lipid droplets. 
Here the in vitro model differs slightly from in vivo mature adipocytes, which have a unilocular 
appearance rather than the multilocular phenotype observed with in vitro differentiated 
adipocytes. The edges of round lipid droplets can easily be seen in the images for each receptor, 
which may indicate that the receptors are present in the cytoplasm. The immunofluorescence for 
P2Y2 receptors in particular displayed a punctate distribution throughout the cell. Although the 
intensity of the staining varied slightly inferences about the relative abundance of each receptor 
cannot be made due to differing antibody affinities. 
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Figure 4.2 Analysis of P2X and P2Y receptor immunofluorescence in primary human in vitro differentiated adipocytes. (A) Immunocytochemical staining for P2Y1, P2Y2, 
P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, P2X4, P2X5 and P2X7 receptors. Images presented are representative of at least ten fields of view for cells extracted from three independent 
donors. Images were taken with a 63x objective on a Zeiss AxioPlan 2ie epifluorescent microscope of permeabilised in vitro differentiated adipocytes labelled with primary 
antibodies against receptor targets and visualized with an Alexa Fluor 488-conjugated secondary antibody (green). Cells were counterstained with DAPI to visualise nuclei 
(blue). The exposure and camera settings remained consistent across all the images taken for each donor. Scale bar represents 30 μm.
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4.4 ATP, ADP and UTP elicit calcium responses in primary human in vitro 
differentiated adipocytes 
Exogenous application of nucleotides can activate purinergic receptors expressed on the surface of 
cells to initiate transient elevations in intracellular Ca2+ levels, due to direct entry of extracellular 
calcium via P2X receptors or via activation of Gq-coupled P2Y receptors to activate PLC-mediated 
release of  Ca2+ from intracellular stores (Burnstock, 2007). To assess whether P2 receptor 
expressed in primary human adipocytes were functionally active, changes in intracellular calcium 
levels were monitored while exogenous nucleotides were applied using a Flexstation III microplate 
reader.  
 
Table 4.2 Characteristics of the calcium responses evoked by maximal concentrations of 
nucleotides in primary human in vitro differentiated adipocytes (N=6). Mean ± SEM. 
Nucleotide Peak magnitude  
(F ratio)a 
Net calcium movement 
(area under the curve)b 
Decay time, τ 
(s)c 
EC50 (μM) 
30 μM ATP 1.37 ± 0.07 72.0 ± 10.2 41.9 ± 1.4 1.84 ± 1.4 
10 μM ADP 1.85 ± 0.09 65.5 ± 2.9 21.6 ± 2.1 0.24 ± 0.05 
100 μM UTP 0.16 ± 0.04 11.4 ± 3.1 33.6 ± 11.0 13.0 ± 4.6 
a Peak magnitude was significantly different between the three nucleotides (p<0.001) as determined by one-way 
ANOVA with a post hoc Tukey test. b The net calcium movement for UTP was significantly different to ATP and ADP 
(p<0.005) as determined by Kruskal-Wallis ANOVA with a post hoc Dunn’s test. C The decay time was significantly faster 
for ADP vs ATP (p<0.05) as determined using a Kruskal-Wallis ANOVA with a post hoc Dunn’s test. 
 
 
Application of ATP, ADP and UTP elicited concentration-dependent increases in intracellular 
calcium, with a rank order of potency ADP (EC50 0.24±0.05μM) > ATP (EC50 1.84±1.4μM) > UTP (EC50 
13.0±4.6μM) (N=6; Table 4.2; Figure 4.3A,C,E). Each nucleotide caused a rapid increase in 
intracellular calcium, which decayed back to baseline calcium concentrations within the recording 
period of 250 seconds (N=6; Figure 4.3B,D,F). The magnitude and kinetics of the responses varied 
significantly between nucleotides (Table 4.2), with a difference of more than 1.5 Fratio between the 
magnitude of the response for ADP (Fratio 1.85 ± 0.09 N=6) and UTP (Fratio 0.16 ± 0.04 N=6). In 
addition, the time-resolved traces shown in Figure 4.3B and D demonstrate that the response to 
ADP clearly decays at a faster rate than the response to maximal concentrations of ATP. This 
difference was quantified by calculating the τ values for the responses, which confirmed that there 
was a significant difference in the decay times for the two nucleotides (Table 4.2). The small 
magnitude and shallow decay of the response to UTP, unfortunately meant that the software 
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struggled to accurately calculate the τ value for some donors, which led to considerable variabilty 
between donors, which in turn meant that although the average τ value for the response to UTP is 
higher than the τ value for ADP and the trace appears to mirror the pattern observed for ADP and 
ATP, the statistical analysis did not reflect this. Instead the statistics suggests there is no significant 
change in the decay kinetics for ATP or ADP versus UTP.   
Adipocytes were insensitive to stimulation with low concentrations of UDP (<30 μM) and UDP-
glucose (<100 μM) (N=6). However, responses were consistently detected at very high agonist 
concentrations of above 30 μM UDP (N=6; Figure 4.4A,B) or greater than 100 μM UDP-glucose (N=6; 
Figure 4.4C,D). Elevated agonist concentrations are unlikely to be representative of physiological 
nucleotide concentrations, so it is unlikely that these results truly show activation of P2Y6 and P2Y14 
receptors, which are preferentially activated by UDP and UDP-glucose respectively (Communi et al., 
1996; Abbracchio et al., 2003). It is likely that these responses are due to ATP or ADP contamination 
of the UDP and UDP-glucose used in this study. The manufacturer’s state that the purity of the UDP 
and UDP-glucose are >96% and >98% respectively.    
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Figure 4.3. ATP, ADP and UTP elicited intracellular calcium responses in primary human in vitro 
differentiated adipocytes. Concentration response curves for the peak magnitude of intracellular 
Ca2+ responses elicited by (A) ATP (N=6), (C) ADP (N=6) and (E) UTP (N=6). Ca2+ responses were 
normalized to the peak magnitude of the agonist concentration that produced the maximal 
response in the majority of donors, which was the response to 30 μM ATP, 10 μM ADP and 100 μM 
UTP respectively. Averaged time-resolved intracellular Ca2+ responses elicited by (B) 30 μM ATP 
(N=6), (D) 10 μM ADP (N =6) and (E) 100 μM UTP (N =6). Traces were normalised to the maximal 
response within a donor and then averaged across donors. Data points represent mean ± SEM. 
137 
 
 
Figure 4.4 Physiological concentrations of UDP and UDP-glucose did not elicit intracellular calcium 
responses in primary human in vitro differentiated adipocytes. Concentration response curves for 
the magnitude of intracellular Ca2+ responses elicited by (A) UDP (N=6) and (C) UDP-glucose (N=6). 
Ca2+ responses were normalized to the peak magnitude of the agonist concentration that produced 
the maximal response in the majority of donors, which was the response to 300 μM UDP and 600 
μM UDP-glucose respectively. Averaged time-resolved intracellular Ca2+ responses elicited by (B) 
10 μM UDP (N=6) and (D) 100 μM UDP-glucose (N=6). Traces were normalised to the maximal 
response within a donor, and averaged across donors. Data points represent mean ± SEM. 
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4.5 Nucleotide-evoked calcium responses in primary human in vitro 
differentiated adipocytes are mediated by metabotropic P2Y receptors 
Concentration-dependent responses to both ATP and ADP persisted in the absence of extracellular 
calcium, without a significant change in the potency of the response to each nucleotide: EC50 (ATP 
+ Ca2+) 0.89 ± 0.7 μM N=6 versus EC50 (ATP - Ca2+) 1.37 ± 0.3 μM N=6; EC50 (ADP + Ca2+) 0.12 ± 0.08 
μM N=3 versus EC50 (ADP - Ca2+) 0.11 ± 0.2 μM N=3). However, the magnitude of the responses to 
both nucleotides were severely diminished when extracellular calcium was removed. The response 
to 30 μM ATP decreased by 90.3 ± 2.7% (N=6; p<0.001; Figure 4.5B) and the response to 10 μM ADP 
decreased by 81.7 ± 2.2% (N=3; p<0.05; Figure 4.5D). The decrease in the magnitude of the 
responses may be due to partial emptying of the intracellular calcium stores, removal of store-
operated calcium entry post-P2Y receptor activation or prevention of downstream P2X receptor 
activity. Although both responses were significantly decreased, which suggests the magnitude of 
the responses are dependent on extracellular calcium the fact that the responses persist in the 
absence of extracellular calcium indicates that at least a component of the ATP and ADP response 
is mediated by metabotropic P2Y receptors.  
There does not appear to be a response to UTP in the absence of extracellular calcium in human 
adipocytes (N=3; Figure 4.5E,F). However, it is likely that the UTP response, like the ATP and ADP 
response, is diminished, rather than abolished, but as the response to UTP is very small even in the 
presence of extracellular calcium (Fratio 0.16 ± 0.04 N=6), the diminished response in the absence of 
calcium could not be resolved using a Flexstation III, as the equipment is not sensitive enough to 
detect a diminished response.   
In support of the argument that the nucleotide-evoked calcium responses in adipocytes are 
mediated by metabotropic receptors, the responses to maximal agonist concentrations are 
abolished in the presence of a PLC inhibitor, U73122 (Figure 4.6). This suggests that the elevation 
of intracellular calcium evoked upon P2 receptor stimulation is mediated by PLC-induced release of 
calcium from the intracellular stores. As the response to UTP is very small, normalisation of the 
response led to the appearance of a very erratic response in the presence of U73122, but even still 
it is clear that the response to UTP is completely abolished in the presence of 10 μM U73122 (N=4; 
Figure 4.6D).  
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Figure 4.5 Removing extracellular calcium leads to a reduction in the magnitude of the response 
evoked by ATP, ADP and UTP in primary human in vitro differentiated adipocytes. Concentration-
response curves in the presence (closed circles) and absence (open circles) of 1.5 mM extracellular 
calcium for (A) ATP (N=6), (C) ADP (N=3) and (E) UTP (N=3). All responses were normalised to the 
response to maximal concentrations of each agonist (30 μM ATP, 10 μM ADP and 100 μM UTP 
respectively) in the presence of extracellular calcium. Average time-resolved traces showing 
response elicited by (B) 30 μM ATP (N=6), (D) 100 μM ADP (N=3) and (F) 30 μM UTP (N=3) in the 
presence (closed circles) and absence (open circles) of extracellular calcium. Data points represent 
the mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 versus the response to equivalent concentrations 
of agonist in the presence of extracellular calcium. 
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Figure 4.6 Inhibition of phospholipase C with U73122 abolishes the response to ATP, ADP and 
UTP in primary human in vitro differentiated adipocytes. (A) ATP concentration response curve in 
the presence (open circles) and the absence (closed circles) of 10 μM U73122. All responses were 
normalised to the response to 30 μM ATP in the absence of U73122. Average time-resolved traces 
showing responses elicited by (B) 30 μM ATP (N=6), (C) 10 μM ADP (N=5) and (D) 30 μM UTP (N=4) 
in the presence (open circles) and absence (closed circles) of 10 μM U73122. Data points represent 
the mean ± SEM. ***p<0.001 versus the response to equivalent concentrations of ATP in the 
absence of U73122. 
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4.6 ADP-evoked calcium response are mediated by P2Y1 and P2Y12 receptors 
ADP is the preferred agonist for P2Y1, P2Y12 and P2Y13 receptors, all of which are expressed in 
primary human adipocytes (Section 4.2 and 4.3). P2Y1 receptors are Gq-coupled, whereas P2Y12 and 
P2Y13 receptors are both Gi-coupled, consequently P2Y1 receptors are the most likely candidate for 
mediating the ADP-evoked calcium response via activation of PLC and downstream release of 
calcium from the intracellular stores. Exogenous application of a P2Y1 selective agonist, MRS2365, 
caused an increase in cytosolic calcium (Figure 4.7D), which suggests that P2Y1 is functionally active 
in these cells. The response magnitude was approximately half of the peak magnitude achieved 
with ADP, but the response to MRS2365 bore a striking similarity to the response to ADP: a very 
fast initial response, that decayed to baseline extremely quickly. In addition, concentration-
dependent antagonism of the response to maximal concentrations of ADP were observed using a 
selective antagonist for P2Y1, MRS2500 (IC50 77.1 ± 37.5 nM N=6; Figure 4.7A). MRS2500 (1 μM) 
achieved a maximum of 45.1 ± 4.7% inhibition of the peak magnitude versus the response in the 
presence of vehicle only (Figure 4.7B; p<0.001, N=6). The fact that the response to ADP was not 
abolished by MRS2500 may indicate that multiple receptors mediate the ADP response or may be 
due to the competition between ADP and the antagonist. MRS2500 has previously been reported 
to be a competitive antagonist of P2Y1 receptors (Kim et al., 2003), and this was confirmed here, as 
there is a clear decrease in the potency of the response to ADP in the presence of 1 μM MRS2500 
(EC50 (-MRS2500) 13.2 ± 2.5 μM N=6 versus EC50 (+MRS2500) 466.9 ± 674 nM N=6; p<0.05), with 
the response magnitude eventually reaching the same response maxima in the presence and 
absence of MRS2500 (Figure 4.7C). This pattern is characteristic of a competitive antagonist.  
Interestingly the ADP-evoked calcium response was also inhibited in the presence of PSB0739, a 
P2Y12 receptor antagonist. Concentration-dependent inhibition of the response to ADP was 
observed (IC50 64.0 ± 56.5 nM N=6), which plateaued after decreasing the peak response magnitude 
by approximately 40% (Figure 4.7E,F). PSB0739, like MRS2500, is reported to be a competitive 
antagonist (Hoffmann et al., 2009). However, although 3 μM PSB0739 caused a shift in the potency 
of the response to ADP (EC50 (-PSB0739) 398 ± 186 nM N=3 versus EC50 (+PSB0739) 1.4 ± 0.4 μM 
N=3; p<0.05; Figure 4.7G), the inhibition caused by the antagonist was insurmountable. An 
insurmountable decrease in the response is characteristic of non-competitive inhibition. This may 
suggest a more complex mechanism of action or interplay between receptors activated by ADP.  
P2Y12 is a Gi-coupled receptor, however it is well documented that there is crosstalk between the 
signalling pathways activated by P2Y1 and P2Y12 receptors in platelets (Hardy et al., 2004), which 
may be the reason that selective P2Y12 antagonism has an unusual effect on the ADP concentration 
response curve. Simultaneous inhibition of both P2Y1 and P2Y12 receptors caused a 62.5 ± 5.3% 
(N=6) decrease in the magnitude of the response to 10 μM ADP, which is more inhibition than was 
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achieved by inhibiting P2Y1 and P2Y12 receptors independently (36.9 ± 7.1% N=6 and 39.2 ± 3.8% 
N=6 inhibition respectively) (Figure 4.7H). Although the level of inhibition is greater with combined 
inhibition, the inhibition achieved is not additive and falls shy of the 76.2% inhibition expected, 
suggesting that there may be some overlap in the action of P2Y1 and P2Y12 in the ADP-evoked 
calcium response. The fact that the response was not abolished by combined antagonism of both 
P2Y1 and P2Y12 receptors may indicate that additional receptors are involved. However, P2Y13 is the 
only other receptor that is preferentially activated by ADP, and selective inhibition of P2Y13 
receptors with MRS2211 only significantly inhibited the peak magnitude or area under the curve of 
response to ADP at very high concentrations of MRS2211 (≥10 μM MRS2211) (Figure 4.8). At these 
elevated concentrations of antagonist, it is likely that the inhibition observed is due to non-specific 
inhibition of other P2 receptors, rather than true inhibition of P2Y13, which suggests that P2Y13 is 
unlikely to play a role in the ADP-evoked calcium response. In addition, although it is not the 
preferred agonist for the receptor, ADP can also activate P2Y6 receptors (Communi et al., 1996). 
Thus, for completeness, the effect of a selective P2Y6 receptor antagonist, MRS2578, was also 
tested, and this revealed that selective inhibition of P2Y6 (< 10 μM MRS2578) had no significant 
effect on the response to 10 μM ADP in primary human adipocytes (Table 4.3). Therefore, it is likely 
that the residual response to ADP after combined antagonism is a consequence of the competitive 
nature of MRS2500 and PSB0739.  
The role of P2Y12 receptors was also confirmed using an alternative P2Y12 receptor antagonist, 
Ticagrelor. Currently, Ticagrelor is used clinically for the prevention of atherothrombotic events in 
acute coronary syndrome patients (Wallentin et al., 2009). Ticagrelor (300 nM) caused a 41.5 ± 7.2% 
(N=6) reduction in the peak magnitude of ADP-evoked Ca2+ response (Figure 4.9A), which very 
closely resembled the maximum amount of inhibition achieved with PSB0739. However, Ticagrelor 
did not display concentration dependence, with higher concentrations (>300 nM) causing less 
inhibition than lower concentrations (≤300 nM) of the drug. It is possible that this effect is due to 
the fact that Ticagrelor also inhibits equilibrative nucleoside transporter 1 (ENT1), an adenosine 
transporter. Inhibition of ENT1 alone, with NMPBR, caused significant potentiation of the 
magnitude of the ADP response. It is possible that higher concentrations of Ticagrelor have a 
greater effect on ENT1, thus reducing the total level of inhibition observed. Slight variability in the 
potency of the effects of Ticagrelor on ENT1 and P2Y12 between donors may also explain the 
difference in the level of inhibition observed with 300 nM Ticagrelor in Figure 4.9A and 4.9B. Co-
application of Ticagrelor and NMPBR neutralises the inhibitory effects of Ticagrelor alone (N=7; 
Figure 4.9B), which eliminates the possibility that the inhibition of the ADP response observed with 
Ticagrelor is due to inhibition of ENT1 rather than P2Y12 receptors. These results confirm P2Y12 
receptors are involved in the ADP-evoked calcium responses in primary human adipocytes.   
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Figure 4.7 The ADP-evoked calcium responses in primary human in vitro differentiated adipocytes are mediated by activation of P2Y1 and P2Y12 receptors.    
Concentration-dependent inhibition of the response to 10 μM ADP using (A) MRS2500 (N=6) and (E) PSB0739 (N=6). Average time-resolved traces showing the response 
to 10 μM ADP in the presence (open circles) or absence (closed circles) of (B) 1 μM MRS2500 (N=6) or (F) 3 μM PSB0739 (N=3). ADP concentration response curves in the 
presence (open circles) or absence (closed circles) of (C) 1 μM MRS2500 or (G) 3 μM PSB0739. (D) Average time-resolved trace showing the response to 100 nM MRS2365 
(a P2Y1 selective agonist) (N=6). (H) Effect of co-inhibition of P2Y1 and P2Y12, using 1 μM MRS2500 and 3 μM PSB0739, on the peak magnitude of the response to 10 μM 
ADP (N=6). All data were normalised to their respective vehicle controls in each donor and then averaged across donors, excluding the response to MRS2365 (D) which 
was not normalised. *p<0.05, **p<0.005, ***p<0.001 versus the response to equivalent concentrations of ADP in the presence of vehicle alone. 
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Figure 4.8 Specific concentrations of MRS2211 (P2Y13 receptor antagonist) do not significantly 
inhibit the response to 10 μM ADP in primary human in vitro differentiated adipocytes. (A) The 
effect of increasing concentrations of MRS2211 on the calcium response evoked by 10 μM ADP 
(N=6). (B) Average time-resolved trace showing the response to 10 μM ADP in the presence (open 
circles) or absence (closed circles) of 10 μM MRS2211 (N=6). All data are normalised to the ADP-
evoked calcium response in the presence of vehicle (control) in each donor and then average across 
donors. *p<0.05, ***p<0.001 versus the response to ADP in the presence of vehicle only. 
 
 
Figure 4.9 The inhibitory effect of Ticagrelor on the ADP-evoked calcium response in primary 
human in vitro differentiated adipocytes is due to inhibition of P2Y12 receptors not ENT1. (A) The 
effect of increasing concentrations of Ticagrelor on the calcium response evoked by 10 μM ADP 
(N=6). (B) Effect of co-application of 300 nM Ticagrelor and 10 nM NBMPR on the response to 10 
μM ADP (N=7). All data are normalised to the ADP-evoked calcium response in the presence of 
vehicle (control) in each donor and then average across donors.  *p<0.05, **p<0.005, ***p<0.001, 
ns not significant (p>0.05) versus the response to ADP in the presence of vehicle alone.   
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4.7 Activation of P2Y12 with ADP causes a decrease in intracellular cAMP 
Activation of Gi-coupled receptors, such as P2Y12, leads to inhibition of adenylate cyclase and 
subsequently a decrease in cAMP production. To identify whether Gi-coupled signalling pathways 
were being activated by ADP in human adipocytes, the amount of intracellular cAMP was 
quantified. Forskolin was used to elevate cAMP by directly stimulating adenylate cyclase (Insel and 
Ostrom, 2003) to  amplify any effects observed for analytical ease. Under these conditions, acute 
stimulation of adipocytes with 10 μM ADP produced a significant reduction in intracellular cAMP, 
which was unaffected by inhibition of P2Y1, but was reversed when P2Y12 receptors were selectively 
antagonised with PSB0739 (Figure 4.10). Interestingly, pre-incubation of adipocytes with PSB0739 
alone caused a significant increase in intracellular cAMP, which suggests that there may be tonic 
P2Y12 receptor activity in these cells. On average the concentration of intracellular cAMP also 
increased in the presence of PSB0739 and ADP, but the variability between donors was too great 
for this increase to be statistically significant. Taken together, these results indicate that there are 
functionally active Gi-coupled P2Y receptors present in primary human adipocytes and this pathway 
is likely to be mediated by P2Y12 receptors, whereas P2Y1 receptors do not play a role in regulating 
intracellular cAMP levels.  
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Figure 4.10 ADP causes a reduction in intracellular cyclic AMP that is reversed in the presence of 
a selective P2Y12 receptor antagonist (N=5). Primary human in vitro differentiated adipocytes were 
stimulated with 10 μM ADP in the presence and absence of 1 μM MRS2500 (P2Y1 receptor 
antagonist) and/or 3 μM PSB0739 (P2Y12 receptor antagonist) and then the intracellular cAMP levels 
were quantified using a CatchPoint cAMP assay. Intracellular cAMP levels were artificially 
augmented by stimulating the cells with 20 μM forksolin. *p<0.05 versus control (cAMP level in the 
presence of forskolin and vehicle alone).  
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4.8 Gi-mediated signalling is involved in the ADP-evoked calcium response in 
primary human adipocytes 
P2Y12 is a Gi-coupled receptor, thus activation of this receptor is classically associated with causing 
downstream blockade of intracellular cAMP production. Therefore, at first glance it may appear 
odd that P2Y12 receptors may be involved in ADP-evoked calcium responses. However, there are 
several studies that show that P2Y12 can control intracellular Ca2+ levels via modulation of the 
concentration of cAMP in the cytosol (Sage et al., 2000; Fox et al., 2004; Hardy et al., 2004). 
Inhibition of Gi signalling pathways using pertussis toxin (PTx) (Katada et al., 1983) decreases the 
magnitude of the Ca2+ response evoked by ADP (Figure 4.11), which supports the hypothesis that a 
changes in intracellular cAMP may influence the ADP-evoked Ca2+ response. It is likely that the Gi-
signalling pathways are mediated through P2Y12 receptor activation, as equivalent levels of 
inhibition were achieved by inhibiting P2Y12 and Gi-signalling independently, and no further 
inhibition was observed with combined blockade of both P2Y12 receptors and Gi signalling (Figure 
4.11B; p>0.05). Furthermore, although inhibition of P2Y1 receptors and impeding Gi-signalling 
caused comparable decreases in the magnitude of the response to ADP, combined antagonism of 
both P2Y1 and Gi-signalling has an additive effect (Figure 4.11C), which suggests that the P2Y1-
mediated component of the ADP response is independent of the Gi-mediated component. 
Interestingly the combined application of PTx and MRS2500 (P2Y1 antagonist) had a greater 
inhibitory effect than simultaneous MRS2500 and PSB0739 (P2Y12 antagonist) treatment (Figure 
4.7H), despite the fact that it is hypothesised here that both of these effects are achieve via 
blockade of the same receptor-mediated pathways. This discrepancy may point towards the 
involvement of additional receptors or alternatively it may just be that PTx is more effective than a 
competitive P2Y12 receptor antagonist. 
In combination with the data presented in Section 4.6 and 4.7, these data indicate that the ADP-
evoked calcium response in primary human adipocytes is mediated via two distinct, but possibly 
synergistic, pathways. P2Y1 receptors activate Gq-mediated release of Ca2+ from the intracellular 
stores, while activation of P2Y12 receptors cause Gi-mediated inhibition of cAMP, which 
subsequently potentiates the Ca2+ response. This proposed mechanism suggests roles for both Gi 
and Gq-mediated signalling pathways. However, although blockade of Gi-signalling diminishes the 
response to ADP, blockade of Gq-mediated pathways, via inhibition of PLC (Figure 4.6), abolishes 
the response to ADP, which suggests a predominant role for Gq-signalling in ADP-evoked calcium 
responses.  
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Figure 4.11 Inhibition of Gi-signalling using pertussis toxin (PTx) diminishes the response to ATP 
and ADP-evoked calcium responses in primary human in vitro differentiated adipocytes. Average 
time-resolved traces showing the response to (A) 10 μM ADP (N=7) or (D) 30 μM ATP (N=6) in the 
presence (open circles) or absence (closed circles) of 100 ng/ml PTx. The effect of PTx in the 
presence and absence of (B) 3 μM PSB0739 (P2Y12 antagonist) (N=6) or (C) 1 μM MRS2500 (P2Y1 
antagonist) (N=6) on the peak magnitude of the ADP-evoked calcium response. All data are 
normalised to the ADP-evoked calcium response in the presence of vehicle (control) in each donor 
and then averaged across donors. ***p<0.001 versus the response to ADP in the presence of vehicle 
control or ***p<0.001 or ns (not significant; p>0.05) between the two conditions under the bar. 
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4.9 ATP and UTP-evoked calcium response are mediated by P2Y2 receptors 
In addition to having a functional response to ADP, primary human adipocytes also exhibit ATP and 
UTP-evoked calcium responses (Figure 4.3). To identify the molecular basis of these responses, the 
nucleotide responses were antagonised with subtype-selective antagonists. This revealed that 
neither P2X4 nor P2X7 receptors were involved in ATP-evoked calcium responses (Figure 4.12A-D). 
The lack of ionotropic P2X involvement in the ATP response is supported by the fact that the ATP 
response is abolished when PLC is inhibited (Figure 4.6A,B), which strongly suggests a 
predominance of metabotropic P2Y receptors. Furthermore, selective antagonism of P2Y11 
receptors also revealed that P2Y11 receptors were not involved in the ATP-evoked calcium response 
(Figure 4.12E,F). This again is perhaps not surprising, as the mRNA transcript analysis revealed 
heterogeneity in the expression of P2Y11 between donors, whereas the ATP response is consistently 
detected across all donors tested.  
Selective antagonism of P2Y2 receptors, using AR-C118925XX, caused a concentration-dependent 
decrease in the peak magnitude (IC50 683 ± 116 nM (N=6); Figure 4.13A) and the area under the 
curve (IC50 434 ± 133 nM (N=6); Figure 4.13B) of the response to 30 μM ATP. Although the IC50 values 
calculated from the magnitude and area under the curve data are almost identical, the amount of 
inhibition of the magnitude and net movement of calcium observed varied greatly (Table 4.3). The 
magnitude was diminished by 20.4 ± 3.6% (N=6) using 10 μM AR-C118925XX, whereas the same 
concentration of antagonist caused a 47 ± 1.7% (N=6) reduction in the area under the curve. 
Selective antagonism of P2Y2 receptors compelled the response to ATP to decay faster than the 
response in the presence of vehicle alone (Figure 4.13C). In fact, in the presence of 10 μM AR-
C118925XX, the response to 30 μM ATP greatly resembles the very fast response observed with 
ADP. These data strongly support the hypothesis that a component of the ATP response, particularly 
the latter decay phase of the response, is mediated by activation of P2Y2 receptors, although 
approximately 50% of the response is resistant to the effects of AR-C118925XX, which indicates 
that other receptors may also play a role.  
The UTP response is abolished when P2Y2 receptors are selectively antagonised with AR-C118925XX 
(Figure 4.13D-F). AR-C118925XX causes concentration-dependent inhibition of the peak magnitude 
(IC50 318 ± 399 nM (N=6); Figure 4.13D) and the area under the curve (IC50 474 ± 527 nM (N=6); 
Figure 4.13E). Although 10 μM AR-C118925XX was sufficient to abolish the response to 30 μM UTP 
in all six donors tested, the effects of AR-C118925XX were more potent in some donors. In four of 
six donors, 3 μM AR-C118925XX caused 100% inhibition of the response to UTP. One donor was 
particularly sensitive to AR-C118925XX and 1 μM was able to eliminate the response to UTP.  
Irrespective of the potency of the effect, these data strongly suggest that the UTP-evoked calcium 
response is mediated by P2Y2 receptors.  
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Figure 4.12 Selective antagonism of P2X4, P2X7 and P2Y11 receptors had no inhibitory effect on 
the ATP-evoked calcium response in primary human in vitro differentiated adipocytes (N=6). (A) 
The response to 100 μM ATP antagonised with increasing concentrations of the selective P2X4 
receptor antagonist, PSB12062. (C) The response to 1 mM ATP antagonised with increasing 
concentrations of the selective P2X7 receptor antagonist, A438079. (E) The response to 30 μM ATP 
antagonised with increasing concentrations of the selective P2Y11 receptor antagonist, NF340. 
Average time-resolved traces showing the response to ATP in the presence (open circles) and 
absence (closed circles) of (B) 10 μM PSB12062, (D) 10 μM A438079 or (F) 10 μM NF340. All data 
points are normalised to their respective agonist responses in the presence of vehicle alone. Data 
points are expressed as mean ± SEM. 
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Figure 4.13 Selective antagonism of P2Y2 receptors with AR-C118925XX has an inhibitory effect on the response to ATP and abolishes the response to UTP in primary 
human in vitro differentiated adipocytes. Effect of AR-C118925XX on the peak magnitude of the response to (A) 30 μM ATP (N=6) and (D) 30 μM UTP (N=6). Effect of AR-
C118925XX on the net movement of calcium caused by (B) 30 μM ATP (N=6) and (E) 30 μM UTP (N=6). (C) Time-resolved traces showing the response to ATP in the presence 
(open circles) and absence (closed circles) of 10 μM AR-C118925XX (N=6). (F) Time-resolved traces showing the response to UTP in the presence (open circles) and absence 
(closed circles) of 30 μM AR-C118925XX (N=6). All data points are normalised to their respective agonist responses in the presence of vehicle alone. Data points are 
expressed as mean ± SEM. * p<0.05, ** p<0.005, *** p<0.001 versus the response to ATP or UTP in the presence of vehicle only.  
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4.10 shRNA-mediated knockdown of P2Y2 receptor expression mimics the 
trends observed with pharmacological inhibition of P2Y2 receptors 
Lentivirus delivery of shRNA was used to successfully decrease the expression of P2Y2 receptors in 
primary human in vitro differentiated adipocytes. Quantitative PCR analysis revealed that receptor 
expression was decreased by 63.5 ± 4.5% (N=4). Most of the general trends observed with 
pharmacological inhibition of P2Y2 on the ATP and UTP-evoked Ca2+ responses were also observed 
with shRNA-mediated knockdown of P2Y2 receptor expression in primary human adipocytes (Figure 
4.14). However, unlike selective antagonism of P2Y2 receptors with AR-C118925XX, shRNA-
mediated knockdown of the receptor does not cause a significant decrease in the peak magnitude 
of the response to ATP. This is perhaps unsurprising as the effect of AR-C118925XX on the peak 
magnitude is quite subtle (Table 4.3; Figure 4.13) and 100% receptor knockdown was not achieved. 
However, it is clear from the time-resolved traces (Figure 4.14A) and the τ values (Figure 4.14C) that 
the response to ATP decayed faster than the response in the scrambled cells, which mirrors the 
effects observed with pharmacological inhibition of P2Y2 receptors (Figure 4.13C). In addition, the 
response to 30 μM UTP was diminished when P2Y2 receptor expression was decreased (Figure 
4.14D-F). As with the ATP response, the effects of shRNA-mediated receptor knockdown are more 
subtle than the effects of pharmacological inhibition. The inhibitory effect on the peak magnitude 
of the UTP was not statistically significant (Figure 4.14E), but the area under the curve was 
significantly decreased post receptor knockdown (Figure 4.14F). Taken together, these data support 
the pharmacological evidence for a role for P2Y2 in the ATP and UTP-evoked calcium responses in 
primary human adipocytes. The slight discrepancies between the pharmacological and shRNA-
mediated knockdown data are likely to be due to incomplete knockdown of P2Y2 receptor 
expression.    
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Figure 4.14 shRNA-mediated knockdown of P2Y2 receptors in primary human in vitro 
differentiated adipocytes mimic many of the effects of pharmacological inhibition of P2Y2 (N=4). 
(A) Average time-resolved traces showing the elevation in intracellular calcium in response to           
30 μM ATP in scrambled control cells (closed symbols) versus P2Y2 receptor knockdown cells (open 
symbols). (B) The peak magnitude and (C) decay time (τ) for the ATP-evoked Ca2+ response. (D) 
Average time-resolved traces for the response to 30 μM UTP in the scrambled control cells (closed 
circles) and P2Y2 receptor knockdown cells (open circles). (E) The peak magnitude data and (F) area 
under the curve data for the UTP-evoked Ca2+ response. All data points are normalised to their 
respective agonist responses in the scrambled control cells, excluding the decay time for the ATP 
response (C) which was not normalised. Data points are expressed as mean ± SEM. * p<0.05 versus 
the agonist response in the scrambled control cells.  
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4.11 ATP-evoked calcium responses are inhibited by selective inhibition of 
P2Y1 and P2Y12 receptors 
As demonstrated in Section 4.9 and 4.10, P2Y2 receptors mediate part of the response to ATP, but 
greater than 50% of the response is resistant to the effect of P2Y2 inhibition, which suggests that 
other purinergic receptors may be involved in this response. P2X receptors and P2Y11 receptors are 
not involved in the response to ATP (Table 4.3; Figure 4.12), but the responses are sensitive to 
pertussis toxin (Figure 4.10D) and in the presence of AR-C118925XX, the response to ATP resembles 
the response to ADP (Figure 4.13C), which suggests that ADP receptors may play a role in the 
response to ATP. This hypothesis was readily confirmed as selective antagonism of P2Y1 receptors 
(IC50 415 ± 160 nM N=6) caused concentration-dependent antagonism of the response to 30 μM 
ATP, with a decrease of 32.3 ± 3.8% (N=6) being observed with maximal concentrations of MRS2500 
(1 μM; P2Y1 antagonist) (Figure 4.15A,B). However, the potency and extent of inhibition was lower 
for the ATP response than the effects observed on the ADP response (Table 4.3). In addition, the 
ATP-evoked calcium response was also inhibited in a concentration dependent manner by the 
selective P2Y12 antagonist, PSB0739 (Figure 4.15C,D; IC50 >10 μM N=6). Maximal concentrations of 
PSB0739 (10 μM) caused a 46.8 ± 4.5% (N=6) decrease in the peak magnitude and a 44.5 ± 5.2% 
(N=6) decrease in the net movement of calcium in response to 30 μM ATP (Table 4.3). Although, 
PSB0739 inhibited the responses to ATP and ADP to the same extent, the effects of PSB0739 were 
less potent on the ATP response than the ADP response (Table 4.3). The most probable explanation 
for the role of ADP receptors in the ATP response is that cell surface ectonucleotidases hydrolyse 
exogenous ATP to ADP, which then activates P2Y1 and P2Y12 receptors (Zimmermann, 2001; 
Yegutkin, 2014).   
Unlike the ADP response, there does not appear to any overlap in the action of P2Y1 and P2Y12 
receptors in the response to ATP, as combined antagonism of P2Y1, P2Y2 and P2Y12 had an additive 
effect (Figure 4.15E). Totalling the average inhibition of the response to ATP caused by each 
antagonist independently suggests that combined antagonism should result in a 61.6% decrease in 
the response magnitude. This value is almost identical to the average amount of inhibition achieved 
by combined antagonism experimentally: 63.0 ± 3.4% (N=6) inhibition. It is important to note that 
the effect of each antagonist (MRS2500, PSB0739 and AR-C118925XX) alone was lower for the 
combined antagonism experiments than the inhibition curve experiments, but these differences 
are likely to be due to donor-to-donor variability, as cells from different donors were used for these 
two experiments.  
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Figure 4.15 Selective antagonism of P2Y1 and P2Y12 receptors has a concentration-dependent 
inhibitory effect on the ATP-evoked calcium response in primary human in vitro differentiated 
adipocytes (N=6). The response to 30 μM ATP antagonised with increasing concentrations of (A) 
MRS2500 (selective P2Y1 antagonist) or (C) PSB0739 (selective P2Y12 antagonist). Average time-
resolved traces showing the response to ATP in the presence (open circles) and absence (closed 
circles) of (B) 1 μM MRS2500 or (D) 10 μM PSB0739. (E) Effect of combined antagonism of P2Y1, 
P2Y2 and P2Y12 receptors. All data points are normalised to the response to ATP in the presence of 
vehicle (control response). Data points are expressed as mean ± SEM. * p<0.05, ** p<0.005, *** 
p<0.001 versus the response to ATP in the presence of vehicle only.
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Table 4.3 The effect of P2 subtype selective antagonism on the nucleotide-evoked calcium responses in primary human in vitro differentiated adipocytes. All the values 
in the maximum inhibition and IC50 columns were determined using cells from six independent donors. 
Selective 
antagonist 
Receptor 
target 
Nucleotide 
[concentration, μM] 
 Antagonist range, 
µM 
Maximum inhibition (%)a 
[antagonist concentration, μM] 
IC50, nMa 
 
Reference 
PSB-12062 P2X4 ATP [100] 0.003 – 30 NS - (Hernandez-Olmos et al., 
2012) 
A438079 P2X7 ATP [1000] 0.003 – 10 NS - (Nelson et al., 2006) 
MRS2500 P2Y1 ATP [30] 0.0001 – 1 32.3 ± 3.8 [1] 
33.6 ± 3.6 [1] 
415 ± 160 
>1000 
(Kim et al., 2003) 
  ADP [10] 0.0001 – 1 45.1 ± 4.7 [1] 
45.4 ± 6.9 [1] 
77.1 ± 37.5 
>1000 
AR-C118925XX P2Y2 ATP [30] 0.003 - 30 20.4 ± 3.6 [10] 
47 ± 1.7 [10] 
683 ± 116 
434 ± 133  
(Rafehi et al., 2017) 
  UTP [30] 0.003 - 30 100% 318 ± 399  
    100% 474 ± 527  
MRS2578 P2Y6 ADP [10] 0.003 – 10 NS - (Mamedova et al., 2004) 
NF340 P2Y11 ATP [30] 0.003 - 10 NS - (Meis et al., 2010) 
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  ADP [10] 0.003 – 10 NS -  
PSB-0739 P2Y12 ATP [30] 0.003 – 10 46.8 ± 4.5 [10] 
44.5 ± 5.2 [10] 
<10,000 
<10,000 
(Hoffmann et al., 2009) 
  ADP [10] 0.003 – 10 38.4 ± 5.1 [10] 
55.4 ± 4.4 [10] 
64.0 ± 56.5 
162 ± 25.4 
 
MRS2211 P2Y13 ATP [30] 0.003 – 3 NS - (Kim et al., 2005) 
  ADP [10] 0.003 – 3 NS - 
aIC50 values and max % inhibition values were calculated with the peak magnitude values (top) and area under the curve data (bottom) for each agonist/antagonist combination. NS indicates 
no significant inhibition at any concentration of antagonist tested.  
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4.12 P2Y1, P2Y2 and P2Y12 are expressed in mature adipocytes in human 
subcutaneous adipose tissue 
In order to confirm that the functional P2 receptors detected in the in vitro model of mature human 
adipocytes were also expressed in mature adipocytes in human adipose tissue, 
immunohistochemistry was performed. This revealed that all three receptors were indeed 
expressed (Figure 4.16). Although, it was not possible to confirm that these receptors are functional 
in human adipocytes in vivo within the scope of this study, positive confirmation of P2Y1, P2Y2 and 
P2Y12 receptors in adipose tissue suggests that there is some symmetry between the cells in human 
adipose tissue and the in vitro differentiated model. However, unlike the in vitro model (Figure 4.2), 
all three receptors are clearly detected at the edge of cell, rather than throughout the cells. This 
may be due to the unilocular morphology of mature adipocytes in human adipose tissue, where the 
large lipid droplet pushes all the other components of the cell to the periphery, thus making it 
difficult to distinguish between true membrane staining and intracellular staining.  
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Figure 4.16 Immunohistochemical staining for P2Y1, P2Y2 and P2Y12 receptors in 6 μm sections of paraffin-embedded primary human subcutaneous abdominal adipose 
tissue. Immunoreactivity visualized using anti-rabbit or anti-goat HRP-conjugated secondary antibodies. Non-specific secondary binding was controlled for in the absence 
of anti-P2Y receptor antibodies (no primary controls). Scale bar represents 200µm. 
160 
 
4.13 Summary  
Primary human in vitro differentiated adipocytes express a wide variety of P2 receptors, including 
P2X4, P2X5, P2X6, P2X7, P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12 and P2Y13, but lack P2X1, P2X2, P2X3 
and P2Y14 receptors. Although there was some heterogeneity in the expression P2 receptor profile 
amongst donors, there was remarkably consistent functional evidence of nucleotide-evoked 
calcium responses in human adipocytes. Exogenous application of ATP, ADP and UTP produced 
transient increases in the concentration of intracellular calcium, whereas physiological 
concentrations of UDP and UDP-glucose did not alter intracellular calcium levels. The lack of a 
functional response to UDP-glucose is perhaps unsurprising as P2Y14 was not detected in the 
majority of donors.    
Although human in vitro differentiated adipocytes appear to express four of the seven known P2X 
receptor subtypes, these P2X receptors do not appear to play a functional role in the ATP-evoked 
Ca2+ responses under the conditions used in this study. This is evidenced by the fact that the 
response to ATP persisted in the absence of extracellular calcium, inhibition of PLC abolished the 
response and selective antagonism of P2X4 and P2X7 had no effect on the response. These results 
may be due to the use of sub-optimum conditions for the activation of P2X receptors, such as the 
use of insufficiently elevated ATP concentrations to activate P2X7 (North, 2002). Alternatively, it is 
possible that the receptors are not expressed at the cell surface, thus exogenous application of 
nucleotides is unable to activate the receptors. For example, P2X4 receptors are known to localise 
to lysosomes and traffic to and from the plasma membrane in other cell types (Ashour and 
Deuchars, 2004; Stokes, 2013). Although P2X receptors do not appear to be directly involved in 
initiating ATP-evoked calcium responses, the magnitude of the response to ATP is heavily 
dependent on the presence of extracellular calcium, so it is conceivable that the initial 
metabotropic response to ATP is potentiated by subsequent Ca2+ entry via P2X receptors.   
All of the known P2Y receptors, excluding P2Y14 receptors, were detected at both the mRNA and 
protein level in adipocytes. However, subtype-specific antagonism of P2Y6, P2Y11 and P2Y13 
receptors had no effect on nucleotide-evoked responses, which suggests that these receptors are 
not functionally active under the conditions used in this study. The UTP response was completely 
abolished by selective antagonism of P2Y2, which indirectly suggests P2Y4 receptors are also non-
functional in these cells. It is not possible to conclusively rule out a role for P2Y4 receptors, as there 
is currently no commercially-available selective antagonist for this receptor (Jacobson et al., 2009).  
The responses to ATP, ADP and UTP were all abolished by inhibition of PLC, which indicates a 
predominance of Gq-mediated signalling, however the responses to ADP and ATP were also 
substantially decreased, but not abolished, when Gi-signalling pathways were inhibited. This 
suggests that multiple signalling pathways may be involved in the nucleotide-evoked calcium 
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responses in human adipocytes. Indeed, subtype-selective antagonism revealed that a combination 
of Gq and Gi-coupled receptors were involved in the ATP and ADP response: P2Y1, P2Y2 and P2Y12 
receptors. It is proposed here that the ATP response is partially mediated by P2Y2 receptor 
activation, but the majority of the increase in intracellular calcium is produced by activation of ADP 
receptors, via liberation of ADP from ATP by cell surface ectonucleotidases (Yegutkin, 2014). The 
ADP is then able to cause PLC-mediated release of Ca2+ from the intracellular stores via activation 
of P2Y1 receptors, while simultaneously activating P2Y12 receptors to potentiate the level of 
intracellular calcium indirectly via modulation of cytosolic cAMP levels (Hardy et al., 2004).  
The data outlined in this Chapter identifies three purinergic receptors that are functionally active 
in primary human in vitro differentiated adipocytes: P2Y1, P2Y2 and P2Y12. These data will be used 
as a foundation for exploring the downstream role of purinergic signalling in human adipocytes. 
Efforts to identify the cellular functions of these receptors will be outlined in Chapter 5.  
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Chapter 5: Determining the role of 
purinergic signalling in basal lipolysis 
and adipokine secretion  
5.1 Introduction 
Adipocytes are highly dynamic cells, which are able to respond to external cues, such as nervous or 
hormonal stimulation, to either store energy as triglycerides via lipogenesis or release energy in the 
form of free fatty acids (FFA) and glycerol via lipolysis (Rutkowski et al., 2015). Prolonged fasting 
induces lipolysis to ensure that FFA are available for β-oxidation to provide energy when glucose 
availability is limited. Fasting initiates sympathetic nervous stimulation of adipose tissue via 
catecholamine-mediated activation of β-adrenoreceptors on the surface of the adipocyte (Fain, 
1973). Activation of β-adrenoreceptors initiates Gs-mediated stimulation of adenylate cyclase to 
elevate cytoplasmic cyclic AMP (cAMP) levels, which then activates protein kinase A (PKA). 
Activated PKA phosphorylates hormone sensitive lipase (HSL) and perilipins on the surface of the 
lipid droplet to allow translocation of HSL from the cytoplasm to the lipid droplet (Miyoshi et al., 
2006). PKA also phosphorylates comparative gene identification-58 (CGI-58) (Sahu-Osen et al., 
2015), a co-activator of adipose triglyceride lipase (ATGL), which increases the activity of ATGL by 
up to 20-fold (Schweiger et al., 2006; Miyoshi et al., 2008). At the surface of the lipid droplet, ATGL, 
HSL and monoglyceride lipase (MGL) catalyse the sequential hydrolysis of triglycerides to 
diglycerides, monoglycerides and finally glycerol. This process also yields three FFA molecules per 
triglyceride. The FFA are recycled or released into the bloodstream where they are able to travel to 
distant organs and be utilised as a cellular energy source (Ahmadian et al., 2010). However, lipolysis 
also occurs spontaneously in the absence of hormonal or nervous stimulation and this is known as 
basal lipolysis. In comparison to stimulated lipolysis, little is currently known regarding the 
underlying mechanisms governing basal lipolysis, though it has been suggested that ATGL plays a 
prominent role (Miyoshi et al., 2008).  
Although storage and release of energy is the primary function of white adipocytes, they are also 
capable of synthesising a wide variety of adipokines that are capable of regulating immunity and 
systemic metabolism (Halberg et al., 2008). Adipokine is a collective term for hormones and 
cytokines secreted by cells within adipose tissue, including, but not limited to, white adipocytes. 
The first adipokine to be identified was leptin (Zhang et al., 1994). Leptin activates receptors in the 
hypothalamus to signal satiety, initiate decreased food intake and increased energy expenditure to 
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maintain an optimal adipose tissue volume (Klok et al., 2007). Other examples of adipokines, 
include adiponectin which inhibits apoptosis, suppresses inflammation and promotes insulin 
sensitivity to improve systemic metabolism (Wang et al., 2016). Adipocytes, and immune cells 
within adipose tissue, are also capable of secreting cytokines to promote tissue inflammation. The 
increase in fat mass associated with obesity leads to an increase in the production of 
proinflammatory cytokines. The resultant chronic inflammatory response has been causally linked 
to the development of metabolic diseases (Hotamisligil, 2006). Adipokine release is tightly 
regulated, however abnormal fat mass accumulation, such as in obesity, is associated with a 
dysregulation of adipokine production. Furthermore, elevated serum FFA levels in obese 
individuals, due to enhanced basal lipolysis, further stimulates inflammation and insulin resistance 
(Wang et al., 2003; Jiao et al., 2011). Additional research is required to fully appreciate the 
molecular mechanisms underlying adipokine release in order to facilitate safe and effective 
interventions to prevent or counteract the dysregulation evident in obesity.  
White adipose tissue is highly innervated (Bartness et al., 2014) and it is well documented that ATP 
is released as a co-transmitter with noradrenaline from sympathetic nerves (Kennedy, 2015). ATP 
is also released physiologically from cells during inflammation and injury, where it acts as a danger-
associated molecular pattern (Gorini et al., 2013). In addition, ATP can be constitutively released by 
cells (Corriden et al., 2010; Sivaramakrishnan et al., 2012). ATP is able to activate a wide repertoire 
of purinergic P2X and P2Y receptors to initiate a diverse range of physiological functions (Burnstock, 
2007). In Chapter 4, it was determined that primary human in vitro differentiated adipocytes 
express functional P2Y1, P2Y2 and P2Y12 receptors. In this Chapter, attempts are made to determine 
whether these P2 receptors have a physiological role in regulating two important functions of 
adipocytes: lipolysis and adipokine secretion. A greater understanding of the molecular basis of 
these functions is vital for the development of novel therapies to combat the global crisis of obesity 
and its myriad of associated comorbidities.    
 
5.2 Human adipocytes release ATP into the extracellular space and modulate 
cytoplasmic calcium tone via constitutive P2Y2 receptor activity 
Cells can regulate purinergic responses in an autocrine manner by constitutively releasing ATP 
(Corriden et al., 2010; Sivaramakrishnan et al., 2012; Campwala et al., 2013). A previous study by 
Adamson et al. (2015) demonstrated that 3T3-L1 mouse adipocytes are capable of secreting ATP 
into the extracellular space. To confirm that primary human in vitro differentiated adipocytes are 
also capable of releasing ATP, the amount of ATP in the supernatant was quantified in the presence 
and absence of apyrase. Apyrase is a highly active ecto-ATPase that catalyses the hydrolysis of ATP 
to AMP. A population of 2x104 adipocytes were capable of conditioning 50 μl of supernatant with 
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approximately 50 nM ATP, which was successfully scavenged by apyrase treatment (N=3; Figure 
5.1). These are bulk phase measurements of ATP and it is likely that the concentration of ATP is 
much higher at the cell surface, which means that under basal conditions human adipocytes secrete 
sufficient concentrations of ATP to activate most P2Y receptor subtypes (Gorini et al., 2013).  
The fact that adipocytes secrete ATP under basal conditions suggests that they are capable of 
constitutively activating P2 receptors expressed on the cell surface (here, and throughout this 
thesis, constitutive receptor activation refers to the continuous activity of a receptor due to the 
omnipresence of agonist achieved via constitutive agonist release, it does not refer to the receptor 
becoming agonist-independent).  However, selective antagonism of P2Y1 and P2Y12 receptors, with 
MRS2500 and PSB0739 respectively, did not have a significant effect on resting intracellular calcium 
levels (N=6; p>0.05; Figure 5.2A,B). On average, there was a slight reduction in the concentration 
of cytoplasmic calcium in the presence of MRS2500, however this trend was not consistently 
observed across donors and consequently this change was not statistically significant (Figure 5.2A). 
This suggests that although there may be some constitutive P2Y1 receptor activity in some donors, 
tonic P2Y1 receptor activity is not a universal trait shared by all donors tested. As a limited number 
of donors were used in this study, it was not possible to fully explore the potential explanations for 
this variability between donors. In addition, although these results suggest persistent P2Y12 
receptor activity does not modulate intracellular calcium levels, this does not definitively rule out 
constitutive P2Y12 receptor activity, as it is possible that P2Y12 is regulating an alternative secondary 
messenger molecule, such as cAMP, rather than calcium (see Section 4.7).   
Unlike P2Y1 and P2Y12 receptors, selective antagonism of P2Y2 receptors with 10 μM AR-C118925XX 
(Figure 5.2C) caused a significant reduction in the concentration of cytoplasmic calcium. Inhibition 
of P2Y2 receptors led to the concentration of intracellular calcium decreasing from 125 ± 19 nM to 
47 ± 9 nM (N=6; p<0.005 vs vehicle control). Furthermore, removal of extracellular ATP with apyrase 
also instigated a significant reduction in intracellular calcium levels (N=3; p<0.05 vs vehicle control; 
Figure 5.2D). Taken together, these data suggest primary human in vitro differentiated adipocytes 
are capable of releasing ATP to act in an autocrine and/or paracrine manner to modulate 
intracellular calcium tone via constitutive activation of P2Y2 receptors.  
It is important to note that there was some variability between donors and the presence of different 
vehicles (water or 0.1% DMSO) appeared to influence the resting cytoplasmic calcium 
concentrations in adipocytes. This meant that the intracellular calcium concentration under control 
conditions varies between approximately 50 and 200 nM calcium in Figure 5.2. Unfortunately, it 
was not possible to avoid this variability, however pairwise comparisons of the effect of each 
antagonist versus their respective vehicle control per donor were conducted to minimise the impact 
of this variation. 
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Figure 5.1 Primary human in vitro differentiated adipocytes secrete ATP which can be scavenged 
by apyrase (N=3). Bulk-phase measurements of ATP released into medium conditioned by human 
in vitro differentiated adipocytes. The ATP concentration was quantified using a luciferase ATP 
Bioluminescence Assay Kit HS II purchased from Roche and performed as per the manufacturer’s 
instructions. Data are expressed as mean ± SEM. **p<0.005 versus basal ATP release.  
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Figure 5.2 Inhibition of P2Y2 receptors and removal of extracellular ATP significantly decreases 
the concentration of cytoplasmic calcium in primary human in vitro differentiated adipocytes. 
Effect of selective antagonism of (A) P2Y1 receptors with 1 μM MRS2500 (N=6), (B) P2Y12 receptors 
with 1 μM PSB0739 (N=6) and (C) P2Y2 receptors with 10 μM AR-C118925XX (N=6) on resting 
cytoplasmic calcium levels. (D) Effect of scavenging extracellular ATP with 4 U/ml apyrase on resting 
cytoplasmic calcium levels (N=3). Data are expressed as mean ± SEM. *p<0.05, **p<0.005 versus 
cytoplasmic calcium levels in the presence of vehicle only (control).  
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5.3 Pharmacological antagonism and shRNA-mediated knockdown of P2Y2 
receptor expression causes an increase in intracellular cAMP 
In Section 5.2, it was demonstrated that constitutive P2Y2 receptor activity regulates cytoplasmic 
calcium tone in primary human adipocytes. However, there are some reports that suggest that 
activation of P2Y2 receptors can also influence intracellular cAMP levels (Post et al., 1998; Gorini et 
al., 2013). To investigate whether tonic P2Y2 activation effects cytoplasmic cAMP levels, the total 
amount of cAMP was measured after pharmacological Inhibition of P2Y2 receptors with 10 μM AR-
C118925XX and shRNA-mediated knockdown of P2Y2 receptor expression. This determined that 
both pharmacological blockade of P2Y2 receptors (Figure 5.3A) and reduced receptor expression 
(Figure 5.3B) instigated an increase in intracellular cAMP in primary human adipocytes. Inhibition 
of P2Y2 receptors resulted in a 23.3 ± 5.8% increase in cAMP above cells treated with vehicle only 
(N=4; p<0.05). However, shRNA-mediated knockdown of P2Y2 receptor expression had a much 
more pronounced effect and caused a 177.2 ± 51.0% increase in cAMP when compared to 
scrambled control counterparts (N=3; p<0.05). As demonstrated by the large standard error of the 
mean associated with the average data for the P2Y2 knockdown cells, there was considerable 
variability in the extent of the increase in cAMP observed per donor. One donor displaying a more 
muted rise of only 33.3 ± 14.6%, whereas the other two donors exhibited increases of greater than 
200%. This variation may be due to varying degrees of P2Y2 receptor knockdown per donor. The 
disparity between the average increase caused by pharmacological inhibition of the receptor versus 
shRNA-mediated knockdown of expression may be due to the fact that knockdown of P2Y2 receptor 
expression is a longer-term change in P2Y2 activity than pharmacological inhibition of P2Y2 
receptors, thus receptor knockdown is able to have a more marked effect.  
In combination with the data presented in Section 5.2, these results suggest that P2Y2 receptors are 
constitutively active and function to regulate both calcium and cAMP tone within primary human 
in vitro differentiated adipocytes. This means that in addition to the transient calcium responses 
evoked by exogenous application of nucleotides (Chapter 4), human adipocytes are also capable of 
regulating their own purinergic response in an autocrine and/or paracrine manner.  
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Figure 5.3 Selective antagonism of P2Y2 receptors and shRNA-mediated knockdown of P2Y2 
receptor expression in primary human in vitro differentiated adipocytes causes an increase in 
cytoplasmic cAMP concentrations. (A) Effect of selective inhibition of P2Y2 receptors with 10 μM 
AR-C118925XX on intracellular cAMP levels (N=4). (B) Effect of shRNA-mediated knockdown of P2Y2 
receptor expression via lentiviral delivery on intracellular cAMP levels (N=3). All data are normalised 
to the basal concentration of cAMP under control (vehicle only) conditions or in cells treated with 
scrambled non-target shRNA. *p<0.05 versus control or scrambled cells.  
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5.4 Human adipocytes have both basal and stimulated lipolytic capabilities 
It is well established that human adipocytes are capable of performing lipolysis both in the presence 
(stimulated) and absence (basal) of external stimuli (Nielsen et al., 2014). To reconfirm the 
assertions made in the literature, the rates of basal and stimulated lipolysis were measured in 
human in vitro differentiated adipocytes by quantifying the concentration of glycerol released into 
the supernatant. Glycerol is a more stable measure of lipolysis than FFA release, as FFA reuptake 
occurs and FFAs are reesterified to create new triglyceride molecules, whereas glycerol is not 
metabolised to a significant extent (Vaughan, 1962). Nervous stimulation was mimicked by applying 
isoprenaline, a β-adrenergic agonist, and forskolin, an adenylate cyclase activator (Litosch et al., 
1982). In line with the previous literature (Nielsen et al., 2014), primary human in vitro 
differentiated adipocytes are capable of releasing glycerol under basal and stimulated (with 
isoprenaline or forskolin) conditions (N=3; Figure 5.4A). The amount of glycerol in the supernatant 
accumulates over time in all three conditions, however the total amount of glycerol is significantly 
higher in the presence of isoprenaline or forskolin versus basal conditions. After three hours, under 
basal conditions the supernatant contained 7.7 ± 1.6 μM glycerol (N=3), whereas cells stimulated 
with forskolin produced 28.9 ± 2.8 μM glycerol (N=3) and similarly, cell treated with isoprenaline 
produced 34.4 ± 4.7 μM glycerol (N=3). Thus, representing an approximately four-fold increase in 
glycerol release under stimulated conditions versus basal conditions (p<0.05). Both isoprenaline 
(Figure 5.4B) and forskolin (Figure 5.4C) treatment caused concentration-dependent increases in 
glycerol release, with EC50 values of 11.2 ± 10.9 nM (N=3) and 3.59 ± 11.7 nM (N=3) respectively.   
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Figure 5.4 Primary human in vitro differentiated adipocytes are capable of both basal and 
stimulated lipolysis (N=3). (A) Basal and stimulated (with 1 μM isoprenaline or 20 μM forskolin) 
glycerol accumulation in the supernatant over three hours. *p<0.05, **p<0.005 isoprenaline-
stimulated glycerol release versus basal glycerol release at the equivalent time point. # p<0.05, ### 
p<0.001 forskolin-stimulated glycerol release versus basal glycerol release at the equivalent time 
point. The effect of increasing concentrations of (B) isoprenaline or (C) forskolin on the amount of 
glycerol released after three hours. Data are normalised to the maximum amount of glycerol 
released per donor and then averaged across donors.  
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5.5 Exogenous nucleotide application and pharmacological blockade of P2Y1 
receptors have no effect on basal or stimulated lipolysis 
Lipolysis has previously been shown to be altered by fluxes in intracellular calcium levels (Xue et al., 
2001). In Chapter 4, it was determined that exogenous application of ATP and ADP elicited transient 
increases in intracellular calcium levels, so here attempts were made to test the hypothesis that 
calcium signalling pathways initiated by P2 receptor activation may affect lipolysis. To this end, it 
was identified that singular application of maximal concentrations of both ATP and ADP (as 
determined via calcium mobilisation assays in Chapter 4) do not significantly alter basal glycerol 
release in human adipocytes (Figure 5.5A,D). Furthermore, exogenous nucleotide application had 
no statistically significantly effect on isoprenaline- (Figure 5.5 B,E) or forskolin-stimulated (Figure 
5.5C,F) lipolysis over a three hour period, despite the fact that EC80 concentrations of both 
isoprenaline (75 nM) and forskolin (60 nM) were used in an attempt to optimise the probability of 
detecting an effect above the lipolytic effects of both stimulants. There appeared to be a slight 
increase in the amount of isoprenaline-stimulated glycerol release in the presence of ADP after 
three hours, however this increase was not statistically significant. It is not known whether this 
trend would have become significant if glycerol release was monitored over a longer time period (> 
3 hours), but if this was the case, it is unlikely that this effect would have been specifically due to 
ADP, as ADP is rapidly degraded (Slakey et al., 1997; Yegutkin, 2014).   
In addition, subtype selective inhibition of P2Y1 receptors with MRS2500 had no significant effect 
on basal or stimulated glycerol release in human adipocytes (Figure 5.6A-C). This lack of effect was 
evident both in the presence and absence of exogenous ADP, which suggests that neither activation 
(with ADP) nor inhibition of P2Y1 receptors (with MRS2500) had any effect on lipolysis under the 
conditions used in this study. The fact that inhibition of P2Y1 receptors with MRS2500 alone had no 
effect on lipolysis, is perhaps unsurprising as MRS2500 had no effect on cytoplasmic calcium (Figure 
5.2A), which suggests that there is no constitutive activity of P2Y1 in primary human adipocytes.   
During the assay, the adipocytes were incubated with serum-free media for two hours prior to the 
addition of vehicle or antagonists, as foetal bovine serum contains a wide variety of hormones and 
other substances that can affect lipolysis. The cells are then incubated with vehicle or antagonist 
for 30 minutes and then the first samples were collected immediately post-nucleotide and DMEM 
(basal) or stimulant (isoprenaline or forskolin) application. This means that the ‘0 hour’ reading 
shown in the time-resolved glycerol release graphs represent 0 hours after agonist/stimulant 
addition, but these supernatant sample have also been conditioned with basal glycerol release for 
2.5 hours (including 30 minutes with vehicle/antagonist) prior to agonist addition. Therefore, small 
quantities of glycerol are present in the supernatant even at ‘0 hours’. This applies to all subsequent 
glycerol quantification data, unless otherwise stated. The glycerol release data presented in this 
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Section, and throughout this Chapter unless otherwise stated, were normalised to the amount of 
glycerol released into the supernatant after three hours to minimise the effects of donor-to-donor 
variation. All the data are relative to the 3 hour timepoint, including 0 hours. This means that the 
relative amount of glycerol at 0 hours under basal conditions appears to be greater than the 0 hour 
concentrations for the stimulated cells. This is, because basal lipolysis occurs at a slower rate and 
with a lower magnitude than stimulated lipolysis (Figure 5.4A), thus when the data are normalised 
to the 3 hour values, the amount of glycerol produced in 2.5 hours (prior to agonist addition) is 
almost equal to the amount of glycerol produced during the time series, thus it appears as if the 
proportion of glycerol at 0 hours is approximately 40% for the basal samples, but only 20% for 
stimulated cells.   
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Figure 5.5 Exogenous nucleotide application has no effect on basal or stimulated lipolysis in primary human in vitro differentiated adipocytes. Effect of a singular 
application of maximal concentrations of exogenous ADP (10 μM; open circles) on (A) basal (N=7), (B) isoprenaline-stimulated lipolysis (N=4) and (C) forskolin-stimulated 
lipolysis (N=4) (closed circles) over a three hour period. Effect of a singular application of maximal concentrations of exogenous ATP (30 μM; open squares) on (D) basal 
(N=3), (E) isoprenaline-stimulated lipolysis (N=4) and (F) forskolin-stimulated lipolysis (N=3) (closed squares) over a three hour period. All data are normalised to the amount 
of glycerol released in the absence of nucleotide addition (control) after three hours. 
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Figure 5.6 Selective inhibition of P2Y1 and P2Y12 receptors have no effect on basal lipolysis and 
inhibition of P2Y1 also has no effect on stimulated lipolysis in primary human in vitro 
differentiated adipocytes (N=3). Effect of a singular application of maximal concentrations of 
exogenous ADP (10 μM; open circles) and selective inhibition of P2Y1 receptors with 1 μM MRS2500 
in the presence (open downward triangles) or absence of 10 μM ADP (closed triangles) on (A) basal, 
(B) isoprenaline-stimulated lipolysis or (C) forskolin-stimulated lipolysis (closed squares) over a 
three hour period. (D) Effect of a singular application of maximal concentrations of exogenous ADP 
(10 μM; open circles) and selective inhibition of P2Y12 receptors with 3 μM PSB0739 in the presence 
(open downward triangles) or absence of 10 μM ADP (closed triangles) on basal lipolysis (closed 
squares). All data are normalised to the amount of glycerol released in the absence of nucleotide 
and antagonist addition (control) after three hours. *p<0.05 ADP only vs vehicle only (control) at 
each timepoint. 
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5.6 Effect of inhibition of P2Y12 receptors on basal and stimulated lipolysis in 
human adipocytes 
It is well established that adenosine has an anti-lipolytic effect, which is mediated via activation of 
Gi-coupled P1 receptors to initiate a reduction in cytoplasmic cAMP levels (Fredholm et al., 1977; 
Ohisalo, 1981; Sollevi et al., 1981; Johansson et al., 2008). P2Y12 receptors are also Gi-coupled and 
ADP was shown to decrease forskolin-stimulated intracellular cAMP levels (Figure 4.10). This led to 
the hypothesis that activation of P2Y12 receptors in human adipocytes may have a similar anti-
lipolytic effect to adenosine. In order to test this hypothesis, P2Y12 receptors were selectively 
antagonised with PSB0739 in the presence and absence of ADP. Although, 3 μM PSB0739 had no 
effect on basal lipolysis, ADP alone caused a significant increase in basal lipolysis after 60 minutes 
(Figure 5.6D). Although the data for the 120 minute timepoint was the only statistically significant 
change, the amount of glycerol released trended higher for samples in the presence of ADP (with 
or without PSB0739) at all timepoints. Contrary to the hypothesis that ADP may act in a similar 
manner to adenosine, this result suggests ADP may have a lipolytic effect, rather than an anti-
lipolytic effect. Although the lack of statistical difference between the effect of ADP and PSB0739 
plus ADP, would suggest that the effect of ADP is not mediated via P2Y12 receptors. However, the 
fact that statistical significance was only demonstrated at one timepoint and data from other 
donors (Figure 5.5A and 5.6A) did not display a significant increase in basal glycerol release in the 
presence of ADP, suggests that this data is unlikely to be a true representation of the effects of ADP 
and that it is more likely that ADP does not alter basal lipolysis, at least in the majority of donors 
tested. Although it may be possible that there is an effect in a subset of donors, but as there is no 
clear indication of which donors may respond to ADP and the number of donors used in this study 
was limited, it was not possible to adequately explore a possible role for ADP in a subset of the 
population within the scope of this study.   
ADP had no effect on forskolin- (Figure 5.7D) or isoprenaline-stimulated lipolysis (Figure 5.7A), but 
selective antagonism of P2Y12 with 3 μM PSB0739 had an anti-lipolytic effect on isoprenaline-
stimulated lipolysis (Figure 5.7A). These results are surprising, because they do not correlate with 
previous data illustrating that PSB0739 increases cAMP (Figure 4.10). However, it appears that the 
anti-lipolytic effects of PSB0739 are only observed with 3 μM PSB0739 and lower concentrations of 
PSB0739 have no inhibitory effect on isoprenaline-stimulated lipolysis after 3 hours (Figure 5.7B). 
In addition, selective inhibition of P2Y12 with an alternative antagonist, Ticagrelor, did not mimic 
the results observed with 3 μM PSB0739. In fact, Ticagrelor did not significantly alter isoprenaline-
stimulated lipolysis at any timepoint (Figure 5.7C), which suggests that the effect of 3 μM PSB0739 
may be due to off-target effects, such as interference with isoprenaline binding. Furthermore, 3 μM 
PSB0739 had no effect on forskolin-stimulated lipolysis, which activates the same pathway as 
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isoprenaline, which again indicates that the effects of 3 μM PSB0739 are likely to be due to off-
target effects. Although, it is unclear what the true causes of these discrepancies are, it is likely that 
the effect of 3 μM PSB0739 on isoprenaline-stimulated lipolysis are anomalous and are not 
representative of the true phenotype.  
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Figure 5.7 Effect of selective inhibition of P2Y12 receptors on isoprenaline- and forskolin-
stimulated glycerol release in primary human in vitro differentiated adipocytes (N=3). (A) Effect 
of a singular application of maximal concentrations of exogenous ADP (10 μM; open circles) and 
inhibition of P2Y12 receptors with 3 μM PSB0739 in the presence (open downward triangles) or 
absence of 10 μM ADP (closed triangles) on isoprenaline-stimulated lipolysis (closed squares) over 
a three hour period. (B) Effect of increasing concentrations of PSB0739 on isoprenaline-stimulated 
glycerol release after 3 hours. (C) Effect of a singular application of maximal concentrations of 
exogenous ADP (10 μM; open circles) and inhibition of P2Y12 receptors with 300 nM Ticagrelor in 
the presence (open downward triangles) or absence of 10 μM ADP (closed triangles) on 
isoprenaline-stimulated lipolysis (closed squares) over a three hour period. (D) Effect of a singular 
application of maximal concentrations of exogenous ADP (10 μM; open circles) and inhibition of 
P2Y12 receptors with 3 μM PSB0739 in the presence (open downward triangles) or absence of 10 
μM ADP (closed triangles) on forskolin-stimulated lipolysis (closed squares) over a three hour 
period. All data are normalised to the maximum glycerol release after 3 hours in the presence of 
vehicle only. Data are expressed as mean ± SEM. *p<0.05, **p<0.005 PSB0739 only vs vehicle only 
at each timepoint; # p<0.05 PSB0739 and ADP vs vehicle only at each timepoint.  
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5.7 Pharmacological inhibition of P2Y2 receptor activity enhances basal and 
stimulated lipolysis  
P2Y2 receptors are expressed by primary human in vitro differentiated adipocytes and activation of 
these receptors leads to an appreciable increase in intracellular calcium, as shown in Chapter 4. In 
addition, it is evident that P2Y2 receptors are constitutively active in human adipocytes and they 
control both cytoplasmic calcium and cAMP tone within the cell (Figure 5.2 and 5.3). Although 
exogenous application of ATP had no effect on basal or stimulated lipolysis (Figure 5.5D-F), 
pharmacological inhibition of the P2Y2 receptor with 10 μM AR-C118925XX enhances both basal 
and stimulated lipolysis (Figure 5.8). The effects are particularly pronounced under basal conditions, 
where 10 μM AR-C118925XX generated a significant and sustained increase in basal glycerol release 
after 40 minutes (Figure 5.8A). Selective antagonism of P2Y2 receptors caused a 32.2 ± 7.8% (N=3) 
increase in basal glycerol release after 3 hours. It is important to note that the cells were 
preincubated with vehicle or antagonist for 30 minutes prior to collection of the first sample, thus 
the 40 minute timepoint actually represents 70 minutes in the presence of antagonist. The fact that 
the cells were preincubated with the antagonist may also explain why the concentration of glycerol 
in the supernatant trended higher for the AR-C118925XX-treated cells even at the 0 hour timepoint. 
Although the general trend suggests that AR-C118925XX caused a very rapid increase in glycerol 
release (from the 0 hour timepoint), these increases were not statistically significant until the 40 
minute timepoint. Selective inhibition of P2Y2 receptors enhanced basal lipolysis both in the 
presence and absence of ATP (Figure 5.8A), which is indicative of tonic P2Y2 receptor activity in 
these cells.  
Inhibition of P2Y2 receptors enhanced basal (Figure 5.8D) and forskolin-stimulated (Figure 5.8B,E) 
lipolysis in a concentration-dependent manner. After 3 hours, 10 μM AR-C118925XX generated a 
total increase in glycerol release of 41.1 ± 9.4% above cells stimulated with forskolin alone (N=3; 
p<0.05; Figure 5.8B). This increase is comparable to the effect observed on basal lipolysis. However, 
although the effects of P2Y2 inhibition on basal and forskolin-stimulated lipolysis share many 
similarities, unlike basal lipolysis, exogenous application of ATP appears to neutralise the effects of 
AR-C118925XX, particularly at the latter timepoints, which suggests that there may be some 
redundancies in the system to allow ATP to limit the amount of glycerol released even after P2Y2 
receptors are inhibited. It is possible that the reason that this rescue phenotype is evident for 
forskolin-stimulated lipolysis, but not basal lipolysis, is that total concentration of glycerol released 
in the presence of forskolin and AR-C118925XX is much higher than under basal conditions. Lipolysis 
is a very tightly regulated process, so it is possible that when a certain threshold of glycerol release 
is surpassed, alternative signalling pathways are engaged to limit the loss of triglyceride and 
maintain stores (Yu and Li, 2017).          
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AR-C118925XX enhances isoprenaline-stimulated lipolysis in a concentration dependent manner, 
with maximal concentrations of AR-C118925XX (10 μM) causing a 15.5 ± 5.7% (N=3) increase in 
isoprenaline-stimulated glycerol release (Figure 5.8F). Although the total level of enhancement 
caused by AR-C118925XX is comparatively less than the effects observed on basal and forskolin-
stimulated lipolysis, the effects of AR-C118925XX were more potent, with 1 μM AR-C118925XX 
causing a small, but significant increase in isoprenaline-stimulated glycerol release, whereas 
equivalent concentrations of AR-C118925XX had no effect on basal or forskolin-stimulated lipolysis. 
However, although a subtle, but clear increase in isoprenaline-stimulated glycerol release was 
observed in Figure 5.8F, when the effects of AR-C118925XX on isoprenaline-stimulated lipolysis was 
monitored over time (Figure 5.8C) no significant increase in glycerol release was observed at any 
timepoint. On average, there did appear to be an increase in glycerol release when the cells were 
treated with AR-C118925XX for two or more hours, but variation between donors meant that this 
increase was not statistically significant. Again, like forskolin-stimulated lipolysis co-application of 
AR-C118925XX and ATP appears to neutralise the slight, albeit non-significant, increase in glycerol 
release.   
There are different mechanisms governing basal and stimulated lipolytic pathways (Miyoshi et al., 
2008). Basal lipolysis is omnipresent, but certain external stimuli can dramatically increase the 
production of FFA and glycerol to augment those released via basal lipolysis. As the effects of P2Y2 
inhibition are largely comparable for both basal and stimulated lipolysis, it is likely that in both cases 
the effect is due to a mechanism that enhances basal lipolysis. Consequently, from this point 
onwards attempts were made to identify the molecular mechanisms underlying the effects on basal 
lipolysis only.    
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Figure 5.8 Selective inhibition of P2Y2 receptors enhances basal and stimulated lipolysis in primary human in vitro differentiated adipocytes (N=3). Effect of selective 
inhibition of P2Y2 receptors with 10 μM AR-C118925XX in the presence (open downward triangles) and absence (closed trianges) of a singular application of 30 μM ATP 
(open circles) on (A) basal, (B) forskolin-stimulated and (C) isoprenaline-stimulated glycerol release (closed squares). *p<0.05, **p<0.005, ***p<0.001 AR-C118925XX only 
versus vehicle only at each timepoint; # p<0.05, ### p<0.001 AR-C118925XX and ATP vs vehicle only at each timepoint. Increase in glycerol release caused by increasing 
concentrations of AR-C118925XX on (D) basal, (E) forskolin-stimulated and (F) isoprenaline-stimulated lipolysis after 3 hours. *p<0.05 vs glycerol release in the presence 
of vehicle only. All data are normalised to maximum glycerol release after 3 hours in the presence of vehicle only. Data are expressed as mean ± SEM.    
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5.8 shRNA-mediated knockdown of P2Y2 receptor expression also enhances 
basal lipolysis  
The increase in glycerol release observed with pharmacological inhibition of P2Y2 was replicated via 
shRNA-mediated knockdown of P2Y2 receptor expression. Lentiviral delivery of shRNA was used to 
successfully decrease mRNA expression of P2Y2 by approximately 50%. Knocking down P2Y2 
expression caused a 31.6 ± 8.6% (N=3) increase in basal glycerol release (p<0.05 versus scrambled 
control cells) (Figure 5.9). Interestingly in addition to causing an increase in glycerol release, 
decreasing expression of P2Y2 receptors in primary human adipocytes produced a phenotypic 
change in the cells. P2Y2 knockdown adipocytes had a greater number of smaller lipid droplets when 
compared to their scrambled counterparts (Figure 5.10). Smaller lipid droplets are consistent with 
an increase in metabolic activity (Khor et al., 2013). Quantification of the average number of lipid 
droplets per adipocyte indicate that there was an approximately 60% increase in the number of 
lipid droplets in P2Y2 knockdown cells versus scrambled cells (Figure 5.10B). In addition, on average 
P2Y2 knockdown cells contain less neutral lipid than their scrambled counterparts, as quantified 
using BODIPY neutral lipid stain (Figure 5.10C). These phenotypic changes are in line with the 
hypothesis that decreasing P2Y2 receptor activity causes an increase in lipolysis, which would 
consequently correspond with a decrease in triglyceride storage. 
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Figure 5.9 shRNA-mediated knockdown of P2Y2 receptor expression causes an increase in basal 
glycerol release in primary human in vitro differentiated adipocytes after 3 hours (N=3). Data are 
normalised to the amount of glycerol released by adipocytes treated with scrambled non-target 
shRNA per donor and then averaged across donors. Data are expressed as mean ± SEM. *p<0.05 
versus scrambled control cells.  
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Figure 5.10 shRNA-mediated knockdown of P2Y2 receptor expression causes a phenotypic change 
in primary human in vitro differentiated adipocytes. (A) Representative images of primary human 
adipocytes treated with non-target scrambled control shRNA (left) or P2Y2 target shRNA (right). (B) 
Average number of lipid droplets per cell. (C) Amount of neutral lipid present in a population of 
scrambled control and P2Y2 knockdown cells as determined by staining the lipids with BODIPY dye 
and then quantifying the fluorescence produced. Fluorescence readings are proportional to the 
amount of neutral lipid present. All data are normalised to the fluorescence reading for the 
scrambled control adipocytes per donor and then averaged across donors. Data is expressed as 
mean ± SEM. *p<0.05, ***p<0.001 versus scrambled control.  
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5.9 Enhancement of basal lipolysis caused by inhibition of P2Y2 receptors is 
replicated by removal of extracellular ATP with apyrase 
Removal of extracellular ATP with apyrase causes a 59.9 ± 20.0% (N=4) increase in basal lipolysis, 
which is equivalent to the 41.1 ± 16.0% (N=4) increase in glycerol release achieved with 10 μM AR-
C118925XX. In addition, simultaneous inhibition of P2Y2 receptors and scavenging extracellular ATP 
produces a 54.1 ± 17.2% (N=4) rise in basal glycerol release, which is comparable to the amount of 
glycerol released with AR-C118925XX and apyrase alone (Figure 5.11). This implies that both 
pharmacological blockade of P2Y2 receptors and removal of extracellular ATP may enhance lipolysis 
via the same mechanism. It is proposed that in both cases, the augmentation of basal lipolysis 
observed is due to inhibition of P2Y2 receptor activity, either via direct inhibition or removal of the 
physiological agonist. This hypothesis corresponds well with earlier data (Figure 5.2) that 
demonstrates that both AR-C118925XX and apyrase are able to modulate basal cytoplasmic calcium 
levels.  
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Figure 5.11 Scavenging extracellular ATP enhances basal glycerol release to the same degree as 
inhibiting P2Y2 receptor activity after 3.5 hours (N=4). P2Y2 receptors were selectively antagonised 
with 10 μM AR-C118925XX and extracellular ATP was removed with 2 U/ml apyrase. Data are 
normalised to basal glycerol release in the presence of vehicle alone. Data are expressed as mean 
± SEM. *p<0.05 versus control; NS implies no significant difference between the conditions under 
the line.  
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5.10 Attempting to determine the mechanism by which P2Y2 inhibition leads 
to an increase in cAMP and subsequent enhancement of basal lipolysis 
Throughout this Chapter, it has been determined that inhibition of P2Y2 receptors causes a decrease 
in cytoplasmic calcium (Figure 5.2), an increase an intracellular cAMP (Figure 5.2) and an 
enhancement of basal glycerol release (Section 5.7 and 5.8). In this Section, three potential 
mechanisms are explored in order to attempt to uncover the molecular mechanism connecting P2Y2 
receptors and basal lipolysis. Firstly, it is possible that P2Y2 receptors in human adipocytes may 
couple to Gi proteins, thus inhibition of P2Y2 receptor activity would alleviate Gi-mediated inhibition 
of adenylate cyclase to encourage cAMP production. Alternatively, elevated cytoplasmic calcium 
due to P2Y2 receptor activation may enhance phosphodiesterase (PDE) activity, therefore blockade 
of P2Y2 receptor would limit cAMP breakdown. Finally, increases in intracellular calcium via P2Y2 
receptor activation may inhibit calcium-sensitive isoforms of adenylate cyclase (AC), which means 
that inhibition of P2Y2 receptors would lower calcium tone and subsequently activate adenylate 
cyclase to increase cAMP production.  
5.10.1 Augmented glycerol release due to P2Y2 receptor inhibition is not achieved via Gi-
mediated signalling  
To determine whether the increase in basal lipolysis observed when P2Y2 receptor activity is 
inhibited is due to reduced Gi-mediated blockade of adenylate cyclase, basal glycerol release was 
measured in the presence and absence of AR-C118925XX and pertussis toxin (PTx). The protocol 
was modified slightly to extend the antagonist incubation time to 4 hours in these experiments to 
allow PTx sufficient time to enter the cells and terminate Gi-mediated signalling pathways. This 
method demonstrated that 100 ng/ml PTx alone did not alter basal glycerol release (Figure 5.12), 
which implies that constitutive Gi-mediated signalling does not suppress basal lipolysis in primary 
human adipocytes. Although PTx alone did not affect basal lipolysis, inhibition of P2Y2 receptors 
with 10 μM AR-C118925XX did increase basal glycerol release irrespective of the presence and 
absence of PTx (Figure 5.12). Taken together, these data indicate that P2Y2 inhibition-induced 
lipolysis is not achieved via blockade of Gi-mediated signalling.   
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Figure 5.12 Enhanced basal glycerol release via selective antagonism of P2Y2 receptors in primary 
human in vitro differentiated adipocytes is not achieved via inhibition of Gi-mediated signalling 
(N=6). P2Y2 receptors were selectively antagonised with 10 μM AR-C118925XX (AR-C) and Gi-
mediated signalling was blocked with 100 ng/ml pertussis toxin (PTx). Cells were preincubated with 
antagonists for four hours prior to assessment of glycerol concentration in the supernatants. Data 
are normalised to basal glycerol release in the presence of vehicle alone. Data are expressed as 
mean ± SEM. **p<0.005, ***p<0.001 versus glycerol release in the presence of vehicle only 
(control). 
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5.10.2 Simultaneous inhibition of P2Y2 receptors and phosphodiesterase isoforms 3 and 4 has 
a synergistic effect on basal lipolysis 
Previous reports describing increases in lipolysis due to changes in intracellular calcium indicated 
that low intracellular calcium levels may inhibit calcium sensitive phosphodiesterase (PDE) 
isoforms, such as PDE1, to facilitate accumulation of cytoplasmic cAMP and downstream 
enhancement of lipolysis (Xue et al., 2001). To ascertain whether P2Y2 inhibition-induced lipolysis 
is due to inhibition of PDE activity, glycerol release was measured in the presence of PDE isoform-
selective antagonists and/or AR-C118925XX. This revealed that selective antagonism of PDE3 (1 μM 
cilostramide) and PDE4 (10 μM rolipram), as well as non-selective PDE blockade with 10 μM 3-
isobutyl-1-methylxanthine (IBMX), caused an increase in basal glycerol production, whereas 
selective inhibition of PDE1 (vinpocetine), PDE2 (PF-05180999) and PDE7 (BRL50481) had no effect 
on basal lipolysis (N=3; Figure 5.13). It is well-known that inhibition of PDE3 increases lipolysis 
(Degerman et al., 1997; Snyder et al., 2005) and there are also some reports that demonstrate that 
inhibition of PDE4 with rolipram also enhances lipolysis (Grønning et al., 2006). It is important to 
note that IBMX is a component of the differentiation media used throughout this study to 
differentiate MSCs to adipocytes, however the differentiation media was removed, and the cells 
were incubated with culture media without IBMX (or the other differentiation media components) 
for three days prior to experimental use. In addition, the cells are washed immediately before 
commencing glycerol release assays to ensure no residual IBMX or other differentiation media 
components are present to affect the functioning of the in vitro differentiated adipocytes.  
Inhibition of P2Y2 was able to enhance spontaneous glycerol release to comparable degrees in the 
presence and absence of PDE1, PDE2 and PDE7 antagonists (Figure 5.13). However, when AR-
C118925XX was coapplied with IBMX, cilostamide or rolipram, more glycerol was released into the 
supernatant than due to P2Y2 receptor or PDE inhibition alone (Figure 5.13). This implies that 
inhibition of P2Y2 does not enhance basal lipolysis by inhibiting PDE-mediated breakdown of cAMP. 
It also indicates that there is synergism between the pathways mediated by P2Y2 and PDEs in 
enhancing basal lipolysis.  
189 
 
C
on
tro
l
AR
C
IB
M
X
IB
M
X+
AR
C
Vi
np
oc
et
in
e
V+
AR
C
PF
-0
51
80
99
9
P+
AR
C
C
ilo
st
ra
m
id
e
C
+A
R
C
R
ol
ip
ra
m
R
+A
R
C
BR
L5
04
81
BR
L+
AR
C
0
100
200
300
****
*
**
*
*
**
***
***
G
ly
c
e
ro
l 
re
le
a
s
e
 (
%
)
**
+
++
+
+
+++ +
 
Figure 5.13 Simultaneous inhibition of P2Y2 receptors and phosphodiesterase isoforms 3 or 4 has 
a synergistic effect on basal glycerol release from primary human in vitro differentiated 
adipocytes (N=3). P2Y2 was inhibited with 10 μM AR-C118925XX, phosphodiesterase (PDE) 
isoforms were inhibited with 10 μM IBMX (pan-PDE inhibitor), 10 μM vinpocetine (PDE1 inhibitor), 
10 μM PF-05180999 (PDE2 inhibitor), 1 μM cilostramide (PDE3 inhibitor), 10 μM rolipram (PDE4 
inhibitor) and 1 μM BRL50481 (PDE7 inhibitor). Glycerol release was measured after the cells were 
exposed to antagonists for 3.5 hours. All data are normalised to glycerol release in the presence of 
vehicle only (control). *p<0.05, **p<0.005, ***p<0.001 versus control. + p<0.05, ++ p<0.005, +++ 
p<0.001 denotes a significant difference between the two conditions below the line.  
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5.10.3 Inhibition of P2Y2 activates calcium-sensitive isoforms of adenylate cyclase to 
encourage basal lipolysis 
There are nine known membrane-bound isoforms of adenylate cyclase, named adenylate cyclase 
(AC) 1-9 respectively. There is also an additional ‘soluble’ isoform, AC10, which has distinct catalytic 
and regulatory properties (Kamenetsky et al., 2006). Non-quantitative RT PCR analysis revealed that 
all of the membrane-bound isoforms of AC were expressed by primary human in vitro differentiated 
adipocytes, excluding AC9 (Figure 5.14). However, there was some heterogeneity in expression for 
AC2, which was only expressed in two of the three donors tested.  
Calcium has been shown to activate and inhibit different isoforms of AC (Sadana et al., 2009), with 
AC5 and AC6 being shown to be directly inhibited by submicromolar concentrations of free calcium 
(Guillou et al., 1999). Previous reports suggest concentrations of below 10 μM SQ22,536 (an AC 
antagonist) are selective for calcium-sensitive isoforms of AC (AC5 and AC6) (Brand et al., 2013). 
Using 1 μM SQ22,536, it was shown that inhibition of AC alone had no effect on basal lipolysis, 
whereas inhibition of P2Y2 receptors enhanced basal lipolysis (Figure 5.15). Interestingly, 
simultaneous inhibition of both AC and P2Y2 receptors abolished the enhancement of basal glycerol 
release observed with AR-C118925XX alone (Figure 5.15). This suggests P2Y2 inhibition-induced 
lipolysis occurs via activation of AC5 and/or AC6. As 1 μM SQ22,536 inhibits both AC5 and AC6, it 
was not possible to distinguish between AC5 and AC6 within the scope of this study. This 
mechanism also explains the synergism between PDE inhibition and P2Y2 receptor inhibition 
(Section 5.10.2). Inhibition of P2Y2 receptors increases production of cAMP, while inhibition of PDEs 
reduces the breakdown of cAMP, thus facilitating a larger accumulation of cytoplasmic cAMP.   
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Figure 5.14 Primary human in vitro differentiated adipocytes express mRNA transcripts for all 
membrane-bound isoforms of adenylate cyclase (AC), excluding isoform 9, as detected by non-
quantitative RT-PCR. Results are representative of the expression patterns for three independent 
donors, although there was some heterogeneity for AC2, which was only expressed in 2 of the 3 
donors tested. HA = human adipocytes, HA’ = control for genomic DNA contamination (no reverse 
transcriptase control).   
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Figure 5.15 Inhibition of calcium-sensitive isoforms of adenylate cyclase abolishes P2Y2-inhibition 
induced enhancement of basal glycerol release from primary human in vitro differentiated 
adipocytes (N=6). P2Y2 receptors were inhibited with 10 μM AR-C118925XX, calcium-sensitive 
isoforms of adenylate cyclase were inhibited with 1 μM SQ22,536. Glycerol release was measured 
after the cells were exposed to antagonists for 3.5 hours. All data are normalised to the glycerol 
release in the presence of vehicle only (control). *p<0.05 signifies a significant difference between 
the two conditions indicated with the line above the bars. 
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5.11 Proposed mechanism for the role of P2Y2 receptors in regulating basal 
lipolysis 
The data presented in this Chapter enables the proposal of a molecular mechanism that links P2Y2 
receptor activity to basal lipolysis in human in vitro differentiated adipocytes. It is proposed that a 
reduction of constitutive P2Y2 receptor activity causes a decrease in intracellular calcium, which 
then negates the inhibitory action of resting cytoplasmic calcium levels on AC5 and/or AC6. This in 
turn leads to an accumulation of cAMP in the cytosol, thus activating PKA, which phosphorylates 
enzymes associated with lipolysis to enhance basal lipolysis and consequently increase glycerol 
release from primary human adipocytes. If this mechanism is correct, then it signifies that the 
physiological role of P2Y2 in primary human adipocytes is to constitutively maintain intracellular 
calcium levels to perpetuate inhibition of AC5 and/or AC6 and limit basal lipolysis in adipocytes, 
thus maintaining triglyceride stocks within the cells. This would imply that P2Y2 receptor activity 
promotes an energy conservative phenotype within primary human in vitro differentiated 
adipocytes. A summary of the proposed mechanism is denoted in Figure 5.16.  
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Figure 5.16 Schematic diagram of the proposed mechanism by which P2Y2 receptor activation 
causes acute suppression of lipolysis in primary human in vitro differentiated adipocytes.  Under 
basal conditions (left hand panel), P2Y2 receptors are activated by ATP or UTP released by the 
adipocytes into the extracellular space, which then subsequently activates phospholipase C (PLC) 
mediated production of diacylglycerol (DAG) and inositol triphosphate (IP3). The IP3 then binds to 
receptors on the surface of the endoplasmic reticulum (ER) to initiate release of calcium ions (Ca2+) 
from the ER into the cytosol. This elevation of cytoplasmic calcium causes tonic inhibition of 
calcium-sensitive adenylate cyclase (AC) isoforms. However, in the absence of P2Y2-receptor 
mediated inhibition of AC due to blockade of P2Y2 receptor signalling (right hand panel), 
intracellular calcium concentrations are lower and therefore AC is not inhibited and consequently 
free to convert ATP to cyclic AMP (cAMP). The increase in intracellular cAMP activates protein 
kinase A (PKA), which is then able to phosphorylate cytoplasmic hormone sensitive lipase (HSL). 
This allows HSL to translocate the lipid droplet. Here, adipose triglyceride lipase (ATGL) catalyses 
the hydrolysis of triglycerides (TG) to diglycerides (DG) and free fatty acid (FA) molecules, then HSL 
catalyses the conversion of DG to monoglycerides (MG) and FAs, finally monoglyceride lipase (MGL) 
catalyses lipolytic breakdown of MG to glycerol and FA. The glycerol and three FA molecules can 
then be transported out of the cell and released into the bloodstream, where they can travel to the 
liver or other organs to be utilised as an energy source.      
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5.12 Exogenous application of ATP and inhibition of P2Y2 receptors alters the 
profile of adipokines secreted by human adipocytes 
In addition to storage and release of energy, adipocytes are also capable of secreting a wide variety 
of adipokines that are capable of regulating immune responses and metabolism (Halberg et al., 
2008). To determine whether there is a role for purinergic signalling in adipokine secretion, a 
Human Obesity Array Q3 multiplex ELISA protein array was used to the assess the secretion of 40 
obesity-related adipokines in the presence and absence of super-maximal concentrations of ATP. 
High concentrations of ATP were used to ensure that sufficient ATP was present to activate most 
of the P2X and P2Y receptor subtypes expressed in human adipocytes (Gorini et al., 2013). 
Furthermore, the effect of selective antagonism of P2Y2 receptors using 10 μM AR-C118925XX was 
ascertained in order to determine whether P2Y2 receptors exerted additional ‘energy-conservative’ 
activity to complement the effects observed on basal lipolysis.  
To mimic the conditions used for the glycerol release experiments, supernatant samples were 
collected from adipocytes that were incubated with DMEM (no serum) for two hours, then exposed 
to a singular dose of vehicle or antagonist for 30 minutes, finally ATP or vehicle was added and the 
first samples were collected immediately (0 hour sample). Subsequent samples were then taken 
after a further 6 and 24 hours had elapsed. Although after 6 hours, samples were only collected for 
cells treated with vehicle or ATP alone and no samples were tested for cells treated with antagonist. 
Supernatant samples from four independent donors were utilised and the data presented in 
Sections 5.12, 5.13 and 5.14 are averaged across all four donors. The data from the array is 
summarised in Table A1, Table A2, Table 5.1 and Figure 5.17.      
Although data was collected for samples taken after 0 and 6 hours, the focus here will be on the 
results for the samples collected after 24 hours. In brief, only 13 adipokines were detected at the 0 
hour timepoint. Of these 13 adipokines, secretion of adiponectin, insulin-like growth factor (IGF) 1, 
IGF binding protein (IGFBP) 2, interleukin (IL) 8, retinol binding protein 4 (RBP4) and tumour 
necrosis factor (TNF) α were not significantly altered, whereas secretion of adipsin, IL-6, 
osteoprotegerin (OPG), plasminogen activator inhibitor-I (PAI-I), thrombospondin 1 (TSP-1),  TNF 
receptor II (TNF RII) and vascular endothelial growth factor (VEGF) were significantly affected by 
ATP and/or AR-C118925XX addition. However, although it is possible that activation/inhibition of 
purinergic receptors may have an immediate effect on the secretion of these adipokines, it is not 
very probable, and it is more likely that these results are anomalies. All the data for the 0 hour 
timepoint is displayed in Table A1 in the appendix. After 6 hours, only 21 adipokines were detected, 
of which eleven were not affected by nucleotide or antagonist addition: adipsin, IGF-1, IGFBP1, 
IGFBP2, IL-6, IL-8, PAI-I, RBP4, serum amyloid A (SAA), TNFα and VEGF. However, the secretion of 
TSP-1 and adiponectin were both augmented, whereas expression of chemerin, growth hormone 
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(GH), IL-12p40, leptin, lipocalin-2, OPG, resistin and TNF RII were reduced in the presence of 100 
μM ATP after 6 hours (Table A2). This suggests that purinergic signalling may be involved in 
modulating the secretion of these ten adipokines. Although it is interesting that these adipokines 
are affected by singular exogenous ATP application, it is not possible to ascribe these effects to a 
specific receptor, as supernatant samples treated with subtype-selective antagonists were not 
analysed. Thus, the primary purpose of this data is to highlight potential targets for future 
exploration. However, it was noteworthy that the secretion of anti-lipolytic adiponectin 
significantly increased (Wedellová et al., 2011), whereas the release of lipolytic adipokines, such as 
chemerin (Fu et al., 2016), GH (Sakharova et al., 2008), leptin (Ruud and Brüning, 2015) and resistin 
(Chen et al., 2014) significantly decreased in the presence of ATP. This implies purinergic signalling 
may promote an anti-lipolytic phenotype after 6 hours, which complements the earlier findings in 
this Chapter that suggest that constitutive purinergic receptor activity via P2Y2 limits basal lipolysis.     
The secretion of almost all of the adipokines in the array increased over time, excluding eight 
adipokines that were not detected regardless of the presence or absence of ATP and/or AR-
C118925XX or timing. These eight adipokines were as follows: Agouti-related peptide (AgRP), brain-
derived neurotrophic factor (BDNF), interferon γ (IFNγ), IL-12p70, pepsinogen I, pepsinogen II, 
platelet-derived growth factor-BB (PDGF-BB) and tumour necrosis factor receptor I (TNF RI). It is 
not possible to definitively state that these adipokines were not secreted by adipocytes, as it is 
possible that these adipokines were expressed at levels that fell below the assay detection limit. 
However, it was not surprising that these eight adipokines were not detected at any time point as 
previous studies suggest that these adipokines are not expressed by adipocytes or display limited 
expression in adipose tissue (Fagerberg et al., 2014; Uhlén et al., 2015; Onogi et al., 2017). An 
additional nine adipokines were detected after 24 hours, but did not appear to be affected by either 
ATP or AR-C118925XX addition. These adipokines were chemerin, IL-1β, IL-1 receptor antagonist 
(IL-1ra), IL-12p40, insulin, lipocalin-2, leptin, MSPα and resistin (Table 5.1). There were a few 
adipokines that were excluded from further study due to technical issues. This included TSP-1, 
which was omitted, because the concentration of TSP-1 exceeded the assay detection limits after 
24 hours, which rendered it impossible to determine whether nucleotide or antagonist addition 
had an effect. This issue could have been overcome by diluting the supernatant samples to ensure 
the concentration of TSP-1 fell within the dynamic range of the assay. Furthermore, the data for 
prolactin was removed, as samples that had undergone multiple freeze-thaw cycles had 
artifactually reduced quantities of prolactin. Repetition of this experiment with fresh sample would 
be a good method of ascertaining whether ATP or AR-C118925XX treatment influenced prolactin 
secretion, but unfortunately time-constraints meant that it was not possible to repeat the 
experiment for TSP-1 or prolactin within the timeframe of this study.  
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Of the remaining adipokines, only five were significantly affected by exogenous ATP application, 
whereas expression of 20 adipokines was altered by selective antagonism of P2Y2 receptors (Table 
5.1, Figure 5.17). It is important to be cautious when interpreting the data produced from this 
protein array. Adipocytes are highly dynamic cells that can adjust their activity in response to 
changes in their environment. Earlier in this Chapter, it was demonstrated that inhibition of P2Y2 
receptors enhances basal lipolysis. It has previously been shown that FFAs can inhibit lipolysis 
(Burns et al., 1975) and cause inflammation (Jiao et al., 2011). This is just one example, but it is 
important to note that the evident changes in adipokine secretion due to inhibition of P2Y2 
receptors may not be due to direct inhibition of P2Y2-mediated pathways. They may be as a result 
of activation of feedback mechanisms triggered by P2Y2 inhibition-induced enhanced lipolysis. 
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Table 5.1 Adipokines secreted by primary human in vitro differentiated adipocytes after 24 hours following singular treatment with vehicle, 100 μM ATP and/or a P2Y2 
receptor antagonist (10 μM AR-C118925XX (AR-C)) (N=4). Adipokines were quantified by protein array and the data are presented as mean ± SEM for four donors. % 
increase and decrease values show the statistically significant changes in expression versus the vehicle control levels. NS indicates no significant change. Cases of donor 
variation are indicated by an * near the adipokine’s name. 
 
Vehicle control 
(pg/ml) 
100 μM ATP 
(pg/ml) 
% increase or 
decrease 
10 μM AR-C 
(pg/ml) 
% increase or 
decrease 
ATP and AR-C 
(pg/ml) 
% increase or 
decrease 
Adiponectin 8542.1 ± 1404 12018.2 ± 931 NS 16001.1 ± 1156 ↑ 87% 15533.5 ± 1492 ↑82% 
Adipsin 1360.5 ± 208 2114.5 ± 337 ↑ 55% 5024.4 ± 1468 ↑ 269% 5334.3 ± 1549 ↑ 292% 
AgRP <14 <14 - <14 - <14 - 
ANGPTL4 432.4 ± 45 670.4 ± 68 NS 119.7 ± 30 ↓ 72% 173.5 ± 20 ↓ 60% 
BDNF <55 <55 - <55 - <55 - 
Chemerin 602.1 ± 140 1328.1 ± 458 NS 374.6 ± 70 NS 311.3 ± 66 NS 
CRP* <27 <27 - 12.6 ± 4 NS 18.7 ± 5 NS 
GH <27 59.5 ± 17 ↑ 100% 45.1 ± 11 NS 75.7 ± 12 ↑ 100% 
IFNγ <14 <14 - <14 - <14 - 
IGFBP-1 15.3 ± 5 39.6 ± 7 NS 346.8 ± 28 ↑ 2162% 390.2 ± 33 ↑ 2446% 
IGFBP-2 756.4 ± 57 1040.1 ± 93 NS 262.9 ± 20 ↓ 65% 292.6 ± 32 ↓ 61% 
IGF-1 4921.0 ± 1077 6558.2 ± 1140 NS 41515.3 ± 2087 ↑ 743.6% 53555.4 ± 2911 ↑ 988.3% 
IL-10* 1.8 ± 0.5 5.9 ± 1  NS 8.5 ± 2 ↑ 369% 17.2 ± 4 ↑ 857% 
IL-12p40 220.2 ± 95 80.2 ± 26 NS 32.2 ± 9 NS 40.0 ± 10 NS 
IL-12p70 <3 <3 - <3 - <3 - 
IL-1β 3.0 ± 0.9 4.3 ± 1 NS 6.1 ± 1 NS 4.8 ± 0.8 NS 
IL-1Ra 358.0 ± 64 421.0 ± 59 NS 188.6 ± 48 NS 204.1 ± 46 NS 
IL-6 836.4 ± 150 1837.0 ± 113 ↑ 120% 1547.0 ± 145 ↑ 85% 1383.1 ± 168 NS 
IL-8 102.4 ± 21 119.6 ± 25 NS 181.4 ± 23 ↑ 77% 238.9 ± 30 ↑ 133% 
Insulin 1127.1 ± 381 5006.0 ± 802 NS 3767.1 ± 1673 NS 668.0 ± 369 NS 
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Leptin 271.1 ± 54 273.2 ± 35  NS 151.4 ± 25 NS 88.3 ± 24 NS 
Lipocalin-2 3.0 ± 0.6 4.0 ± 0.7 NS 4.9 ± 1 NS 2.6 ± 1 NS 
MSPα 182.3 ± 55 237.6 ± 55 NS 121.1 ± 39 NS 99.1 ± 26 NS 
OPG 2309.1 ± 351 1862.0 ± 143 NS 1775.1 ± 264 NS 828.8 ± 166 ↓ 64% 
PAI-I 6450.2 ± 1172 6707.2 ± 621 NS 1738.6 ± 322 ↓ 73% 1355.1 ± 292 ↓ 79% 
PDGF-BB <3 <3 - <3 - <3 - 
Pepsinogen 1 <27 <27 - <27 - <27 - 
Pepsinogen 2 <55 <55 - <55 - <55 - 
Procalcitonin 393.7 ± 120 896.2 ± 339 NS <137 ↓ 100% <137 ↓ 100% 
RANTES 282.4 ± 98 541.6 ± 191 ↑ 92% 53.5 ± 15 NS 89.1 ± 23 NS 
RBP4 6459.1 ± 751 6158.5 ± 628 NS 2739.7 ± 90 ↓ 58% 2045.0 ± 253 ↓ 68% 
Resistin 579.2 ± 203 1118.3 ± 350 NS 70.3 ± 21 NS 21.6 ± 10 NS 
SAA <137 <137 NS 1816.1 ± 186 ↑ 100% 1839.5 ± 341 ↑ 100% 
TGFβ1* <137 <137 NS 278.4 ± 66 ↑ 100% 269.6 ± 70 NS 
TSP-1 >200,000 >200,000 - >200,000 - >200,000 - 
TNF RI <137 <137 - <137 - <137 - 
TNF RII 70.7 ± 7 141.5 ± 11 NS 24.7 ± 4 NS 18.3 ± 4 ↓ 74% 
TNFα 98.8 ± 16 319.8 ± 125 NS 48.1 ± 8 NS 21.9 ± 8 ↓ 78% 
VEGF 1593.2 ± 73 2039.7 ± 118 ↑ 28% 979.0 ± 39 ↓ 39% 842.4 ± 113 ↓ 47% 
*CRP and IL-10 were only detected in 2 of 4 donors tested; TGFβ1 was only detected in 3 of 4 donors tested. 
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Figure 5.17 Heatmap summarising the changes in adipokine secretion after 24 hours following 
singular treatment with 100 μM ATP and/or 10 μM AR-C118925XX (AR-C) (N=4). Data are shown 
relative to the control levels of each respective adipokine. Red represents low secretion/not 
detected, black represents no change and green represents an increase in secretion.  Heatmap was 
generated using Origin Pro software. 
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5.13 Inhibition of P2Y2 receptors promotes release of chemokines, cytokines 
and acute phase proteins 
Obesity is associated with an increase in adipocytokine production (Halberg et al., 2008; Fain, 2010), 
that contributes to chronic low grade inflammation of adipose tissue, which in turn is thought to 
influence the development of obesity-related comorbidities (Després et al., 2006; van 
Greevenbroek et al., 2013). Obesity is also associated with elevated fasting FFA levels due to an 
increased rate of basal lipolysis (Wang et al., 2003) and FFA are known to promote inflammation 
and insulin resistance (Jiao et al., 2011). Earlier in this Chapter, it was determined that inhibition of 
P2Y2 causes an acute increase in basal glycerol release. Although FFA release was not directly 
measured, it can be assumed that enhanced glycerol release would be accompanied by augmented 
FFA production too, thus it was hypothesised that blockade of P2Y2 receptors may promote 
secretion of proinflammatory cytokines. In support of this theory, inhibition of P2Y2 receptors for 
24 hours appears to increase secretion of proinflammatory cytokines and acute phase proteins, 
such as IL-6, IL-8, C-reactive protein (CRP), serum amyloid A (SAA) and transforming growth factor 
(TGF) β1, as well as causing a decrease in secretion of TNF RII, thus reducing its capacity to block 
the proinflammatory action of TNFα (Table 5.1; Figure 5.18). IL-6 secretion was also significantly 
increased in the presence of 100 μM ATP for 24 hours (Figure 5.18A), which suggests that other 
purinergic receptors are also involved in modulating IL-6 secretion. CRP, SAA and TGF β1 were only 
detected when P2Y2 receptors were inhibited (Figure 5.18C-E). However, CRP secretion was only 
observed in two of the four donors tested, so when the data for all four donors was analysed, the 
increase in CRP secretion was not deemed statistically significant (Figure 5.18C). On average, TNF 
RII secretion appears to increase in the presence of ATP alone and decrease in the presence of AR-
C118925XX, however these changes were not statistically significant, although co-application of 
ATP and AR-C118925XX did cause a significant reduction (Figure 5.18F). Taken together, this data 
suggests that inhibition of P2Y2 receptors promotes inflammation, which may be indirectly due to 
P2Y2-inhibition induced enhancement of basal lipolysis or directly due to inhibition of tonic P2Y2 
activity. If it is the latter explanation, then this would imply that tonic activation of P2Y2 receptors 
act to reduce inflammation via suppression of proinflammatory adipokine release.   
However, in addition to AR-C118925XX treatment inducing an increase in proinflammatory 
cytokines, blockade of P2Y2 receptors for 24 hours also appears to increase the release of anti-
inflammatory cytokines, such as IL-10, as well as diminishing the secretion of some acute phase 
reactants, including PAI-I and procalcitonin (Whicher et al., 2001). Pharmacological blockade of P2Y2 
receptors increases the secretion of IL-10 from 1.8 ± 0.5 pg/ml to 17.2 ± 4 pg/ml (N=4; p<0.005) and 
8.5 ± 1.9 pg/ml (N=4; p<0.05) in the presence and absence of 100 μM ATP respectively (Figure 
5.19A). Furthermore, ATP increases the secretion of RANTES (regulated on activation, normal T cell 
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expressed and secreted), a chemotactic factor that encourages the recruitment of immune cells 
(Appay and Rowland-Jones, 2001), but this increase is neutralised when P2Y2 receptors are 
inhibited, which suggests that the ATP-induced secretion of RANTES is mediated by P2Y2 receptor 
activity. Constitutive activity of P2Y2 receptors appears to have no effect on RANTES secretion as 
AR-C118925XX alone did not significantly alter the concentration of RANTES produced. Together 
these findings suggest that in addition to encouraging the secretion of proinflammatory cytokines, 
inhibition of P2Y2 receptors also endorses an anti-inflammatory phenotype. Within the scope of this 
study, it was not determined whether the increase in anti-inflammatory cytokines was directly due 
to P2Y2 inhibition or due to activation of homeostatic pathways to manage the effects of the 
increased presence of pro-inflammatory mediators or vice versa.  
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Figure 5.18 Inhibition of P2Y2 receptors enhances the secretion of proinflammatory adipokines, 
as well as reducing the secretion of some anti-inflammatory adipokines (N=4). Effect of singular 
treatment with 100 μM ATP, 10 μM AR-C118925XX (P2Y2 receptor antagonist) and co-application 
of ATP and AR-C118925XX on the secretion of (A) interleukin 6 (IL-6), (B) interleukin 8 (IL-8), (C) C-
reactive protein (CRP), (D) serum amyloid A (SAA), (E) transforming growth factor (TGF) β1 and (F) 
tumour necrosis factor receptor II (TNF RII) from primary human in vitro differentiated adipocytes 
after 24 hours. All adipokines were quantified using a Human Obesity Array Q3 multiplex ELISA 
protein array from Ray Biotech. All data are expressed as mean ± SEM. *p<0.05, **p<0.005, 
***p<0.001, ns p>0.05 versus secretion of each adipokine under control conditions (vehicle only).   
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Figure 5.19 Inhibition of P2Y2 receptors enhances the secretion of anti-inflammatory cytokines 
(IL-10), decreases expression of acute phase reactants (PAI-I and procalcitonin) and neutralises 
ATP-induced secretion of RANTES (N=4). Effect of singular treatment with 100 μM ATP, 10 μM AR-
C118925XX (P2Y2 receptor antagonist) and co-application of ATP and AR-C118925XX on the 
secretion of (A) interleukin 10 (IL-10), (B) plasminogen activator inhibitor-I (PAI-I), (C) procalcitonin 
and (D) RANTES from primary human in vitro differentiated adipocytes after 24 hours. All 
adipokines were quantified using a Human Obesity Array Q3 multiplex ELISA protein array from Ray 
Biotech. All data are expressed as mean ± SEM. *p<0.05, **p<0.005, ***p<0.001, ns p>0.05 versus 
secretion of each adipokine under control conditions (vehicle only).   
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5.14 After 24 hours, inhibition of P2Y2 receptors enhances secretion of anti-
lipolytic adipokines and decreases basal glycerol release  
The results of the protein array appear to demonstrate that longer term (24 hours) treatment of 
primary human in vitro differentiated adipocytes with 10 μM AR-C118925XX promotes an anti-
lipolytic phenotype, which is contrary to the earlier findings that indicate that inhibition of P2Y2 
receptors enhances basal lipolysis. Pharmacological inhibition of P2Y2 dramatically enhances 
secretion of adipokines with anti-lipolytic activity including adiponectin (Qiao et al., 2011; 
Wedellová et al., 2011) and adipsin (Van Harmelen et al., 1999; Ronti et al., 2006; Liu et al., 2015) 
(Figure 5.20). Although a slight increase in adiponectin secretion was observed in the presence of 
ATP alone, this increase was not significant and instead these data suggest inhibition of P2Y2 
receptors, irrespective of whether ATP is present or not, increases secretion of adiponectin (Figure 
5.20A). Similarly, AR-C118925XX treatment with and without ATP caused an increase in adipsin 
secretion, although ATP alone also caused a significant increase (Figure 5.20B), which indicates that 
P2Y2 activity may suppress adipsin secretion, while activation of another purinergic receptor may 
augment adipsin release. In addition to causing an increase in anti-lipolytic adipokine secretion, 
selective inhibition of P2Y2 also led to a down-regulation of several adipokines that stimulate 
lipolysis, including angiopoietin-like 4 (ANGPTL4) protein (Gray et al., 2012; La Paglia et al., 2017), 
retinol-binding protein 4 (RBP4) (Lee et al., 2016) and tumour necrosis factor α (TNFα) (H. H. Zhang 
et al., 2002). The secretion of both ANGPTL4 and TNFα are non-significantly increased with ATP 
alone, but significantly decreased with AR-C118925XX treatment (Figure 5.20C,E), albeit in the case 
of TNFα the decrease observed is only statistically significant when the cells are treated with both 
ATP and AR-C118925XX simultaneously (Figure 5.20E). The fact that inhibition of P2Y2 decreased 
release of ANGPTL4 and TNFα suggests that tonic P2Y2 activity may encourage secretion of both 
adipokines and exogenous application of ATP may further augment secretion, but currently the 
data suggests exogenous ATP has no effect. Previous reports indicate that overexpression of human 
RBP4 in mouse adipocytes stimulates lipolysis via RBP4-induced inflammation (Lee et al., 2016). 
RBP4 expression is also decreased following treatment with AR-C118925XX for 24 hours, but unlike, 
ANGPTL4 and TNFα, there is no indication that exogenous ATP may potentially influence RBP4 
secretion (Figure 5.20D).  
To test whether the augmented release of anti-lipolytic adipokines and diminished secretion of 
lipolytic adipokines (Figure 5.20) coincided with a reduction in basal glycerol release after 24 hours, 
the amount of glycerol in the supernatant was quantified following 0.5, 3.5 and 24.5 hours 
treatment with a singular dose of 10 μM AR-C118925XX. This demonstrated that there was a 
gradual accumulation of glycerol in the supernatant over time. Furthermore, it confirmed that 
blocking P2Y2 receptor activity led to an increase in basal glycerol release after 0.5 and 3.5 hours, 
206 
 
but interestingly, it also established that selective antagonism of P2Y2 caused a reduction in the 
glycerol concentration in the supernatant after 24.5 hours (Figure 5.21). These data indicate that 
acute inhibition of P2Y2 receptors enhances lipolysis, whereas prolonged blockade of P2Y2 receptors 
inhibits lipolysis. It is possible that this change in phenotype is due to the activation of feedback 
mechanisms triggered by an acute increase in lipolysis, which enhances the secretion of anti-
lipolytic adipokines to overcome the lipolytic effects of P2Y2 inhibition. However, to confirm this 
hypothesis additional experiments would be required.  
In keeping with the energy storage theme of P2Y2 receptor inhibition after 24 hours, selective 
antagonism of the receptor also seems to encourage the release of adipokines that may stimulate 
adipose tissue expansion and enhance glucose uptake (Figure 5.22). As well as being anti-lipolytic 
agents, both adiponectin and adipsin act to enhance glucose uptake (Sniderman and Cianflone, 
1994; Tao et al., 2014). In addition, a substantial increase in insulin-like growth factor (IGF) 1 and 
IGF binding protein (IGFBP) 1 and a decrease in IGFBP2 was detected after 24 hours in the presence 
of 10 μM AR-C118925XX (N=4; Figure 5.22). in addition, IGFBP2 secretion is enhanced by exogenous 
ATP treatment (Figure 5.22C). IGF-1 has been shown to be critical for cell proliferation and 
differentiation of adipocyte precursor cells (Smith et al., 1988; Scavo et al., 2004), as well as 
stimulating glucose uptake (Clemmons, 2004). The activity of IGF-1 is regulated by IGF binding 
proteins (IGFBP). Both IGFBP1 and IGFBP2 have been shown to inhibit the action of IGF-1, but 
IGFBP1 can also potentiate IGF-1 activity (Rajaram et al., 1997).  
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Figure 5.20 Inhibition of P2Y2 receptors increases the release of anti-lipolytic adipokines and 
downregulates the secretion of lipolytic adipokines (N=4). Effect of singular treatment with 100 
μM ATP, 10 μM AR-C118925XX (P2Y2 receptor antagonist) and co-application of ATP and AR-
C118925XX on the secretion of (A) adiponectin, (B) adipsin, (C) angiopoietin-like 4 (ANGPTL4), (D) 
retinol-binding protein 4 (RBP4) and (E) tumour necrosis factor α (TNFα). All adipokines were 
quantified using a Human Obesity Array Q3 multiplex ELISA protein array from Ray Biotech. All data 
are expressed as mean ± SEM. *p<0.05, **p<0.005, ***p<0.001, ns p>0.05 versus secretion of each 
adipokine under control conditions (vehicle only).   
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Figure 5.21 Pharmacological inhibition of P2Y2 receptors in primary human in vitro differentiated 
adipocytes causes an acute increase in basal glycerol release, but longer-term receptor 
antagonism leads to a reduction in basal glycerol release (N=4).  P2Y2 receptors were inhibited 
with 10 μM AR-C118925XX (AR-C). All data are normalised to the glycerol release after 24 hours in 
the presence of vehicle only (control). *p<0.05, **p<0.005 signifies a significant difference between 
the two conditions under the line above the bars. 
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Figure 5.22 Inhibition of P2Y2 receptors encourages release of adipokines that promote glucose 
uptake and tissue expansion after 24 hours (N=4). Effect of singular treatment with 100 μM ATP, 
10 μM AR-C118925XX (P2Y2 receptor antagonist) and co-application of ATP and AR-C118925XX on 
the secretion of (A) insulin-like growth factor 1 (IGF-1), (B) insulin-like growth factor binding protein 
1 (IGFBP1) and (C) insulin-like growth factor binding protein 2 (IGFBP2). All adipokines were 
quantified using a Human Obesity Array Q3 multiplex ELISA protein array from Ray Biotech. All data 
are expressed as mean ± SEM. *p<0.05, **p<0.005, ***p<0.001, ns p>0.05 versus secretion of each 
adipokine under control conditions (vehicle only).   
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5.15 Selective antagonism of P2Y2 receptors in primary human subcutaneous 
adipose tissue samples ex vivo causes a decrease in basal glycerol release  
The results presented in thesis were almost exclusively obtained using primary human cells cultured 
in vitro. In order to determine whether the effects observed in vitro are mimicked ex vivo, small 
pieces of primary human subcutaneous adipose tissue were treated with 10 μM AR-C118925XX or 
vehicle and the amount of glycerol released into the supernatant was calculated. Via this method, 
it was evident that there were discrepancies between the in vitro and ex vivo model. Unlike the in 
vitro model, where inhibition of P2Y2 receptors caused an acute increase in basal lipolysis (Figure 
5.8), in the ex vivo model selective antagonism of P2Y2 receptor caused an acute decrease in basal 
lipolysis (Figure 5.23). The differences between these two models may be due to numerous factors, 
including the fact that the ex vivo model contains multiple interacting cells types, whereas the in 
vitro cells are a relatively pure population of adipocytes, in addition the tissue is likely to have a 
much larger number of cells than the in vitro model. The differences between the two models will 
be discussed further in Chapter 6. It has already been confirmed that the lipolytic action of P2Y2 
inhibition is reversed with time, so it is evidently a dynamic process and these data may indicate 
that P2Y2 receptors act as a ‘molecular switch’ that are capable of promoting or suppressing basal 
lipolysis in response to different conditions. It is possible that altering the ex vivo conditions may 
change the phenotype observed, however more research is needed to fully understand the 
mechanism that links P2Y2 receptor activity and lipolysis. By understanding the mechanism fully, it 
may be possible to decipher how different factors such as interaction with other cell types or 
secretion of adipokines may influence this mechanism. Although the results suggest that there is 
disparity between the in vitro and ex vivo model, both models confirm that P2Y2 receptors play a 
role in altering basal lipolysis, thus indicating that P2Y2 receptors represent an interesting target to 
explore with a view to controlling triglyceride reserve usage.  
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Figure 5.23 Inhibition of P2Y2 receptors in primary human subcutaneous adipose tissue ex vivo 
causes a subtle decrease in basal glycerol release (N=3). P2Y2 receptors were selectively 
antagonised with 10 μM AR-C118925XX. Basal samples were taken every 20 minutes for the first 
hour, then vehicle or antagonist was added, and samples were collected every 20 minutes for 2 
hours.  Finally, 1 μM isoprenaline was added as a positive control to verify that the tissue was 
capable of responding to a known lipolytic agent. Glycerol release was normalised to the weight of 
the tissue sample and the amount of glycerol present in the supernatant at time 0. *p<0.05 versus 
glycerol release in the presence of vehicle only.
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5.16 Summary   
Utilising primary human in vitro differentiated subcutaneous adipocytes, it was determined that 
these cells are capable of secreting sufficiently high concentrations of ATP to activate P2Y2 
receptors expressed on the surface of the cells in an autocrine and/or paracrine manner. This means 
that under basal conditions P2Y2 receptors may be constitutively active. P2Y2 receptors primarily 
couple to Gq proteins, thus activation of these receptors leads to activation of PLC and subsequent 
production of IP3 and DAG. The IP3 is then able to bind to receptors on the surface of the 
endoplasmic reticulum, which initiate the release of calcium from the intracellular stores. Thus, 
constitutive P2Y2 activity may be able to control calcium tone within primary human adipocytes. 
This maintenance of ‘elevated’ intracellular calcium levels inhibits calcium-sensitive isoforms of AC 
(AC5 and/or AC6), which limits the production of cAMP, which in turn means that P2Y2 activity may 
control cytoplasmic cAMP tone within adipocytes as well. The limiting of cAMP accumulation means 
that PKA is not activated and therefore cannot phosphorylate CGI-58, perilipins or HSL, which in 
turn means that the extent of basal lipolysis is limited. This is evident in the fact that inhibition of 
P2Y2 and shRNA-mediated knockdown of P2Y2 receptor expression causes an increase in basal 
glycerol release, thus implying that constitutive P2Y2 receptor activation limits basal glycerol release 
in primary human adipocytes. Furthermore, exogenous ATP application enhances the secretion of 
anti-lipolytic adiponectin, while also reducing the expression of lipolytic adipokines, such as 
chemerin, GH, leptin and resistin after 6 hours. This signifies that activation of purinergic signalling 
pathways promotes an anti-lipolytic phenotype in primary human adipocytes. Although currently it 
is not possible to ascribe these actions to P2Y2 receptors specifically.  
Although short-term inhibition of P2Y2 (<4 hours) causes an increase in basal lipolysis, longer-term 
(24 hours) antagonism of P2Y2 receptors appears to cause a decrease in basal glycerol release. This 
coincides with an enhancement in the secretion of anti-lipolytic adipokines, such as adiponectin 
and adipsin, while also reducing the expression of lipolytic adipokines, including ANGPTL4, RBP4 
and TNFα. Longer term inhibition of P2Y2 receptors also appears to promote a largely 
proinflammatory phenotype via augmented release of proinflammatory cytokines, chemokines and 
acute phase proteins. It is unclear whether these changes in the adipokine secretion profiles are 
directly due to inhibition of P2Y2-mediated pathways or triggered by the activation of feedback 
mechanisms to rectify the loss of triglycerides due to P2Y2-inhibition induced lipolysis. However, it 
is more likely that the effects are primarily due to the latter explanation. If the effects were 
predominantly due to direct inhibition of P2Y2-mediated adipokine release or suppression, then it 
would be anticipated that knocking down P2Y2 receptor expression would mimic the longer-term 
phenotype, rather than the shorter-term phenotype, which was not the case. However, irrespective 
of the cause, the development of a proinflammatory phenotype following treatment with a P2Y2 
antagonist proposes a potential hurdle for clinical use of P2Y2 receptor antagonist, because it may 
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indicate that although inhibition of P2Y2 receptors may be an attractive target for modulating basal 
lipolysis to control adipose tissue mass, this may also have unintended consequences such as 
inducing inflammation of adipose tissue, which is known to exacerbate the metabolically 
unfavourable consequences of obesity (Tilg and Moschen, 2008; Després, 2012). The adipocyte 
secretome is complex and highly regulated. A significant amount of additional work would be 
required to identify the exact mechanisms that lead to the up/down-regulation of each adipokine 
and how they may link to P2Y2 receptor activity. The results of this protein array provide a good 
overview of some of the adipokines secreted after P2Y2 receptors are inhibited, but the data 
presented here does not provide any definitive information regarding the mechanism that links 
P2Y2 receptor activity and adipokine secretion. The protein array data presented in this Chapter 
should be viewed as an initial probe that highlights potential candidates for further investigation. 
Despite the fact that all the data from the in vitro differentiated adipocytes suggests acute inhibition 
of P2Y2 receptors enhances basal lipolysis, these findings were not replicated when primary human 
adipose tissue pieces were stimulated with AR-C118925XX (a P2Y2 antagonist). In fact, using this ex 
vivo model, it was revealed that P2Y2 receptor inhibition decreased basal glycerol release, which 
implies that constitutive P2Y2 receptor activity enhances basal glycerol release, rather than limits 
it. Further experimentation is required to determine the reason for the differences observed 
between these two models. However, these results may suggest that P2Y2 receptors may act as a 
‘molecular switch’ in adipocytes that can promote or inhibit lipolysis under different conditions. 
Regardless of the discrepancies between the in vitro and ex vivo models, these data reveal P2Y2 
receptors as an interesting target for pharmacologically manipulating basal lipolysis in humans.  
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Chapter 6: Discussion 
6.1 Project overview 
Obesity is characterised by an excessive accumulation of adipose tissue that impacts of an 
individual’s health. In recent years, there has been a global surge in the numbers of overweight and 
obese adults and children (WHO, 2018). This presents a substantial health issue, as obesity is linked 
to the development a number of chronic metabolic disorders, such as type 2 diabetes and 
cardiovascular disease. There is an almost log-linear increase in the risk of mortality as an 
individual’s body weight increases over the healthy body mass index (BMI) range of 18 to 25 kg/m2 
(Di Angelantonio et al., 2016), where each 5 kg/m2 increase in BMI above the healthy range is 
associated with a 41% increase in risk of vascular mortality and 210% elevated probability of 
diabetic mortality, as well as a 29% higher risk of overall mortality (Whitlock et al., 2009).  
The global rise in the incidence of obesity has initiated a rise in research into adipose tissue biology 
to enable attempts to identify novel drug targets that can be of use in the fight against obesity and 
related comorbidities. It has been identified that adipose tissue expands through hyperplasia via 
stimulation of adipogenesis in tissue-resident adipocyte progenitor cells and hypertrophy of mature 
adipocytes due to enhanced storage of neutral lipids (White et al., 2014). Although many efforts 
have been made to identify the cellular signalling mechanisms involved in adipose tissue regulation, 
very little research has been conducted to investigate the potential role of purinergic signalling in 
white adipose tissue (WAT). Cellular signalling mechanisms mediated via extracellular nucleotides 
have been implicated in a wide variety of physiological processes including smooth muscle 
contraction, immune responses, embryonic development and maintaining homeostasis (Yegutkin 
2014). Purinergic receptors represent a very attractive drug target and they have been successfully 
targeted in other cell types for therapeutic gain. However, purinergic signalling in adipose tissue 
remains a largely unexplored area of research. Through this project, I hoped to characterise the 
molecular basis of nucleotide-evoked responses in primary human adipose-derived mesenchymal 
stromal cells (AD-MSCs) and in in vitro differentiated adipocytes and attribute the identified 
receptors to physiological functions within each cell type.  
 
6.2 Key findings  
6.2.1 P2Y2 and P2Y6 receptor activation elicits intracellular calcium responses in primary 
human adipose-derived mesenchymal stromal cells 
Primary human AD-MSCs express all the known subtypes of P2 receptors, excluding P2X2, P2X3 and 
P2Y12, although there is some heterogeneity in the expression of P2Y11, P2Y13 and P2Y14 across 
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donors. Coupled with evidence of changes in intracellular calcium levels in response to exogenous 
nucleotide (ATP, ADP or UTP) application, positive identification of P2 receptors indicates that AD-
MSCs possess functional purinergic receptors. These findings are supported by previous studies, 
which have also demonstrated evidence of functional purinergic responses in human AD-MSCs 
(Zippel et al., 2012; Kotova et al., 2018). However, the repertoire of P2 receptors detected differ 
slightly between this project and those previously reported. Zippel et al. (2012) identified mRNA 
expression of all P2 receptor subtypes, excluding P2X1 and P2X2, whereas Kotova et al. (2018) 
reported mRNA expression of P2X2, P2X4, P2X7 and all of the P2Y receptors except P2Y12. It is 
perhaps unsurprising that there would be differences between the receptor profiles determined by 
different groups using different donor cells, as heterogeneity in receptor expression was even 
identified between the relatively small number of donors used within this study. Despite the slight 
variation in the receptor profiles identified, there is remarkable consistency in the functional 
evidence of the presence of purinergic receptors, with ATP, ADP and UTP, but not UDP, producing 
detectable changes in intracellular calcium levels both in this study and those previously reported 
by others (Zippel et al., 2012; Kotova et al., 2018).  
Although AD-MSCs appear to express almost all known P2X receptor subtypes, the evidence 
presented in Chapter 3 demonstrates a clear predominance of metabotropic Gq-coupled P2Y 
receptors in the nucleotide-evoked calcium responses. This was demonstrated by the fact that the 
nucleotide responses persisted in the absence of extracellular calcium but were abolished when 
phospholipase C (PLC) and sarco/endoplasmic reticulum Ca2+-ATPase, which are both downstream 
effectors of Gq-mediated signalling, were inhibited. In addition, subtype-selective antagonism of 
P2X4 and P2X7 receptors had no effect on the response to ATP in these cells. Taken together this 
data suggests the nucleotide-evoked calcium responses in primary human AD-MSCs are mediated 
by activation of P2Y receptors, with little/no contribution from the ionotropic P2X receptors 
present. These findings are supported by a study conducted by Kotova et al. (2018) which 
demonstrates that ATP-evoked calcium responses in human AD-MSCs are abolished by PLC and 
inositol triphosphate receptor inhibition, but persist when the extracellular calcium concentration 
was reduced (Kotova et al., 2018). A lack of P2X5 and P2X6 receptor contribution is unsurprising, as 
these receptors are not functional in humans (Torres et al., 1999; Ormond, 2006; Kotnis et al., 
2010). A possible explanation for the lack of P2X4 and P2X7 involvement may be that neither 
receptor is located at the cell surface under the conditions used in this study. P2X4 receptors are 
known to localise to lysosomes and traffic to and from the plasma membrane in other cell types 
(Ashour et al., 2004; Stokes, 2013), so one explanation for the lack of effect of P2X4 receptor 
antagonism is that very few P2X4 receptors may be expressed at the cell surface. Other groups have 
demonstrated presence of P2X7 receptors in mesenchymal stem cells (Madec et al., 2011), but in 
this study, we were unable to demonstrate functional P2X7 receptors, possibly due the use of 
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insufficiently elevated concentrations of ATP in this study or the unusual localisation of the P2X7 
receptor in the nuclear/perinuclear region. 
While all P2Y receptor subtypes (excluding P2Y12 receptors) were detected in primary human AD-
MSCs, the data suggests that only P2Y2 and P2Y6 receptors are involved in mediating nucleotide-
evoked calcium responses. Possible explanations for these findings include limited cell surface 
expression of certain receptor subtypes and/or heterologous desensitisation due to P2Y2 receptor 
activation (Govindan and Taylor, 2012). It is likely that the other P2 receptors (excluding P2Y2 and 
P2Y6) play a functional role in these cells, but this study suggests that they are not primarily involved 
in mediating changes in intracellular Ca2+ levels in response to exogenous nucleotide stimulation. 
They may be involved in non-Ca2+ dependent pathways, only activated under certain circumstances 
or have intracellular functions which are beyond the scope of this study. 
Although inhibition of P2Y2 receptors abolishes the response to UTP, approximately 25% of the peak 
ATP response is resistant to the effects of selective P2Y2 antagonism. This residual response may be 
simply due to the competitive nature of the antagonist used (Rafehi et al., 2017), ADP 
contamination of the ATP used or due to the liberation of ADP (and/or AMP and adenosine) from 
ATP by ectonucleotidases, such as CD39 (Kaebisch et al., 2015; Kerkelä et al., 2016), resulting in the 
activation of other P2 receptors. This may also explain the variation in the level of inhibition 
observed between donors, which may be due to the differing efficiencies of ectonucleotidase 
activity per donor. No genetic analysis of the donors used in this study was conducted, but previous 
reports suggest that mutations in the ENTPD1 (CD39) gene can lead to a reduction in the activity of 
CD39 (Nardi-Schreiber et al., 2017) and there have also been reports to suggest that CD39 surface 
expression levels are dynamic and can increase under certain conditions (Saldanha-Araujo et al., 
2011).  
 
The presence of a UTP-evoked calcium response in human AD-MSCs may be indicative of P2Y4 
receptor involvement. Unfortunately, there is currently no commercially available selective 
antagonist for P2Y4 receptors (Jacobson et al., 2009), so it is not possible to conclusively eliminate 
the possibility that P2Y4 receptors may have a role in the UTP-evoked calcium response, however 
the evidence presented here strongly supports the hypothesis that the ATP and UTP responses are 
mediated by P2Y2 receptors. The calculated EC50 values for ATP and UTP and the IC50 values in the 
presence of a selective P2Y2 receptor antagonist are comparable, which fits with reports that ATP 
and UTP act equipotently on P2Y2 receptors (Parr et al., 1994), whereas P2Y4 receptors are 
antagonised by ATP (Kennedy et al., 2000; Herold et al., 2004). In addition, the ATP responses are 
blocked and the UTP responses are abolished by a P2Y2 receptor selective antagonist, which 
strongly suggests P2Y2 receptor involvement, and precludes P2Y4 receptor contribution. It has 
recently been suggested that the P2Y2 receptor may play a role in driving BM-MSC adipogenesis 
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while suppressing osteogenesis, without affecting the rate of cell proliferation (Li et al., 2015). 
Although the role of P2Y2 receptors in differentiation was not explored within the scope of this 
study, it was determined that P2Y2 receptors are not involved in proliferation or migration of 
primary human AD-MSCs which supports some of the findings presented by Li et al. (2015). If P2Y2 
receptor-mediated signalling does promote adipogenesis in AD-MSCs, then this could provide an 
opportunity to develop pharmacological tools to target the P2Y2 receptor specifically to drive MSCs 
towards/away from an adipogenic phenotype in vivo, thus providing a route to control the number 
of new adipocytes present in adipose tissue and potentially regulate weight gain.  
 
AD-MSCs exhibited a robust ADP response, which was resistant to inhibition in the presence of all 
the subtype-selective antagonists tested, excluding AR-C118925XX (P2Y2) and MRS2578 (P2Y6). AR-
C118925XX only significantly inhibited the net movement of Ca2+ in the latter decay phase of the 
response to ADP and not the initial peak. ADP is not the preferred agonist for P2Y2 receptors, so 
these results may indicate indirect activation of the P2Y2 receptor via ADP-induced release of ATP 
(Jiang, Mousawi, et al., 2017). The ADP response was also inhibited by MRS2578. ADP has been 
shown to elicit a calcium response in 1321N1 astrocytoma cells over-expressing P2Y6 receptors, but 
its effects are much less potent than the preferred agonist of P2Y6 receptors, UDP (Communi et al., 
1996), so it was surprising that MRS2578 abolished the response to ADP in MSCs, when these cells 
lack a UDP-elicited Ca2+ response. It is important to note that UDP does elicit a Ca2+ response in 
MSCs, but only at very high agonist concentrations that are more than ten-fold higher than the 
concentration required to maximally activate the P2Y6 receptor (Communi et al., 1996). One 
possible explanation for this may be that P2Y6 receptors may exist as a heterodimer thus altering 
the agonist profile in these cells. P2Y6 receptors have been shown to form heterodimers with other 
GPCRs (D’Ambrosi et al., 2007; Nishimura et al., 2016) and hetero-oligomerization of other P2Y 
receptors can alter the agonist sensitivity of these receptors (Ecke et al., 2008). After the initial 
peak, blockade of the ADP response with MRS2578 leads to a decrease in the concentration of 
intracellular Ca2+ to below baseline Ca2+ levels, suggesting there is either efflux or internalisation of 
Ca2+. It is unclear why P2Y6 receptor inhibition would have this effect and these observations imply 
that the role of the P2Y6 receptor in MSCs is complex. Although, it was not possible to positively 
identify the functional role of P2Y6 within the scope of this study, P2Y6 receptors have been shown 
to promote osteogenesis in BM-MSCs (Noronha-Matos et al., 2012) and have also been implicated 
in increasing IL-6 expression (Satrawaha et al., 2011). It has been suggested that IL-6 is important 
for maintaining the immunoprivilege stasis of MSCs (Li et al., 2013), so if P2Y6 receptors are involved 
in IL-6 secretion it may prove to be a valuable target for prolonging AD-MSC viability for therapeutic 
use. However additional work is required to clarify both the molecular mechanism and functional 
role of P2Y6 receptor activation in these cells.   
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The findings presented in Chapter 3 encompass a comprehensive characterisation of the functional 
P2 receptors expressed in primary human AD-MSCs, however caution must be applied when 
interpreting these results. Only female patients were recruited and no information about ethnicity 
or lifestyle was collected. The mean age of the recruited donors was 55.5 ± 1.4, and aging has been 
shown to increase cellular senescence and AD-MSCs extracted from elderly patients (age 60-73) 
have been shown to have diminished migration and differentiation capabilities (Liu et al., 2017). 
The molecular mechanisms underlying these changes are not fully understood, so it is not possible 
to rule out potential changes in the P2 receptor expression and/or functioning as a possible cause. 
However, data presented by Zippel et al. (2012) included younger donors and they demonstrated 
functional responses to both ATP and UTP in AD-MSCs extracted from younger patients and they 
also detected a very similar P2 receptor profile to the profile determined in this study (Zippel et al., 
2012). However, it is important to note that Zippel et al. (2012) only used cells isolated from a total 
of three donors, so a much more extensive study would be required to clarify whether the results 
presented here are applicable to younger donors as well. In combination, these factors mean that 
the data presented here is limited to profiling the P2 receptor responses in AD-MSCs extracted from 
older women. Also, although all the recruited patients were cancer-free at the time of recruitment, 
each donor has been treated for breast cancer in the past. Although previous reports suggest some 
chemotherapeutic agents do not affect surface marker expression, proliferation and differentiation 
of AD-MSCs (Liang et al., 2011), it is not known whether cancer and/or subsequent cancer 
treatment resulted in long-term alterations in the expression and function of purinergic receptors 
in these cells.  
 
A key limitation of the study is the use of an in vitro system. Cell culture has been previously shown 
to cause changes in the behaviour of MSCs (Hagmann et al., 2013; Lee et al., 2014; Turinetto et al., 
2016), so this in vitro model may not accurately reflect conditions in vivo. This study depends heavily 
on the selectivity of available pharmacological probes and antibodies. Although all the 
pharmacological antagonists used in this study are reported to be selective for their target receptor, 
it is not possible to rule out the possibility that these antagonists affect non-specific targets in these 
cells. Similarly, despite the fact that the manufacturers of all of antibodies used throughout this 
study state that their antibodies specifically target the protein of interest and many of the 
antibodies used have been utilised in previously published reports, most of the antibodies have not 
been knockout validated. This introduces the possibility of non-specific antibody staining interfering 
with the accuracy of the immunocytochemistry, immunohistochemistry and flow cytometry data. 
In addition, although controls treated with secondary antibodies in the absence of primary 
antibodies were used to control for non-specific secondary antibody binding, neither western 
blotting nor positive or negative controls were performed to confirm the specificity of the primary 
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antibodies used. In particular, negative controls would have been an excellent addition to rule out 
non-specific primary antibody binding, however as purinergic receptors are rather ubiquitously 
expressed, it was difficult to locate human negative control cells or tissue. This study would greatly 
benefit from a thorough characterisation of the specificity of the primary antibodies used and/or 
the development of more specific antibodies. Although this is undoubtedly a limitation of this study, 
the substantial functional evidence of purinergic receptor activity conclusively demonstrates that 
purinergic receptors are present in human MSCs. Another limitation is that all of the 
pharmacological data presented here is based on analysis of a population level response, which 
does not account for cell-to-cell variation in response patterns. Single cell calcium imaging would 
be a good method to investigate any heterogeneity within the population.  
 
6.2.2 P2Y1, P2Y2 and P2Y12 receptor activation elicits intracellular calcium responses in primary 
human in vitro differentiated adipocytes 
There are many similarities between the purinergic response characteristics in primary human AD-
MSCs (Chapter 3) and in vitro differentiated adipocytes (Chapter 4), so to avoid repetition where 
possible general points that have already been explored in Section 6.2.1 will not be discussed again 
in this Section. 
Primary human in vitro differentiated adipocytes express all known P2 receptor subtypes, excluding 
P2X1, P2X2, P2X3 and P2Y14 receptors. This repertoire of receptors is largely supported by previous 
studies characterising the expression of P2 receptors in white adipocytes (Zippel et al., 2012). 
Exogenous application of ATP, ADP and UTP produced transient increases in the concentration of 
intracellular calcium, whereas physiological concentrations of UDP and UDP-glucose did not alter 
intracellular calcium levels. The lack of a functional response to UDP-glucose is perhaps unsurprising 
as P2Y14 receptor expression was not detected in most donors.    
Like AD-MSCs, subtype-specific antagonism of P2X receptors and P2Y6, P2Y11 and P2Y13 receptors 
had no effect on nucleotide-evoked responses, which suggests that these receptors are not 
functionally active under the conditions employed in this study. The molecular mechanisms 
underlying the lack of involvement of these receptors were not fully investigated, but possible 
explanations are discussed in Section 6.2.1. Although P2X receptors do not appear to be directly 
involved in initiating ATP-evoked calcium responses, the magnitude of the response to ATP is 
heavily dependent on the presence of extracellular calcium, so it is conceivable that the initial 
metabotropic response to ATP is potentiated by subsequent Ca2+ entry via P2X receptors.   
The responses to ATP, ADP and UTP were all abolished by inhibition of PLC, which indicates a 
predominance of Gq-mediated signalling, however the responses to ADP and ATP were also 
substantially decreased, but not abolished, when Gi-signalling pathways were inhibited. This 
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suggests that multiple signalling pathways may be involved in the nucleotide-evoked calcium 
responses in human adipocytes. Indeed, subtype-selective antagonism revealed that a combination 
of classically Gq and Gi-coupled receptors are involved in the ATP and ADP response: P2Y1, P2Y2 and 
P2Y12 receptors. It is not unprecedented that there may be crosstalk between P2Y receptor 
subtypes, for example it is well documented that P2Y1 and P2Y12 receptors work in coordination to 
sustain platelet aggregation (Jagroop et al., 2003; Hardy et al., 2004).  
It is proposed here that the ATP response is partially mediated by P2Y2 receptor activation. 
However, it is important to acknowledge that data from Chapter 5 demonstrates that selective 
inhibition of P2Y2 receptors results in a reduction of the basal intracellular calcium level, and as the 
baseline is zeroed for the pharmacological data presented in Chapter 4 to normalise for the 
expected well-to-well variability in basal calcium concentrations, it is not possible to definitively 
conclude that the evident decrease in the responses is due to genuine P2Y2 receptor contribution 
to ATP and UTP-evoked calcium responses. It is possible that the lower basal calcium concentrations 
prior to agonist application are responsible for the diminished magnitude of the nucleotide-evoked 
responses. Although the data from Chapter 5 raises some ambiguity regarding the contribution of 
P2Y2 receptors in the exogenous nucleotide evoked Ca2+ responses, neither pharmacological 
inhibition of P2Y1 nor P2Y12 receptors had a significant effect on the basal calcium concentration. 
This indicates that the inhibitory effects of these antagonists on the ATP-evoked Ca2+ response 
imply P2Y1 and P2Y12 receptors play predominant roles in the ATP-evoked responses. As both P2Y1 
and P2Y12 are preferentially activated by ADP, it is possible that this occurs via liberation of ADP 
from ATP by cell surface ectonucleotidases (Yegutkin, 2014). The ADP can then cause PLC-induced 
release of Ca2+ from the intracellular stores via activation of P2Y1 receptors, while simultaneously 
activating P2Y12 receptors to potentiate the level of intracellular calcium indirectly via modulation 
of cytosolic cAMP levels (Hardy et al., 2004). However, an alternative explanation is that P2Y1 and 
P2Y12 receptors are activated by contaminating ADP in the ATP used in these experiments. 
However, the ATP used throughout this study was greater than 99% pure, so it is unlikely that this 
was the case. In addition, the effects of P2Y1 and P2Y12 antagonism are less potent on the ATP 
response than the ADP response. If there was ADP contamination of 30 μM ATP, then the 
concentration of ADP would be expected to be much lower than the 10 μM ADP that was used for 
the ADP experiments. As both antagonists are competitive (Kim et al., 2003; Hoffmann et al., 2009), 
logically a lower agonist concentration should result in more, not less, potent effects of competitive 
antagonism. 
The expression of P2Y1, P2Y2 and P2Y12 receptors was confirmed in primary human subcutaneous 
white adipose tissue sections, which suggests that there is some symmetry between the findings in 
the in vitro model and adipocytes in primary tissue. This also highlighted the morphological 
differences between mature adipocytes in situ and in vitro differentiated adipocytes, where the 
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white adipocytes in situ have a unilocular morphology, whereas the in vitro differentiated 
adipocytes are multilocular. Due to the technical difficulties of working with mature adipocytes, in 
vitro differentiated adipocytes are a commonly used model. However, it would be interesting to 
replicate key pharmacological assays on freshly isolated unilocular mature adipocytes to determine 
whether there are any differences, beyond the morphological differences, between the two 
models.  
 
6.2.3 Constitutive P2Y2 receptor activity regulates basal lipolysis in human adipocytes 
Primary human in vitro differentiated adipocytes secrete sufficient concentrations of ATP to 
activate P2Y2 receptors expressed on the surface of the cells (Lazarowski et al., 1995). This is 
supported by previous reports that indicate that cells are capable of constitutively secreting ATP to 
regulate purinergic responses in an autocrine or paracrine manner (Corriden et al., 2010; 
Sivaramakrishnan et al., 2012; Campwala et al., 2013). The presence of ATP in the 
microenvironment means that under basal conditions P2Y2 receptors may be constitutively 
activated in human adipocytes. P2Y2 receptors primarily couple to Gq proteins, thus activation of 
these receptor leads to activation of Gαq-PLCβ-IP3 pathway to initiate the release of calcium from 
the intracellular stores (Erb et al., 2012), which suggests constitutive P2Y2 activity may be able to 
control calcium tone within primary human adipocytes. This hypothesis is supported by the finding 
that pharmacological inhibition of P2Y2 receptors caused a decrease in the basal intracellular 
calcium concentration. However, a change in basal calcium concentrations was not observed when 
P2Y2 receptor expression was knocked down using shRNA (versus scrambled control cells). This may 
be, because 100% receptor knockdown was not achieved, resulting in a more subtle decrease in 
intracellular calcium levels that could not be detected due to the limited sensitivity of the assay 
used, or it may be due to unknown changes caused by the lentivirus-mediated shRNA knockdown 
procedure employed. It is not known whether lentiviral delivery of shRNA (scrambled and P2Y2 
shRNA) altered basal intracellular calcium levels, because control cells that were not treated with 
lentivirus/shRNA were not routinely included alongside the scrambled and P2Y2 knockdown cells. 
However, the fact that there is good correlation (excluding the effects on basal intracellular calcium) 
between the pharmacological data using the adipocytes (non-shRNA treated cells) and the 
knockdown data is encouraging. It is also important to note that neither removal of extracellular 
ATP nor inhibition of P2Y2 receptors was able to reduce basal cytoplasmic Ca2+ levels to zero, thus 
indicating that mechanisms independent of purinergic signalling are also involved in maintaining 
cytoplasmic Ca2+ tone, such as mechanisms involving Na+/Ca2+ exchangers or voltage-gated Ca2+ 
channels (Pershadsingh et al., 1989; Clapham, 2007), although this was not explored fully within 
this study. The pharmacological data suggests P2Y2 receptor mediated maintenance of ‘elevated’ 
intracellular calcium levels inhibits calcium-sensitive isoforms of adenylate cyclase (AC5 and/or 
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AC6) (Guillou et al., 1999; Sunahara and Taussig, 2002), which limits the production of cAMP, which 
in turn means that P2Y2 activity may control cytoplasmic cAMP tone within adipocytes as well. An 
increase in intracellular cAMP levels was observed with both pharmacological inhibition of P2Y2 
receptors and shRNA-mediated knockdown of P2Y2 receptor expression. The raw intracellular 
concentrations of cAMP varied between donors, so only the normalised data was included in Figure 
5.3, however the absolute intracellular cAMP values for the adipocytes treated with vehicle control 
and scrambled shRNA were equivalent, which suggests that the process of lentivirus-mediated 
shRNA knockdown does not alter basal cAMP levels. However, it is not possible to conclusively rule 
this out, as control cells that were not treated with lentivirus/shRNA were not run alongside their 
shRNA-treated counterparts. It is important to note that although the basal cAMP concentrations 
were comparable between the two sets of control cells (vehicle control and scrambled control), 
shRNA-mediated knockdown of P2Y2 receptor expression led to an almost three-fold increase in 
intracellular cAMP, whereas pharmacological inhibition of P2Y2 receptors only led to an increase of 
approximately 33%. However, these disparities can be explained by donor-to-donor variation 
and/or the shorter timescale of pharmacological inhibition of P2Y2 than shRNA-mediated receptor 
knockdown. Limiting of cAMP accumulation means that protein kinase A (PKA), a major effector of 
cAMP, is not activated and therefore cannot phosphorylate CGI-58, perilipins or hormone sensitive 
lipase (Miyoshi et al., 2006, 2008; Schweiger et al., 2006; Ahmadian et al., 2010; Sahu-Osen et al., 
2015), which in turn means that extent of basal lipolysis is limited. This is evident in the fact that 
inhibition of P2Y2 receptors using AR-C118925XX (a selective P2Y2 antagonist) and shRNA-mediated 
knockdown of P2Y2 receptor expression caused an increase in basal glycerol release, thus implying 
that constitutive P2Y2 receptor activation limits basal glycerol release in primary human adipocytes. 
However, it is important to acknowledge that the enhancement of basal glycerol release was only 
observed with concentrations of AR-C118925XX that were greater than the reported IC50 for the 
antagonist (1 μM; Kemp et al., 2004), and the majority of the glycerol release experiments were 
exclusively conducted with maximal concentrations of AR-C118925XX (10 μM). This concentration 
was selected, because it resulted in the largest increase in glycerol release, thus facilitating greater 
ease in identifying changes to this enhanced response. Although, it is a maximal concentration, 
previous selectivity studies conducted by Rafehi et al. (2018) suggest that the only P2 receptors that 
may be affected by 10 μM AR-C118925XX, other than P2Y2, are P2X1, P2X3 and P2Y11. Data 
presented in Chapter 4 indicates that P2X1 and P2X3 receptors are not expressed in the majority of 
human in vitro differentiated adipocytes tested, and the expression of P2Y11 varied between 
donors, whereas P2Y2 receptors were expressed in all donors tested, the effects of AR-C118925XX 
on basal lipolysis were consistently observed across donors and the effects were mimicked by 
shRNA-mediated knockdown of P2Y2 receptor expression.  
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Furthermore, exogenous ATP application enhanced the secretion of anti-lipolytic adiponectin 
(Wedellová et al., 2011), while also reducing the expression of lipolytic adipokines, such as 
chemerin (Fu et al., 2016), growth hormone (Johansen et al., 2003; Sakharova et al., 2008), leptin 
(Ruud et al., 2015) and resistin (Chen et al., 2014) after 6 hours. This signifies that activation of 
purinergic signalling pathways promotes an anti-lipolytic phenotype in primary human adipocytes. 
Although currently it is not possible to ascribe the secretion of adipokines directly to P2Y2 receptor 
activity, as the secretion of these adipokines may be indirectly due to enhanced P2Y2 inhibition-
induced lipolysis. AR-C118925XX, the P2Y2 antagonist, used throughout this study, displays very 
high stability in mice and humans (Rafehi et al., 2017), so although the amount of AR-C118925XX 
in the supernatant was not determined after three, six or 24 hours, it is possible that the antagonist 
may still be present despite the fact that the cells were only exposed to a singular dose. 
Alternatively, it is also possible that the antagonist is metabolised over time and the longer-term 
effects observed are largely due to the activation of homeostatic mechanisms within the cells to 
counteract the acute effects of P2Y2 inhibition on basal lipolysis. It would be interesting to 
determine the stability of AR-C118925XX in this system, as this may help to decipher whether there 
is a direct or indirect relationship between P2Y2 activity and adipokine secretion.   
Although short-term inhibition of P2Y2 (less than four hours) causes an increase in basal lipolysis, 
longer-term (24 hours) antagonism of P2Y2 receptors appears to cause a decrease in basal glycerol 
release. This coincides with an enhancement in the secretion of anti-lipolytic adipokines, such as 
adiponectin (Wedellová et al., 2011) and adipsin (Sniderman et al., 1994), while also reducing the 
expression of lipolytic adipokines, including angiopoietin Like 4 (Gray et al., 2012), retinol binding 
protein 4 (Lee et al., 2016) and tumour necrosis factor α (H. H. Zhang et al., 2002). Longer term 
inhibition of P2Y2 receptors also appears to promote a largely proinflammatory phenotype via 
augmented release of proinflammatory cytokines, chemokines and acute phase proteins. It is 
unclear whether these changes in the adipokine secretion profiles are directly due to inhibition of 
P2Y2-mediated pathways or triggered by the activation of feedback mechanisms to rectify the loss 
of triglycerides due to P2Y2-inhibition induced lipolysis. Obese individuals have been shown to have 
enhanced basal lipolysis (Wang et al., 2003), which elevate their levels of circulating free fatty acids 
(FFA) and high FFA levels are known to induce inflammation (Jiao et al., 2011), it is perhaps not 
surprising that longer-term induction of enhanced basal lipolysis is associated with a 
proinflammatory phenotype. In support of the hypothesis that the changes in adipokine secretion 
observed are due to enhanced basal lipolysis rather than P2Y2 activity directly, is the fact that 
shRNA-mediated knockdown of P2Y2 receptor expression mimics the shorter-term lipolytic 
phenotype, rather than the longer term anti-lipolytic phenotype. However, irrespective of the 
cause, the development of a proinflammatory phenotype following treatment with a P2Y2 
antagonist proposes a potential hurdle for clinical use of a P2Y2 receptor antagonist, because it may 
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indicate that although these findings suggest inhibition of P2Y2 receptors may be an attractive 
target for modulating basal lipolysis to control adipose tissue mass, this may also have unintended 
consequences, such as inducing inflammation of adipose tissue, which is known to exacerbate the 
metabolically unfavourable consequences of obesity (Tilg et al., 2008; Després, 2012). The 
adipocyte secretome is complex and highly regulated. A significant amount of additional work 
would be required to identify the exact mechanisms that lead to the up/down-regulation of each 
adipokine and how they may link to P2Y2 receptor activity. The results of this protein array provide 
a good overview of some of the adipokines secreted after P2Y2 receptors are inhibited, but the data 
presented here does not provide any definitive information regarding the mechanism that links 
P2Y2 receptor activity and adipokine secretion. The protein array data presented in this Chapter 
should be viewed as an initial probe that highlights potential candidates for further investigation. 
Despite the fact that all the data from the in vitro differentiated adipocytes suggests acute inhibition 
of P2Y2 receptors enhances basal lipolysis, these findings were not replicated when primary human 
adipose tissue pieces were stimulated with AR-C118925XX (a P2Y2 antagonist). In fact, using this ex 
vivo model, it was revealed that P2Y2 receptor inhibition decreased basal glycerol release, which 
implies that constitutive P2Y2 receptor activity enhances basal glycerol release, rather than limits 
it. Further experimentation is required to determine the reason for the differences observed 
between these two models. There are numerous possible explanations for the discrepancies 
between the in vitro and ex vivo models, including the fact that the ex vivo model contains multiple 
interacting cells types (Sheldon, 2011), whereas the in vitro cells are a relatively pure population of 
adipocytes, in addition the tissue is likely to have a much larger number of cells than the in vitro 
model. Furthermore, as discussed briefly in Section 6.2.2, there is a morphological difference 
between white adipocytes in situ and in vitro differentiated adipocytes, which may also play a role. 
Multiple smaller lipid droplets, such as in the in vitro model cells, have a larger surface area than a 
single large lipid droplet (ex vivo model), and are consequently more prone to lipolysis (Paar et al., 
2012). It has already be elucidated, in this study and previously, that adipokines influence lipolysis 
(Ronti et al., 2006; Rosen et al., 2006). It is likely that the adipokine profile is different for freshly 
dissected human subcutaneous adipose tissue sections than cells that have been maintained in 
vitro for an extended period (almost a month before experimental use), thus it would be interesting 
to characterise the adipokine profile to see whether this is a factor. Regardless of the discrepancies 
between the in vitro and ex vivo models, these data reveal P2Y2 receptors as an interesting 
candidate for pharmacologically manipulating basal lipolysis in humans.  
 
6.3 Future work 
The research presented in this thesis provides an excellent insight into the complex roles of 
purinergic signalling in primary human adipose-derived mesenchymal stromal cells (AD-MSCs) and 
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in vitro differentiated adipocytes. However, the research presented here also exposes many 
potential avenues to pursue in the future. One of these potential areas of interest is determining 
the functional role of P2 receptors in primary human AD-MSCs. In this study, I was able to identify 
the expression of many P2 receptors, including P2Y2 and P2Y6 receptors, which appear to be 
involved in nucleotide-evoked calcium responses. However, neither receptor appeared to be 
involved in cell migration or proliferation, so it would be interesting to see whether P2Y2 or P2Y6 
receptors (or indeed any other P2 receptors) play a role in differentiation or the 
immunomodulatory properties of MSCs. Similarly, many P2 receptors were identified in primary 
human in vitro differentiated adipocytes, but I was only able to determine the role of P2Y2 receptors 
within the scope of this study. Further exploration of the possible functional roles of the other P2 
receptors, in particular P2Y1 and P2Y12 receptors which appear to be involved in calcium signalling, 
would be an excellent way to extend the findings presented here. In addition, the adipokine protein 
array data presented here is very much an initial glimpse and it would be interesting to follow up 
the findings in a more comprehensive manner, using multiple agonists and/or antagonists, 
investigating additional timepoints and so on.  
In the longer term, it would also be very interesting to explore the mechanisms underlying the 
differences between the in vitro and ex vivo model cells. Currently, there are some very interesting 
findings that suggest P2Y2 global knockout mice are resistant to diet-induced obesity and that this 
may be achieved via enhanced metabolic activity in these mice (Kishore et al., 2016). These findings 
correspond well with the in vitro results presented in this thesis. Gaining access to or developing 
in-house P2Y2 knockout mice would greatly enhance the findings of this investigation by providing 
insight into the role of P2Y2 in vivo. It would be particularly interesting to develop tissue-specific 
knockout of P2Y2 in white adipose tissue to see whether the effects observed in vitro (or ex vivo) 
are replicated in vivo. It would also be fascinating to observe the effects of dosing wildtype and/or 
obese mice with a selective P2Y2 antagonist to see whether this had any effect on the plasma free 
fatty acid, glycerol and adipokine levels, the mass of the white adipose tissue depots and overall 
weight of the mice. If these animal studies correlated well with the in vitro data presented in this 
thesis and no significant adverse effects were identified, then it would be extremely interesting to 
perform clinical trials on humans to see whether inhibiting P2Y2 receptors may provide a novel 
method for stimulating weight loss. This would provide invaluable information regarding the 
potential usefulness and/or challenges of attempting to pharmacological manipulate P2Y2 receptor 
mediated signalling in adipose tissue to control obesity.  
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6.4 Concluding remarks 
In conclusion, the data presented in this thesis provides a much-needed insight into the role of 
purinergic signalling in primary human adipose-derived mesenchymal stromal cells and in vitro 
differentiated adipocytes. Despite the enormous potential of purinergic signalling and the societal 
need for solutions to the growing problem of obesity, there is currently very little literature 
surrounding the role of purinergic signalling in both cell types. It is hoped that the comprehensive 
pharmacological characterisation of the P2 receptors expressed in each cell type provided will 
provide a solid foundation upon which future research in this field can flourish.  
At the beginning of this project, I set out to meet three key aims: to identify the molecular basis of 
nucleotide-evoked responses in primary human mesenchymal stromal cells, to characterise the P2 
receptor profile in in vitro differentiated adipocytes and to determine the physiological role of P2 
receptors in each cell type. Although, I was unable to uncover the physiological role of purinergic 
signalling in primary human AD-MSCs, I believe that I have successfully met all of my initial aims. 
During this study, I have determined that almost all the known subtypes of P2 receptors are 
expressed in both cell types, but only P2Y2 and P2Y6 receptors are involved in nucleotide-evoked 
calcium responses in AD-MSCs, whereas P2Y1, P2Y2 and P2Y12 receptors are functionally active in 
human adipocytes. In addition, I have discovered that constitutive P2Y2 receptor activity is 
important for the regulation of basal lipolysis in primary human adipocytes, thus proposing P2Y2 
receptors as a novel drug target for controlling the expansion of adipose tissue. I hope that this 
finding will help in future efforts to manage the detrimental effects of adipose tissue expansion 
observed in obesity.  
As mentioned in Section 6.3, there is still much more research that needs to be done to fully 
elucidate the role of purinergic signalling in human AD-MSCs and adipocytes, but I believe that 
significant steps have been taken throughout the course of this study. I hope that the findings 
presented in this thesis will be useful to the wider scientific community and hopefully eventually 
the public too. 
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Appendix  
Table A1 Adipokines secreted by primary human in vitro differentiated adipocytes following singular treatment with vehicle, 100 μM ATP and/or P2Y2 receptor 
antagonist (10 μM AR-C118925XX (AR-C)) (N=4). Supernatant samples were collected from primary human in vitro differentiated adipocytes that had been incubated with 
DMEM (no serum) for two hours, then exposed to a singular dose of vehicle or antagonist for 30 minutes, and finally ATP or vehicle was added and the first samples were 
collected immediately. Adipokines are quantified by protein array and data are presented as mean ± SEM for four donors. % increase and decrease values show the 
statistically significant changes in expression versus the vehicle control levels. NS indicates no significant change. Cases of donor variation are indicated by an * near the 
adipokines name. 
 
Vehicle control 
(pg/ml) 
100 μM ATP 
(pg/ml) 
% increase or 
decrease 
10 μM AR-C 
(pg/ml) 
% increase or 
decrease 
ATP and AR-C 
(pg/ml) 
% increase or 
decrease 
Adiponectin 4708.8 ± 437 5177.9 ± 525 NS 4494.6 ± 529 NS 5362.4 ± 870 NS 
Adipsin 154.4 ± 21 234.2 ± 33  ↑  446.1 ± 142 NS 571 ± 181 ↑  
AgRP <14 <14 - <14 - <14 - 
ANGPTL4 <137 <137 - <137 - <137 - 
BDNF <55 <55 - <55 - <55 - 
Chemerin <137 <137 - <137 - <137 - 
CRP <27 <27 - <27 - <27 - 
GH <27 <27 - <27 - <27 - 
IFNγ <14 <14 - <14 - <14 - 
IGFBP-1 <27 <27 - <27 - <27 - 
IGFBP-2 75.5 ± 16 104.6 ± 17 NS 15.3 ± 5 NS 18.2 ± 6 NS 
IGF-1 4950.8 ± 1489 5863.1 ± 1528 NS 6931.8 ± 786 NS 123.4 ± 63 NS 
IL-10 <3 <3 - <3 - <3 - 
IL-12p40 <14 <14 - <14 - <14 - 
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IL-12p70 <3 <3 - <3 - <3 - 
IL-1β <3 <3 - <3 - <3 - 
IL-1Ra <27 <27 - <27 - <27 - 
IL-6 66.1 ± 14 62.7 ± 6 NS 26.6 ± 3.6 ↓ 30.8 ± 4 ↓ 
IL-8* 1.1 ± 0.5 2.5 ± 0.8 NS 2.3 ± 0.8 NS 1.4 ± 0.6 NS 
Insulin <274 <274 - <274 - <274 - 
Leptin <55 <55 - <55 - <55 - 
Lipocalin-2 <3 <3 - <3 - <3 - 
MSPα <137 <137 - <137 - <137 - 
OPG 75.1 ± 7 26.8 ± 6 ↓ 40.2 ± 12  NS <27 ↓ 
PAI-I 975.7 ± 98 1027 ± 136 NS 350.8 ± 87 ↓ 374.3 ± 123 NS 
PDGF-BB <3 <3 - <3 - <3 - 
Pepsinogen 1 <27 <27 - <27 - <27 - 
Pepsinogen 2 <55 <55 - <55 - <55 - 
Procalcitonin <137 <137 - <137 - <137 - 
RANTES <3 <3 - <3 - <3 - 
RBP4 2317.7 ± 258 3345.0 ± 515 NS 1904.7 ± 109 NS 1844.6 ± 121 NS 
Resistin <55 <55 - <55 - <55 - 
SAA <137 <137 - <137 - <137 - 
TGFβ1 <137 <137 - <137 - <137 - 
TSP-1 111923.2 ± 14413   73501.6 ± 19053   NS 28104.9 ± 2523 ↓ 3217.6 ± 486 ↓ 
TNF RI <137 <137 - <137 - <137 - 
TNF RII 26.0 ± 4 23.4 ± 5 - 2.9 ± 1 ↓ 2.8 ± 2 ↓ 
TNFα 38.5 ± 11 55.6 ± 14 NS 9.3 ± 2 NS 3.0 ± 1 NS 
VEGF 215.3 ± 20 284.2 ± 13 NS 73.6 ± 9 ↓ 55.2 ± 6 ↓ 
* IL-8 was only detected in one of four donors. 
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Table A2 Adipokines secreted by primary human in vitro differentiated adipocytes following 
singular treatment with vehicle or 100 μM ATP for 6 hours (N=4). Supernatant samples were 
collected from primary human in vitro differentiated adipocytes that had been incubated with 
DMEM (no serum) for two hours, then exposed to a singular dose of 0.1% DMSO for 30 minutes, 
and finally ATP or vehicle was added, and the samples were collected after 6 hours. Adipokines are 
quantified by protein array and data are presented as mean ± SEM for four donors. % increase and 
decrease values show the statistically significant changes in expression versus the vehicle control 
levels. NS indicates no significant change.  
 
 
Vehicle control 
(pg/ml) 
100 μM ATP 
(pg/ml) 
% increase or 
decrease 
Adiponectin 11164 ± 1527 15554 ± 1482 ↑ 
Adipsin 2547.5 ± 867 2428.1 ± 782 NS 
AgRP <14 <14 - 
ANGPTL4 <137 <137 - 
BDNF <55 <55 - 
Chemerin 544.7 ± 148 114.1 ± 50 ↓ 
CRP <27 <27 - 
GH 61.8 ± 15 26.3 ± 7 ↓ 
IFNγ <14 <14 - 
IGFBP-1 49.5 ± 9 27.0 ± 8 NS 
IGFBP-2 62.9 ± 7 63.4 ± 15 NS 
IGF-1 24561.9 ± 7133 36907.2 ± 10376 NS 
IL-10 <3 <3 - 
IL-12p40 25.5 ± 3 7.4 ± 3 ↓ 
IL-12p70 <3 <3 - 
IL-1β <3 <3 - 
IL-1Ra <27 <27 - 
IL-6 120.8 ± 17 136.4 ± 24 NS 
IL-8 11.0 ± 2 35.0 ± 11 NS 
Insulin <274 <274 - 
Leptin 191.8 ± 26 34.3 ± 12  ↓ 
Lipocalin-2 4.8 ± 0.9 1.6 ± 0.7 ↓ 
MSPα <137 <137 - 
OPG 223.9 ± 36 126.6 ± 25 ↓ 
PAI-I 2821.3 ± 688 1621.8 ± 212 NS 
PDGF-BB <3 <3 - 
Pepsinogen 1 <27 <27 - 
Pepsinogen 2 <55 <55 - 
Procalcitonin <137 <137 - - 
RANTES <3 <3 - 
RBP4 2724.1 ± 303 2535.8 ± 122 NS 
Resistin 88.5 ± 18 25.5 ± 10 ↓ 
SAA 200.0 ± 32 201.4 ± 59 NS 
TGFβ1 <137 <137 - 
TSP-1 95202.2 ± 16229   112023.9 ± 13362  ↑ 
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TNF RI <137 <137 - 
TNF RII 14.7 ± 3 3.1 ± 0.9 ↓ 
TNFα 20.1 ± 5 15.7 ± 4 NS 
VEGF 324.0 ± 75 358.7 ± 47 NS 
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